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NOVEL EXTRACELLULAR PRODUCTS OF MYCOBACTERIUM TUBERCULOSIS: 
COMPOSITION, SYNTHESIS, AND RELEVANCE TO DISEASE 
 
Mycobacterium tuberculosis (Mtb) is a bacterium causing great morbidity and mortality 
especially in developing countries. In order to identify possible areas of intervention to positively 
alter the history of the disease, a better identification and characterization of Mtb virulence 
determinants is required. Specifically, biosynthetic routes for these virulence determinants 
should be pursued. Furthermore, the interaction between the host and Mtb virulence determinants 
should be characterized at a molecular level. It is hoped that unraveling these pathogenesis 
mechanisms could lead to novel strategies to combat the infection. 
In Chapter II, the identification of secreted Mtb molecules that induce macrophage 
apoptosis was performed. Apoptosis is a mechanism of host cell death and in the life cycle of 
Mtb, different modalities of host cell death have been suggested to tip the balance between 
bacterial eradication and multiplication. However, a systematic approach to identify and 
characterize secreted Mtb molecules that modulate host cell death, has not been performed. 
Surprisingly, extracellular Mtb RNA fragments were identified as a potent inducer of host cell 
apoptosis. This extracellular RNA was identified as predominantly rRNA and tRNA fragments 
that accumulated early during in vitro culture of Mtb. Mechanistic studies determined that the 
Mtb RNA induced macrophage apoptosis through a caspase-8-dependent, TNF-α-independent 
mechanism. Importantly, Mtb RNA abrogated the macrophage’s ability to control an Mtb 
infection.  In Chapter II, the first description of an extracellular Mtb RNA with potent biological 
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activity was performed. This opens an exciting field in research of host interactions with 
pathogen nucleic acids. 
Chapters III and IV were devoted to identifying the biochemical pathway involved in α-
L-polyGlutamine (α-L-polyGln) biosynthesis and determining its role in pathogenesis in the 
murine model of TB. α-L-polyGln is an Mtb and Mycobacterium bovis (M. bovis) specific 
product and its presence in virulent Mycobacterium spp., suggest that it could play an important 
role in pathogenesis. Bacillus anthracis (B. anthracis) synthesizes γ-D-polyGlutamate (γ-D-
polyGlu), an amino acid polymer that is present in its capsule and is absolutely required for 
pathogenicity. As the pathway for B. anthracis γ-D-polyGlu biosynthesis has been well 
characterized, it was used as a model to start elucidating the Mtb α-L-polyGln biosynthetic 
pathway. Bioinformatics analysis suggested that Rv0574c and Rv2394 are the Mtb homologues 
for B. anthracis CapA and CapD, respectively. In Chapter III, a complete biochemical 
characterization of Rv2394 was performed. Similar to other γ-glutamyltranspeptidases (GGTs), 
Rv2394 had a conserved catalytic motif consisting of a Threonine (Thr) residue. Mutating this 
Thr residue to Alanine (Ala) abrogated the enzymatic activity of Rv2394, including its 
autocatalytic activation. In contrast to eukaryote GGT, Rv2394 was able to perform a GGT 
activity in the presence of physiological relevant acceptors such as di- or oligopeptides 
containing Glutamate (Glu) or Glutamine (Gln). In addition to its autocatalytic activation, 
Rv2394 was shown to be post-translationally modified with hexose residues. A putative 
phosphorylation and acylation modification also seemed to be present in Rv2394. 
In Chapter IV, Mtb mutants for rv0574c and rv2394 were engineered and characterized 
biochemically to determine if the amount of α-L-polyGln had been altered. Furthermore, the 
mutant’s virulence was evaluated in the murine model of TB. Consistent with a putative role in 
iv 
 
α-L-polyGln, both mutants had reduced amounts of Glu and ammonia in the cell wall. 
Furthermore, preliminary analysis suggested that the apolar lipid profiles were also altered by 
these mutations. In the murine model, Mtb mutants had a tendency to grow faster in the initial 
stages of disease. However, the difference between wild type (WT) and mutant strains was not 
statistically significant and normalized during the later stages of disease. Furthermore, mutant 
Mtb also seemed to induce more lung damage. In contrast to bacterial burden, this difference 
persisted throughout the course of the study. Altogether, these results suggest that Rv0574c and 
Rv2394 participate in the biosynthesis of α-L-polyGln. Remarkably, similar biochemical and 
phenotypic results were obtained for both mutants despite being encoded in different loci. These 
initial results provide the foundation for future studies characterizing the biochemical pathway 
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1.1  Introduction 
 After the advent of antibiotics in the second half of the twentieth century, there was a feeling that 
infectious diseases were going to be eradicated. This feeling could be best exemplified by the following 
infamous phrase attributed to Dr. William H. Stewart, the US Surgeon General during the late 1960’s: “It 
is time to close the book on infectious diseases, and declare the war against pestilence won” [1]. Twenty 
years later (1986) some infectious disease experts like Dr. Robert Petersdorf still believed that fellows in 
infectious diseases were soon to be jobless as he reflected on the number of students graduating each 
year: “the millennium where fellow in infectious disease will culture one another is almost here” [2]. 
Only seven years had passed after this comment when in 1993 the World Health Organization (WHO) 
declared tuberculosis (TB) a public health emergency. As described below, there was plenty of evidence 
that TB was once again a major health threat like it had been before the antibiotic era. In contrast to the 
optimistic quote from Dr. Stewart, the war against pestilence (specifically for TB) had basically re-
started. WHO’s declaration should be considered a major milestone in the field of TB as it brought the 
disease back to the spotlight. Enormous economical and intellectual efforts have started paying their 
dividends and some of the ominous trends in the field of TB have been regressing.  
 
1.2 Epidemiology 
 When in 1993 WHO declared TB as a public health emergency, it was estimated that 6-8 million 
people per year were getting sick with Mtb. Furthermore, 1.3-1.6 million people died annually of TB. In 
the latest WHO report released for the year 2011 [3], the absolute numbers are similar as approximately 
8.5-9.2 million new cases and 1.2-1.5 million deaths were estimated to occur. Taking into consideration 




have actually decreased significantly. It has been reported that the incidence has been decreasing at a rate 
of 1.3% annually since 2006 and more significantly, deaths have been reduced by one third since 1990. 
Indeed, if this trend continues the goal set by the Stop TB strategy of eliminating TB for the year 2050 (1 
case/1 million population/year), might be met.                                             
TB is a disease that predominantly affects men (64%) in their most productive time of their life 
(ages 15-59). Most cases of TB are diagnosed in 22 developing countries and approximately 65% of the 
cases occur in China and India [3]. 
The gold standard for diagnosing TB is culturing, however in most countries this is hardly 
performed. Instead, identification of acid fast bacilli by light microscopy is the predominant diagnosis 
technique. However, it has been estimated that only 57% of the diagnosed TB cases came from 
individuals with acid fast bacilli in their sputum. Thus, it can easily be appreciated that many TB patients 
are not being promptly diagnosed and treated. In fact, the current case detection rate is 65% and it is 
hoped that by 2050, all TB cases are diagnosed [3].  
The current drug treatment against Mtb consists of 2 months of rifampicin, ethambutol, isoniazid 
(INH), and pyrazinamide, followed by 4 months of rifampicin and INH. When correctly applied, directly 
observed treatment short (DOTS) course, leads to a 90% success rate. Since the implementation of DOTS 
in 1995, more than 50 million people have been treated and approximately 7 million lives have been 
saved. However, treatment non-compliance is common and this seems to be leading to the appearance of 
antibiotic resistant strains. It is currently estimated that approximately 5% of all TB cases are attributed to 
multiple-drug-resistant (MDR) strains. Unfortunately, only 18% of MDR cases are reported. Ideally all 
Mtb isolates should be evaluated for drug susceptibility; however, this only occurs in 2% of the cases. In 
contrast to the 6 month treatment required for drug susceptible strains, treatment against MDR strains 





Fortunately, the international community has become aware of the magnitude of the TB epidemic 
and has doubled the funding in the last five years. Several new antibiotics are already in phase II and III 
clinical trials. In addition, nine vaccines are currently in some stage of clinical trials [3]. It is hoped that 
new successful interventions can significantly alter the trend so as to achieve Stop TB goals by 2050. 
 
1.3 Mtb life cycle. 
Mtb life cycle starts by the airborne transmission from an infected individual to a naïve one, 
reaching the alveolar sacs in the lower respiratory airways [4-6]. Resident macrophages engulf and 
internalize Mtb by phagocytosis and several outcomes can result from this initial interaction: bacteria can 
be eradicated, alternatively bacteria thrive intracellularly and replicate, or bacteria can remain in a 
metabolic quiescent state know as dormancy to microbiologists. As discussed above in the epidemiology 
section, statistical data suggests that this initial interaction is critical: 10% of the infected individuals 
progress to an acute form of the disease (bacteria thrived after the initial contact), whereas 90% of 
infected individuals harbor dormant bacilli and are referred as having latent disease [3]. A note of caution 
should be taken to avoid using the terms dormancy and latency interchangeably. Whereas the former term 
refers to a physiological and metabolic bacterial state characterized by minimal activity, the later terms 
refers to a clinical condition in which individuals are infected but there’s no clinical evidence of ongoing 
disease. As discussed in Chapter V, failure to separate these terms created enough confusion in the TB 
field so as to affect some lines of experimentation. The third outcome of this initial interaction in which 
mycobacteria are eradicated after being deposited in the alveolar sacs, is certainly the ideal situation. 
Unfortunately, we don’t know its frequency and if containment of low numbers of Mtb is sufficient for 
purified protein derivative (PPD) conversion, falsely incrementing the statistics for latent disease. 
As Mtb starts replicating exponentially (either during acute infection or after re-emergence from 
dormancy), an initial inflammatory response begins accumulating at the site of infection. Animal models 




the murine and guinea pig model, the initial inflammatory response occurring during the first 20 days of 
infection is characterized by monocytic mononuclear cells [7]. The guinea pig model has also revealed the 
presence of an initial wave of granulocytic cells termed heterophils, but this is not paralleled in the murine 
model [8]. As adaptive immunity (see below) takes hold during the third week of infection, greater influx 




 T cells as well as B cells is observed. In addition, activation of 
the adaptive immune response culminates the phase of exponential mycobacterial growth. Failure to do so 
such as in the interferon-γ knock-out (GKO) mice model, leads to the animal rapidly succumbing to 
disease [9]. In contrast, in the immunocompetent murine model, activation of the adaptive immune 
response results in a fairly constant mycobacterial burden lasting several months, whereas a gradual but 
persistent increase in mycobacterial numbers occurs in the guinea pig model.  
The end result of accumulating inflammatory cells is the granuloma, a hallmark of TB and other 
infectious and non-infectious chronic diseases [10]. Histologically, the mycobacterial granuloma is 
characterized by a central area predominantly composed of monocytic mononuclear cells. Surrounding 
this central area is a rim of CD4
+
 T cells, B cells and fibroblasts. Further outside, scuffs of CD8
+
 T cells 
are observed in discrete patches. Similar histological structures are not only found in the lungs, but in 
other organs where Mtb has disseminated.  
Recently, it has become evident that granulomas are more dynamic than previously recognized. 
Granulomas can necrotize and either liquefy or calcify. Alternatively, granulomas can regress if proper 
medication is given [11, 12]. Finally, granuloma structure can also disorganize in the presence of 
immunosuppression. Antibiotic-induced granuloma regression has been widely studied in animal models. 
In this case, the majority of cellular infiltrates are cleared as bacteria are removed and normal lung 
structure and function is left. Drug treatment does not remove necrotic granulomas [11, 13], which will be 
discussed below. In terms of disorganized granuloma architecture, the best examples have been obtained 
during acquired immunosuppression such as in AIDS patients and in humans or animals receiving anti-




mycobacterial numbers clearly indicating that granuloma have an important role in mycobacteria 
containment. In regards to the pathogenesis and life cycle of Mtb, granuloma necrosis is a significant 
event. Two major outcomes of necrosis have been readily documented in both humans and animal 
models: necrotic granulomas can calcify and heal or liquefy. From a clinical perspective, the advantage of 
calcified granulomas was the possibility to identify them by simple X-ray techniques that became 
available in the late 1800s. Alternatively, necrotic granulomas that don’t heal can rupture and the necrotic 
fluid containing multiple Mtb is discharged into nearby airways. If this process continues for some time, 
enough tissue disruption can originate cavity formation significantly enhancing Mtb transmission 
potential. This last process of cavity formation is rarely seen in animal models except in the rabbit [17-
19]. Actually, several of the previous steps leading to cavity formation such as liquefaction and even 
granuloma necrosis also don’t occur in animal models. Except for immunocompromised mice such as the 
GKO, recombinant activation gene (RAG) and nitric oxide synthase-2 (NOS-2) KO mice, granuloma 
necrosis doesn’t occur [20]. Recently, it was appreciated that the immunocompetent C3HeJ/F strain also 
develops necrotic granulomas during Mtb infection [21]. Necrotic granulomas do occur in the guinea pig 
and rabbit model [19]. Lack of necrotic granulomas in mice, has been one of the major drawbacks for 
using the murine model to study some aspects of TB.  
Necrotic granulomas have two additional properties worth considering in the life cycle of Mtb. A 
major characteristic of necrotic granulomas is their low oxygen tension. Since the beginning it was 
proposed that necrotic granulomas could be hypoxic. Recent experimental evidence has indeed confirmed 
this. Immunohistochemical staining with pimonidazole, a reagent binding hypoxic zones has identified 
the necrotic rim as the interphase where hypoxia begins [11]. Hypoxia would certainly extend into the 
necrotic area inside the rim but its low permeability hinders pimonidazole diffusion and labeling of 
necrotic contents. More importantly, subsequent data obtained by inserting oxygen-sensing electrodes 
into necrotic granulomas of living guinea pigs and rabbits, unequivocally confirmed hypoxia in these 




same technique [24]. From Mtb’s perspective, hypoxia represents a condition hindering its metabolism 
and replication, possibly leading to mycobacterial dormancy.  Life in the necrotic granuloma isn’t 
completely deleterious to Mtb [25-27]. It has recently been determined that the necrotic milieu is rich in 
potential nutrients for Mtb such as fatty acids, cholesterol esters and diacylglycerol [28]. Metabolism of 
these nutrients is probably slowly occurring during dormancy and could certainly fulfill Mtb future 
metabolic demands once the necrotic granuloma ruptures, liquefies and is discharged into more aerophilic 
conditions. Additionally, even though granulomas have been considered a mechanism to wall off Mtb, 
necrotic granulomas also represent a niche where Mtb is protected from the immune response onslaught. 
From a clinical point of view, it’s believed that these necrotic granulomas represent a major barrier 
limiting antibiotic levels during therapy.  
Mtb life cycle is completed when bacteria are transmitted from the lung of a sick patient to the 
outside world. As Mtb resides in the lower respiratory tract, significant force through coughing is required 
for Mtb to become airborne. This explains why the young and elderly are usually not as contagious as 
young adults, and also why cavity formation has been associated with increase transmission risk (Mtb’s 
adaptation to transmission will be discussed in Chapter V).  In the following sections, several critical 
aspects of Mtb life cycle will be emphasized. Specifically, the initial encounter between Mtb and host 
phagocytes, the innate and adaptive immune response against Mtb, and transmission will be further 
discussed.  
 
1.4  Initial encounter and innate immune response. 
1.4.1 Interaction with the alveolar sac’s acellular constituents.  
Once inhaled into the lower respiratory tract, mycobacteria are housed in the alveolar sac, a 
special niche consisting of three principal components: surfactant, alveolar respiratory epithelium cells 
and resident macrophages. Surfactant is a fluid predominantly consisting of lipids and proteins [29], and 




tension between air (gas) and blood (liquid) is widely known due to the severe respiratory distress in 
premature infants lacking it. In contrast, it has only recently been appreciated that surfactant has a role in 
the lung’s innate immunity. One of surfactant’s major protein is collectin, a sugar-binding protein (lectin) 
that binds to sugars present on the surface of microorganisms. Collectin activates the complement 
pathway and efficiently opsonizes these invading microorganisms [30]. In turn, opszonization assists 
phagocytosis and microbial clearance by resident macrophages [31, 32]. The interaction of Mtb and 
surfactant has been evaluated in vitro [33]. Mtb is coated by surfactant and this interaction is 
predominantly dependent on the presence of lipoarabinomannan (LAM), a glycolipid present on the 
bacterium’s surface [34]. Surfactant-coated Mtb is readily phagocytosed and its intra-cellular survival is 
reduced in comparison to untreated Mtb [33]. 
 
1.4.2 Interaction with the alveolar respiratory epithelium.  
The most abundant cellular component present in alveolar sacs is the alveolar respiratory 
epithelium. The interaction of Mtb and respiratory epithelial cells has also been evaluated in in vitro 
models, but it has also been documented during post-mortem microscopical evaluation of human lung 
tissues [35].  In general, three major observations have been derived from these studies: alveolar epithelial 
cells can harbor intracellular Mtb and sustain its growth, Mtb can migrate to the basolateral side of 
alveolar epithelial cells and finally, alveolar epithelial cells can die by necrosis during the infectious 
process [36, 37]. Intracellular Mtb can gain access to the basolateral side by a process called trancytosis, a 
dynamic endosome shuttling that transports cargo (in this case Mtb) between the luminal and basolateral 
side [38]. Alternatively, Mtb also reaches the basolateral side by migrating through intercellular junctions 
between alveolar respiratory cells. The other outcome of Mtb and alveolar epithelial cell interaction is the 
demise of the alveolar cell by necrosis [39]. At a molecular level, necrosis of alveolar cells was shown to 
be dependent on the mycobacterial proteins encoded by the RD1 region, which collectively constitute a 




was not evaluated experimentally, necrosis of the alveolar epithelium would in essence generate an ulcer, 
allowing the bacterial’s access to the basolateral side. Reminiscent of the intestinal epithelium necrosis 
induced by Salmonella and Shigella, accessing the basolateral space endows Mtb with the potential to 
disseminate via lymphatic or blood vessels.  
The interaction between pneumocytes and Mtb has been characterized at the molecular level. 
Proteoglycans present on the surface of pneumocytes act as the ligand for at least two mycobacterial 
proteins: the mycobacterial protein heparin-binding haemagglutinin (HbHA) [40, 41] and the 
mycobacterial DNA-binding protein 1 [42]. In a cell free assay, enzymatic removal of the pneumocytes’ 
proteoglycans abrogated HbHA’s binding. Subsequently, it was shown that proteoglycan removal 
inhibited the interaction between Mtb and pneumocytes. As described below, this interaction between Mtb 
HbHA and pneumocytes was further shown to be critical for Mtb in vivo dissemination [40]. 
 Altogether, these results suggest that alveolar epithelial cells do not represent a major barrier or 
defense against Mtb, beyond the production of surfactant by type II pneumocytes.  
 
1.4.3 Interaction with the macrophage.  
As macrophages are the host cell target of Mtb, understanding the outcome of this interaction has 
been a priority [43]. Contacts between Mtb and macrophages are mediated by their respective surface 
molecules. In addition, Mtb can be covered or opsonized by host molecules present in serum and 
surfactant [33], such as immunoglobulins (Ig), complement or lectins [44, 45]. In general, opsonization 
has several consequences benefitting the host such as enhancing phagocytosis, host cell activation and 
microbicidal activity. The macrophage is endowed with several receptors that can mediate phagocytosis 
and/or activation, and there’s significant cross-talk between them. Regarding the process of phagocytosis, 
it’s become evident that multiple receptors may participate during Mtb phagocytosis and there’s really not 




For non-opsonized Mtb, phagocytosis can be mediated by lectin receptors such as the macrophage 
mannose receptor (MMR) [48], DC-SIGN (this applies for dendritic cells discussed below) and 
complement receptor 3 (CR3 or CD11b/CD18 [30, 49]. At the molecular level, the mycobacterial surface-
exposed molecules mannosylated lipoarabinomannan (ManLAM), lipomannan (LM), phosphatidyl-
inositol mannosides (PIMs) and glucan seem to be principally targeted by these receptors, respectively. 
For ManLAM, mannosylation of its non-reducing end is essential for binding to occur to MMR [50, 51]. 
Enzymatic removal of the ManLAM’s non-reducing mannose residues readily diminishes uptake of 
LAM-coated beads. Furthermore, phagocytosis of Mycobacterium smegmatis (M. smeg), LAM-coated 
beads is severely hindered. This has been attributed to the fact that M. smeg LAM is not mannosylated at 
its non-reducing end, instead displaying alternative modifications such as inositol phosphates [52]. An 
additional line of evidence that phagocytosis of Mtb and ManLAM-coated beads occurs through the 
MMR, is the reduced rate at which this proceeds in the presence of antibodies blocking the MMR.  
Mtb binding to macrophages has also been shown to be mediated by CR3 [30, 44, 53]. In addition 
to the C3 binding motifs, CR3 also has a well characterized lectin domain. At the molecular level, CR3 
can bind to the mycobacterial surface exposed glucan, a poly-saccharide consisting exclusively of a 
polymer of glucose residues in α-1-4 linkage [54]. (See section 1.6.2.2 for glucan discussion)  
In contrast to non-opsonic phagocytosis, opsonic phagocytosis has been associated with increased 
macrophage bactericidal activity. Several Fc receptors (FcR) are present on macrophages and for 
mycobacteria, receptors for IgA, IgG and IgM have been readily studied. IgA is the predominant Ig 
present in respiratory mucosa. An isolated study showed increased protection against Mtb when an anti-
ManLAM vaccine was designed to enhance IgA levels against this mycobacterial glycolipid [55-57]. The 
majority of experiments evaluating immunoglobulin opsonization have been performed with either IgG or 
IgM. Two major cellular mechanisms have been found to increase the macrophage’s mycobactericidal 
activity when macrophages engage and engulf antibody-opsonized mycobacteria through its FcR: 




antibody-opsonized mycobacteria induce greater intracellular Ca
+
 fluxes required for phagosomal 
maturation [58-60]. Ca
+
 fluxes are targeted by non-opsonized mycobacteria through an active process as 
evidenced by the fact that opsonized but dead mycobacteria are incapable to do so. Despite the in vitro 
data suggesting that antibody-mediated immunity could be important to control mycobacterial infections, 
it should be pointed out that the in vivo role of antibodies in TB is highly controversial. Except for the 
previously discussed Man-LAM vaccines aimed at enhancing mucosal IgA levels, antibody generation is 
not a major objective of anti-mycobacterial vaccines.  
Simultaneous to the mycobacteria engaging macrophage receptors directly involved in 
phagocytosis, additional interaction occurs with other macrophage surface receptors which participate in 
cell activation but have minor or no role in phagocytosis. Activation of these receptors leads to signal 
transduction across the plasma membrane, usually culminating in gene expression. Specifically to Mtb, 
probably the most important macrophage activation receptor is Toll-like receptor (TLR)-2.  Several 
mycobacterial products have been shown to activate TLR-2. In addition to the mannosylated glycolipids 
mentioned above, mycobacterial lipoproteins have been consistently shown to activate macrophages 
through the TLR-2 pathway [61]. Mycobacterial lipoproteins belong to an abundant family of proteins 
which are characterized by the post-translational addition of lipid moieties in their respective N-terminus 
[62]. The presence of these mycobacterial lipids confers lipoproteins with TLR-2 triggering activity. In 
regards to the host-pathogen relationship, activation of TLR-2 has both beneficial and detrimental effects 
to the host and Mtb. From the host perspective, TLR-2 activation is important in downstream signaling 
events leading to macrophage activation. Indeed, in murine macrophages mycobacterial lipoprotein 
activation of TLR-2 was shown to generate mycobactericidal concentrations of nitric oxide [63]. 
Macrophage apoptosis leading to diminished Mtb survival was also observed when this interaction 
occurred (apoptosis will be discussed below). Furthermore, it was recently described that in human 
macrophages, TLR-2 activation induced a VitaminD-dependant mycobactericidal activity [64]. From the 




levels in macrophages [65, 66]. As MHC-II molecules participate in antigen presentation to T cells, 
reduction of MHC-II is an important Mtb virulence factor. Recent experimental evidence suggested that 
TLR-2 activation by Mtb induced arginase-I production in macrophages [67]. Reduction of arginine levels 
by this enzyme curtailed the efficiency of T cell response. It was hoped that the generation of TLR-2 KO 
mice could help clarify the role of this receptor. Unfortunately, contradictory reports were published 
regarding the effect of TLR-2’s deficit on mycobacterial burden [68, 69] and infections with higher 
bacterial numbers were usually required to see an effect. In humans, polymorphisms in TLR-2 and other 
TLRs have been associated with a minor but statistical significant increase in susceptibility to TB [70, 
71]. Altogether, these results highlight the complex downstream consequences emanating from host-
pathogen interaction. 
Another example of an important cell surface receptor that interacts with Mtb but doesn’t 
participate during phagocytosis is Mincle. Mincle was identified as the receptor for trehalose-di-mycolate 
(TDM) or cord factor [72, 73]. TDM is a mycobacterial lipid with potent immunomodulatory and 
granulomatous-inducing activities and is widely accepted as being one of the Mtb virulence factors [74-
77]. Consequently, the identification of the elusive host receptor for TDM had created great expectations 
to explain some of Mtb pathogenesis mechanisms. Similar to TLR-2, generation of Mincle KO mice did 
not show any overall effect in the pathogenesis of TB [78]. Besides being a warning for the importance of 
translational science in which in vitro experiments are evaluated in in vivo settings, one consideration is 
that the innate immune system is endowed with multiple and redundant mechanisms to ensure proper 
identification of foreign or dangerous signals.   
Once particles or microorganisms are internalized into vesicles by phagocytosis, the default 
pathway is a complex cell biology event progressing to phagosome maturation and lysosomal fusion. This 
default pathway guarantees at least two events: microorganism inactivation and destruction in the more 
acidic lysosomal compartment, and antigen processing and presentation to activate the adaptive immune 




identified failure of phagosome maturation as a major culprit interfering with Mtb eradication [79, 80]. 
These studies also suggested high ammonia concentrations being produced by Mtb as one of the 
mechanisms behind the failed maturation process [81]. This hypothesis has not been pursued to a great 
extent, but one conclusion that has endured years of experimentation is that arresting phagosome 
maturation is an active mycobacterial process requiring live bacilli. Furthermore, phagosomal arrest was 
exclusive to pathogenic bacteria such as Mtb, M. bovis and even the more attenuated M. bovis Bacillus 
Calmette-Guerin (BCG). In contrast, avirulent mycobacteria such as M. smeg lacked this property, thus 
phagosomal maturation arrest is still considered one of the most important Mtb virulence factor. 
Subsequent immunohistochemistry studies provided evidence that mycobacteria-containing phagosomes 
were stalled at the early endosomal stage [82, 83]. Mycobacterial phagosomes were identified to contain 
the transferrin receptor [82], a recycling receptor known to releases its cargo at the early endosomal stage 
before returning to the cell membrane. Later on, proteomic studies characterizing Mtb-containing 
phagosomes demonstrated these were devoid of H
+
-ATPase responsible for lysosome acidification [84].  
In conjunction with cell biology studies, the mycobacterial phagosome was also shown to retain the early 
endosomal marker rab5 but was lacking the late endosomal marker rab7 [85-88]. Finally, the lack of 
phosphatidyl-inositol-3-phosphate kinase (PI3K) on the phagosomal cytoplasmic surface was identified 
as one of the major culprits explaining the failed phagosomal maturation [87, 89, 90]. The lipid 
phosphatidylinositol-3-phosphate (PI3P) is the product of the enzymatic activity of PI3K. This lipid plays 
an important role in regulating protein-lipid interactions required for membrane fusion events [91]. More 
importantly, the similar structure of PI3P and some of Mtb phosphatidylmannosides could explain at the 
molecular level the reason for phagosomal maturation arrest. Indeed this was confirmed to be the case, 
and PIMs have been clearly identified as one of the principal molecules participating in this virulence 
mechanism [92, 93]. Other Mtb lipids like sulfolipids and TDMs have also been described to inhibit 
phagosome-lysosome fusion [94]. Thus, it seems Mtb is endowed with redundant mechanisms to 




For Mtb, life in the macrophage’s early endosome has several advantages. Intracellular Mtb are 
protected from extracellular innate immune components like serum Igs and complement. More 
importantly, it has become evident that its location in early endosomes will allow Mtb to access nutrients 
that the macrophage is internalizing through the endosomal pathway. In addition to the iron present in 
transferrin [95], Mtb also has access to lipoproteins en route to the lysosome [96]. Elemental analysis of 
the Mtb phagosome has confirmed the presence of other metals such as zinc [97], that could be used by 
Mtb. As described below, the cytokine IFN-γ potently activates macrophages to control Mtb. One 
mechanism by which IFN-γ activates macrophages is by circumventing Mtb-induced phagosomal arrest 
[98]. IFN-γ has been shown to induce the expression of additional GTPases which enhance phagosomal 
maturation as well as oxidative burst, autophagy and anti-microbial peptides [99]. As Mtb is efficiently 
shuttled to the lysosome, it becomes exposed to a low pH which is critical for activation of host proteases, 
lipases etc. that inflict damage to Mtb [83]. In addition, the Mtb would be denied of the nutrients available 
in the early endosomes. Once again, elemental analysis of Mtb phagosomes from IFN-γ activated 
macrophages has shown a significant reduction of the ions available in the early endosome [97]. In 
conclusion, Mtb has developed several mechanisms guaranteeing its presence in the comfortable niche of 
early endosomes but fortunately the immune system can circumvent this. The outcome of this 
“positional” battle is an important determinant of Mtb survival’s or death.  
As mentioned, IFN-γ is an important cytokine activating the macrophage to control Mtb [100]. 
Even though this cytokine is produced by innate immune cells such as NK and γδ T cells, the role of these 
cells in controlling Mtb is not completely understood. Instead, IFN- γ is the classical cytokine of a TH1 
acquired immune response and is the major target sought by vaccination strategies. As this response is 
delayed by almost three weeks during Mtb, certainly other innate immune responses are in place to 
minimize mycobacterial growth while the development of the acquired adaptive immune response is 
achieved. In the last couple of years, several additional macrophage mechanisms have been described to 




proteins or even organelles are targeted to the lysosome for destruction, has been recently described to 
play a significant role in innate immune responses to Mtb [101]. During autophagy, components destined 
for degradation are enclosed in a double membrane bi-layer as opposed to the single membrane bi-layer 
present in most organelles. Ultrastructural studies of Mtb-infected macrophages have confirmed that some 
Mtb phagosomes are actually enclosed with an additional membrane constituting an autophagic vesicle 
[101]. Similar to the classical endosomal pathway, this cellular process is also dependent on the 
production of PI3P and can be activated by GTPases. Mtb molecules blocking autophagy have not been 
described but PI3P production could also be targeted by mycobacterial lipids. Again, as occurs with the 
endosomal pathway, IFN-γ has also been shown to increase the formation of Mtb-loaded autophagic 
vesicles [102].  So in essence, the mechanism by which autophagy participates in controlling Mtb is by 
ensuring its delivery to the lysosome. 
In contrast to autophagy, the mechanism by which macrophage apoptosis diminishes 
mycobacterial survival is not completely clear (apoptosis will be thoroughly discussed in Chapter II). 
Apoptosis is a cell death mechanism dependent on the activation of caspases which induce cell death by 
cleaving essential proteins required for normal cellular processes. This cell death mechanism is a tightly 
controlled process in contrast to necrosis which is a catastrophic mechanism of cell death. Initial studies 
suggested that apoptosis as opposed to necrosis led to mycobacterial death [103]. Mechanistic studies 
revealed that macrophage apoptosis during Mtb infection was dependent on several factors such as 
caspase activation, TNF-α production, mitochondrial depolarization and Ca+ fluxes [104-107]. 
Furthermore, downstream events during apoptosis such as membrane micro-disruptions and the 
translocation of phosphatidyserine (PS) to the extracellular leaflet of the plasma membrane were 
dependent on the balance of lipidic intermediates such as lipoxins and prostaglandins [108-110]. As 
expected, some mycobacterial products have been shown to inhibit apoptosis. ManLAM was shown to 
inhibit Ca
+
 fluxes as well as to induce the production of IL-10, a cytokine that counteracts some of the 




by Akt [111]. Downstream effects of Akt include the induction of gene transcription and phosphorylation 
of proteins such as BAD and BID, that control apoptosis through the mitochondrial pathway. As 
mentioned, despite the abundance of literature implicating macrophage apoptosis as a cellular process 
controlling mycobacterial growth, the mechanism(s) has not been fully elucidated. In some 
circumstances, macrophage apoptosis correlates with the induction of high concentrations of the 
mycobactericidal product nitric oxide [112]. It could be further argued that by committing suicide, the 
macrophage is altruistically eradicating the niche for mycobacterial growth.  
 
1.5 Dissemination and acquired immune response.  
1.5.1 Dissemination.  
Even though Mtb is transmitted via the aerosol route, dissemination to other organs besides the 
lungs might seem like a dead end. Mtb affecting the majority of organs has been described, a testimony to 
Mtb potential to disseminate. Mtb dissemination causes several significant morbidity and/or mortality 
such as during meningeal, renal, pericardial and musculoskeletal TB amongst other forms of the disease. 
Fortunately, with the advent of antibiotic therapy and better diagnostic methods, these TB complications 
have been reduced. Furthermore, even though the available TB vaccine BCG doesn’t seem to have a 
major impact in protecting against lung disease, it has a clear effect in reducing complicated TB in 
younger children. 
In the murine model, it has been clearly determined that the thoracic lymph nodes are the first site 
of dissemination in pulmonary TB. Viable bacteria have been detected at approximately 10 days after an 
aerosol infection but the low numbers of mycobacteria precludes earlier detection [113]. This event is 
critical during the development of the acquired immune response as it has been shown that T cell priming 
occurs at the local lymph nodes rather than at the lungs (discussed in section 1.4.2) [113, 114].  It’s 
presumed that dissemination to the thoracic lymph nodes is also an early event in humans as evidenced by 




defined as the identification of a calcified focus in the lung parenchyma in addition to a calcified thoracic 
lymph node. Actually sometimes the Ghon complex is the only evidence for previous or latent TB. 
Besides the morbidity attributed to Mtb dissemination, it has been speculated that extrapulmonary Mtb 
might be responsible for reactivation or antibiotic failure. Recently, Mtb was discovered in the adipose 
tissue but interestingly these mycobacteria had a dormant phenotype [115]. As mycobacterial dormancy 
has been associated with enhanced antibiotic tolerance, adipose tissue-embedded mycobacteria could 
certainly predispose to reactivation.  
One aspect of the dissemination process which is still debated is how Mtb disseminates. The 
classical story tells that dendritic cells with high migration capabilities are responsible for transporting 
peripherally encountered antigens or microbes to the lymph nodes. Dendritic cells have been shown to be 
infected with Mtb both in vivo and in vitro [116, 117]. It is widely accepted that Mtb has the potential to 
inhibit dendritic cell maturation and migration [118]. Alternatively, some studies have suggested that 
neutrophils shuttle mycobacteria to lymph nodes via afferent lymphatics. One characteristic of guinea pig 
pulmonary TB is the early lymphatic involvement. In this case, heterophils in the pulmonary lymphatic 
system (the guinea pig equivalents of neutrophils) were observed to be loaded with intracellular 
mycobacteria [119, 120]. In the murine model, this clear observation hasn’t been reported yet. 
Nevertheless, neutrophils were also shown to be the cells transporting BCG from the site of subcutaneous 
inoculation to the lymph node [121]. In contrast to the “Trojan horse” mechanism in which Mtb is being 
transported intracellularly by host cells, mycobacteria could also be disseminating extracellularly. As 
mentioned above, mycobacteria have been reported to transverse respiratory epithelium to the basolateral 
side or alternatively, to de-epithelialize the respiratory mucosa by inducing cell death of the epithelium 
lining it. The Mtb mutant for HbHA was unable to bind to respiratory epithelial cells [40]. More 
importantly, this mycobacterial mutant was severely compromised in its ability to disseminate to the 
spleen after an aerosol infection. Meanwhile, the mutant Mtb was able to thrive in the spleens of animals 




by the authors, it would be highly unlikely that host cells could not phagocytose the HbHA-mutant Mtb 
taking in consideration the redundant mechanisms involved in Mtb phagocytosis. Instead, failure to 
adhere to the respiratory epithelial cells and to disseminate could be a better indication that Mtb 
significantly disseminates extracellularly.  
 
1.5.2  Acquired immune response.  
Multiple lines of evidence have robustly confirmed that T cells are responsible for protection 
against Mtb. Adoptive transfer experiments initially pointed out the role of CD4
+
 T cells as being the 
primary cells against Mtb infection [122-124]. In contrast, adoptive transfer of immune serum also ruled 
out a major role for the antibody response during TB [123]. As described above, the high susceptibility to 
TB in AIDS patients with low CD4
+
 T cells, plainly confirmed their role in TB [3]. In murine models, 
depletion of CD4
+
 T cells by injection of anti-CD4
+
 antibodies has additionally substantiated this [125]. 
Furthermore, non-human primates infected with simian immune deficiency virus (SIV), are also highly 
susceptible to Mtb when a significant decrease in CD4
+
 T cells has occurred [126, 127].  
CD4
+
 T cells are the archetype of “helper” cells. Not only do they “help” B cells during the 
generation of antibodies, but most importantly, they “help” macrophages control intracellular 
microorganisms like Mtb [100]. Activated CD4
+
 T cells release cytokines such as TNF-α and IFN-γ 
which activate macrophages. Furthermore, activated T cells display co-stimulatory surface molecules or 
receptors which further enhance macrophage activation after interacting with their cognate receptors 
present on the macrophage’s surface. It’s well established that patients with mutations in the IFN-γ 
receptor pathway are highly susceptible to Mtb and a similar propensity has been reported for GKO mice 
[9, 128, 129]. A similar increased susceptibility to Mtb has also been observed in patients with mutations 
in the IL-12 pathway [129]. This cytokine is released by macrophages and dendritic cells, and activate the 




the IL-12 produced by macrophages, leading to IFN-γ production by T cells, in turn reciprocally 
activating macrophages [100]. 
In TB, naïve CD4
+
 T cells are primed by antigen presenting cells (APCs) displaying on its surface 
a mycobacterial peptide in the context of the Major Histocompatibility Complex (MHC)-II [100]. In the 
MHC-II pathway, proteolytic cleavage of proteins from endosomally-located microorganisms like Mtb, 
generate peptides which are loaded onto endosomally-residing MHC-II molecules. The complex of MHC-
II-mycobacterial peptide is then shuttled to the macrophage’s surface. If sufficient affinity is present 
between the MHC-II-mycobacterial peptide and a cognate T cell receptor (TCR) being displayed on the T 
cell’s surface, T cell activation ensues. Besides the TCR, additional crosslinking between T cell 
molecules and cognate receptors on the APC’s surface is important for efficient T cell activation. In this 
context, the interaction between the T cell’s CD4
+
 and the macrophage’s MHC-II is critical, hence the 
importance of CD4
+
 T cells in TB. As expected and as described above, Mtb residence in phagosomes as 
opposed to lysosomes, minimizes Mtb antigen processing and presentation. Furthermore, it has been 
described that Mtb lipoproteins reduce the expression of MHC-II on the APC’s surface by reducing the 
class II transactivator [65, 66, 130]. T cell-derived IFN-γ counteracts and circumvents these immune 
evasion mechanisms by increasing phagosome-lysosome fusion and enhancing antigen presentation [98]. 
Recently, it was also described that T cell derived IFN-γ increased the macrophage’s mycobactericidal 
activity by inducing the anti-microbial peptide cathelicidin [64, 131, 132]. More importantly, this 
pathway was dependent on the levels of VitaminD [133]. Lower levels of VitaminD are present in 
African-Americans and this correlates with an increase risk to TB. In vitro addition of VitaminD was able 
to correct the reduced mycobactericidal activity of macrophages obtained from African-Americans, thus it 
has been suggested that VitaminD should be used during anti-TB treatment.  
Besides “helping” with macrophage activation via cytokines and cell surface receptors, a direct 
mycobactericidal effect has been described in CD4
+
 T cells. In the skin of leprosy patients, CD4
+
 T cells 




mycobacterial cell wall and by inducing permeability alterations, ultimately compromise the 
mycobacterial’s integrity. Previously an anti-mycobacterial role had been proposed for granulysin from 






 double negative cells) [134]. In contrast, granulysin was not 
only shown to be present in the granules of CD4
+
 T cells in leprosy lesions, but most importantly its 
release from degranulating CD4
+
 T cells had a mycobactericidal effect. The role of granulysin-containing 
CD4
+
 T cells in TB has not been reported.  
Detailed kinetic studies evaluating the acquired immune system in TB have concluded that 
priming of naïve CD4
+ 
T cells occur in the thoracic lymph nodes but not in the lung [114, 135]. Sufficient 
Mtb antigens are required for efficient T cell priming, but unfortunately this doesn’t occur until 10-14 
days after infection. The reason for this delay in T cell priming is unknown but could be attributed to the 
slower mycobacterial replication rate, in addition to the immune evasion mechanisms described above. 
Indeed, experiments in which animals have been infected with higher numbers of Mtb have detected 
earlier Mtb-specific T cell responses in the thoracic lymph nodes. This window of time between infection 
and T cell priming certainly benefits Mtb as unrestricted bacterial growth occurs for the first 20 days after 
infection. In turn, this could also limit the efficacy of anti-mycobacterial vaccines aimed at controlling 
infection.  
Different subsets of CD4
+ 
T cells have been described to participate in the adaptive immune 
response to Mtb [136]. Besides the IFN-γ-producing TH1 CD4
+ 
T cells described above, TH17 CD4
+ 
T 
cells [137] and CD4+CD25+FoxP3+ T regulatory cells [138] have also been shown to have a role in TB. 
TH17 cells are characterized by the production of IL-17. This cytokine was shown to be important for 
efficient activation of the IL-12-IFN-γ axis. Mice with mutations in the IL-17 receptor were susceptible to 
Mtb and had increased bacterial burden [137]. As occurs with TH1 CD4
+ 
T cells, both effector and 
memory cells have been described for TH17 cells. In general terms, effector cells principally localize to 
the affected organ and could be described as the cells doing the “dirty work”. These cells are activating 




principally localized in the secondary lymphoid organs. As implied by their name, these cells have 
originated from a previous or ongoing infection and have the potential to generate effector cells when re-
encountering their cognate antigen. Even though the distinct function and importance of effector and 
memory cells has been characterized in viral infections, this has not been the case in TB. Both cell subsets 
have been identified in acute and chronic infection [139]. Furthermore, BCG vaccination only leads to a 
temporal increase in memory CD4
+ 
T cells [139]. In fact, it has been hypothesized that BCG fails to 
protect against pulmonary TB because it’s unable to induce sufficient memory T cells [140]. Further 
adoptive transfer studies should help understand the role of memory and effector cells in TB.  
Several lines of evidence suggest that CD8 T cells also play an important role in the immune 
response against Mtb. Initially, it was observed that adoptive transfer of these cells could give some 
degree of protection to naïve animals infected with Mtb [141]. Conversely, it was also reported that 
antibody-mediated depletion of CD8 T cells enhanced susceptibility to Mtb [142]. This line of research 
got a major boost when it was reported that β2 microglobulin (β2M)-deficient mice were highly 
susceptible to Mtb infection [143].  β2M is a constituent of the MHCI that is required during CD8 T cell 
ontogeny [143]. Therefore, β2M-deficient mice do not express MCHI molecules and lack CD8 T cells 
[143]. However, it was later noted that β2M not only associated with MHCI molecules but also with CD1 
(see below), transferrin receptor (see below) and other non-classical MHC molecules. Thus, other 
immunological defects besides the absence of CD8 T cells could explain the enhanced susceptibility of 
β2M-deficient mice. In order to accurately evaluate the role of CD8 T cells in the response against Mtb, 
mice with mutations in TAP-1, CD8α and perforin were subsequently evaluated [144, 145]. TAP-1 
transports cytoplasm-derived peptides into the rough endoplasmic reticulum, where the peptides are 
loaded onto MHCI molecules [144]. Similar to the β2M, TAP-1 knockout mice are also deficient in CD8 
T cells and are highly susceptible to Mtb infection [144, 145]. Perforin, on the other hand, is required for 
CD8 T cell cytolytic activity. Importantly, perforin deficient mice did not have any significant alterations 




not dependent on its cytolytic function but could be attributed to other properties such as cytokine 
production [145].  One major caveat to these experiments was the fact that mice had been infected via the 
IV route with a high bacterial burden. Using the more physiological aerosol route, North reevaluated the 
role of CD8 T cells after infecting with a low dose of bacilli [146]. In this case, β2M-deficient mice were 
not as susceptible to Mtb infection; however, bacterial burden was 10 times higher than WT controls. 
Furthermore, depletion of CD8 T cells in animals already lacking CD4 T cells, worsen the outcome [146]. 
Altogether, these results suggest that CD8 T cells have a protective role against Mtb, albeit significantly 
less than CD4 T cells. In humans it has become clear that CD8 T cells are being primed against Mtb 
antigens [147, 148]. In vitro studies using CD8 T cell clones obtained from human patients have resulted 
in IFN-γ secretion when stimulated with their cognate Mtb antigens. Moreover, CD8 T cells have been 
shown to participate in the granulomatous response during TB and they localize in small clusters in the 
periphery of granulomas from infected animals [149]. Finally, it is noteworthy to mention that targeting 
CD8 T cells is being considered as way to increase the efficacy of anti-Mtb vaccines [150].  
In addition to conventional CD4 and CD8 T cells, recent evidence has suggested that other 
subsets of non-classically activated
 
T cells can also participate in the adaptive immune system against Mtb 
[151]. In humans, human leukocyte antigen (HLA)-E restricted CD8
+ 
T cells have been characterized 
[152]. In general, these T cells react with self-signal peptides derived from MHC molecules that are being 
presented in the context of HLA-E. HLA-E restricted T cells have been proposed to represent an immune 
surveillance mechanism to detect down regulation of MHC presentation occurring during some viral 
infections and cancer. Specifically in TB, several mycobacterial antigens have been confirmed to be 
presented via this specialized pathway [153]. The significance and mechanism of HLA-E restricted T 
cells is not completely known.  
In addition to HLA-E-restricted T cells, CD1-restricted T cells have also been identified 
predominantly in the murine model. The CD1 pathway was discovered to represent a specialized antigen 




consideration that Mtb is endowed with multiple immunomodulatory lipids, understanding the CD1 
restricted pathway was a major endeavor [155]. In TB, initial experimental evidence for CD1 restricted T 
cells was suggested in KO models deficient for β2M [144]. This protein paired with CD1 for efficient 
antigen presentation and surface localization. Unfortunately β2M is also required for MHC-I restricted 
CD8
+
 T cell response, in addition to the transferrin receptor pathway. In the later situation, deficiency in 
the transferrin receptor led to iron-overload and increased susceptibility to Mtb. Indeed, correction of the 
iron-overload present in β2M KO mice was able to almost normalize susceptibility to Mtb [156]. Final 
proof that CD1-restricted T cells were not critical in the immune response against Mtb was achieved when 
CD1 KO mice were finally obtained [144]. It should be pointed out though, that mice only have one 
isoform of CD1 (CD1d) whereas the situation in humans is more complex due to the presence of four 
isoforms. Therefore, in humans CD1-restricted T cells could still play an important part in the immune 
response against Mtb. 
The severe susceptibility to Mtb in AIDS patients or in those having mutations in the IL-12 and 
IFN-γ axis has highlighted the importance of the adaptive immune response in TB [100]. Despite this, it 
has also become clear that the TB is a chronic inflammatory disease and the adaptive immune response 
could negatively be participating in the disease’s pathogenesis. The adaptive immune system could be 
inducing severe inflammation and lung damage. Initial studies suggested in rabbits developing necrotic 
granulomas, reported that necrosis and tissue damage became evident once the adaptive immune response 
became operational [157]. Thus, the inflammation generated by the adaptive immune response could be 
affecting the lung’s integrity and function. Supporting this concept that the adaptive immune system in 
TB causes lung damage, AIDS patients in which the CD4
+ 
-mediated adaptive immune system is non-
functional, tend to have inconspicuous organ damage despite dramatic bacterial burdens [158]. Recently, 
it was provocatively hypothesized that the adaptive immune response could also be negatively impacting 
transmission [159]. After evaluating hundreds of Mtb T cell epitopes in humans, it became evident that 




the sequence of essential mycobacterial genes should be the most conserved in order to guarantee the 
protein’s function.   The majority of mutations affecting essential genes should therefore be synonymous 
in nature. That is, the nucleotide mutation should not lead to a change in the amino acid sequence. Even 
though this was corroborated for essential genes, the surprising finding was the T cell epitopes had fewer 
mutations than essential genes and furthermore, mutations in T cell epitopes were even more synonymous 
than in essential genes. A well-known immune evasion mechanism is antigen variation. The adaptive 
immune system cannot mount an effective response to antigen with a different sequence than the initial 
antigen that drove B or T cell priming. In contrast, these results suggest that Mtb has been under a 
selective pressure to conserve T cell epitopes. Inducing a strong T cell activation could lead to significant 
tissue inflammation and damage, facilitating transmission. The specific subset of CD4
+ 
T cells causing 
tissue damage has not been completely defined. One possibility is TH17 cells. Even though these cells 
have been shown to be important in the early protection against Mtb, they can also induce potent 
inflammation through IL-17 secretion and neutrophil recruitment. In fact, instead of increasing protection 
against Mtb, repetitive BCG vaccination severely compromised the lung of Mtb-infected mice by 
overdriving TH17 cells [160]. In essence, there’s a delicate balance between what an adequate immune 
response to Mtb is and what causes tissue damage. 
   
1.6 Mtb virulence determinants. 
In the following section, specific Mtb virulence determinants will be covered in depth. For each 
virulence determinant, the identification, characterization and role in pathogenesis will be discussed. The 
rationale for selecting these virulence determinants is based on its relationship with the pathogenesis 
mechanisms evaluated in this dissertation. As a secreted RNA was identified in the Mtb CF, specialized 
secretion systems such as the Esx-1, SecA2 and Tat are reviewed. Taking in consideration α-L-polyGln’s 




of an Mtb polymer, as well as PDIM and mycobactin as examples of Mtb products synthesized by the 
non-conventional non-ribosomal peptide and polyketide synthatase, respectively. 
 
1.6.1 Protein secretion mechanisms. 
1.6.1.1 Esx-1 
 Esx-1 is probably the most intensely studied, Mtb protein secretion system. Identification of this 
secretion machinery started with genomic studies aimed at determining the mechanism by which BCG 
became attenuated [161].  Subtractive genomic hybridization between BCG and M. bovis or Mtb, initially 
identified three regions of difference (RD) that were missing in BCG. The RD1 region was particularly 
interesting as it seemed to be missing in all BCG strains, suggesting that its deletion was a major 
attenuation mechanism. Subsequent genomic studies with DNA microarrays determined that BCG 
actually had 13 RD with M. bovis, however it was confirmed that deletion of RD1 was the first event in 
BCG attenuation as it was absent from all BCG strains [162]. In silico analysis suggested that the RD1 
could be associated with virulence, as it was conserved in all virulent Mycobacterium including M. 
leprae, M. bovis, and M. marinum [163]. However, it should be noted that the RD1 was also detected in 
the avirulent M. smeg, therefore its presence is not sufficient for virulence. To confirm that the RD1 
mutation led to attenuation this locus was complemented back into BCG and evaluated in vivo in the 
murine model of TB [164]. Remarkably, RD1-complemented BCG was more virulent as determined by 
increased number of granulomas and bacterial burden. In contrast, complementing with other RD did not 
have the same effect. Finally, it was shown that mutating RD1 in Mtb caused a significant in vivo 
attenuation that resembled the one observed for BCG [165]. Altogether, these results suggested that BCG 
attenuation was mostly attributed to the loss of the RD1. 
Several lines of evidence suggested that the RD1 encoded for a specialized protein secretion 
system. Similar to the requirements for Sec-mediated protein transport, the RD1 encoded for some 




Furthermore, proteomics analysis in BCG demonstrated that complementing the RD1 restored the 
secreted protein profile observed in M. bovis and Mtb [161]. ESAT-6 and CFP10, which are encoded in 
the RD1, were amongst the identified proteins accumulating in the CF after complementation of RD1 
[164]. Subsequently, it was shown that restoring protein secretion required complementation with the 
entire region [166]. Conversely, mutating any individual RD1 gene would abrogate ESAT-6 and CFP10 
secretion [167]. Extensive protein-protein interaction was reported for ESAT-6 and CFP10, as well as for 
other proteins encoded in the RD1 and this could explain why mutating one gene could have such a 
generalized effect during protein secretion. During analysis of the crystal structure for the ESAT-6/CFP10 
heterodimer, it was noted that the C-terminal region in CFP10 did not participate in their interaction 
[168]. Instead, this region protruded from the protein and it was suggested that it could represent a signal 
peptide-like motif that would facilitate secretion. Indeed, it was observed that mutating this sequence 
impacted secretion of both proteins. Furthermore, this motif could mediate secretion of a fungal protein, 
clearly confirming its role as a signal peptide. Additional Esx-1-like systems have been identified in Mtb 
and other Gram positive bacteria such as Listeria monocytogenes, Bacillus anthracis (B. anthracis) and 
Staphylococcus aureus [163].  To keep in line with the nomenclature of other bacterial protein secretion 
systems, the Esx-like system has been named type VII [169].  
In regards to the host-pathogen interaction and the critical role that Esx-1 plays in virulence, 
multiple functions have been reported for this secretion system. However, an underlying theme is that 
ESAT-6 has a significant ability to make pores in host membranes. Indeed, ESAT-6 but not CFP10 has 
been shown to interact with liposomes [170]. Furthermore, an Esx-1 dependent pore was observed by 
electron microscopy in host cell membranes after infection with M. marinum [171]. Pore formation has 
been associated primarily with three outcomes: host cell death, mycobacterial escape from the phagosome 
or secretion of bacterial effector molecules into the host cytoplasm. Esx-1 mediated host cell death has 
been reported both in vitro and in vivo. Initial studies reported that the Esx-1 system induced pneumocyte 




WT strains due to a defect in the initial interaction with pneumocytes. In vivo studies have also suggested 
that the Esx-1 system is important for inducing the formation of necrotic granulomas [173]. In contrast to 
infections with WT Mtb, Esx-1 mutants fail to induce necrotic granulomas that normally develop in GKO 
mice. This could be explained with results coming out of the zebra fish model during M. marinum 
infection. It was observed that granuloma formation was Esx-1 dependent [26]. Smaller granulomas were 
observed in mutant M. marinum and this correlated with decreased bacterial burden [174]. Subsequent 
studies suggested that the Esx-1 secretion apparatus was inducing metalloproteinases by the host 
epithelium and this event led to macrophage recruitment [175]. In turn, freshly arrived macrophages could 
be a niche where M. marinum could thrive and cause macrophage death. Eventually, multiple rounds of 
this infectious cycle would lead to sufficient host cell death and possibly generate necrotic granulomas. 
Escaping from the phagosome is a second outcome induced by pore formation through an Esx-1 
dependent mechanism. Indeed, initial studies with M. marinum observed that it would eventually localize 
in the host cytoplasm and spread to neighboring cells through actin polymerization [176]. Even though 
Mtb and M. leprae are generally not considered to reside in the host cytoplasm, some recent results 
suggest bacteria gain access to the cytoplasm after prolonged infection [177].  For these three 
Mycobacterium spp, translocation into the host cytoplasm required the Esx-1 secretion system. Finally, it 
has recently been reported that by creating pores in the host cell membrane, Mtb Esx-1 mediates secretion 
of effector molecules into the host cytoplasm [178]. Specifically, mycobacterial DNA has been suggested 
as one of the translocated molecules [179]. This is in line with the previous observation that M. smeg Esx-
1 could participate in bacterial conjugation [180]. The presence of bacterial DNA inside the host 
cytoplasm has been shown to be a potent stimulus for the induction of type-I IFNs which seem to benefit 
bacterial survival [178].  
In conclusion, Esx-1 is the prototype of a new protein (and maybe nucleic acid) secretion system 





1.6.1.2 SecA2 pathway. 
One of the surprises encountered in 1998 when the Mtb genome was sequenced, was the presence 
of a second SecA protein with approximately 50% homology to the previously characterized and 
ubiquitous SecA1 [181]. At that time, it constituted the first example of a microorganism encoding for 
two copies of the SecA protein and the term SecA2 was coined to describe the second variant. 
Subsequently, it was determined that two copies of secA were also encoded in the genomes of most 
Mycobacterium spp, but most important, in several highly pathogenic bacteria such as B. anthracis, M. 
leprae, Listeria monocytogenes, Staphylococcus aureus and Streptococcus pneumonia [182]. The 
presence of SecA2 in these pathogenic bacteria suggested that it constituted a specialized secretion system 
involved in virulence.  
The first attempt to characterize SecA2’s function was performed by Braunstein et al in 2001 
[183]. It was initially determined that SecA2 was not essential in M. smeg and Mtb whereas SecA1 was 
essential and could only be mutated in a merodiploid strain. Interestingly, despite the high amino acid 
sequence identity, SecA2 overexpression could not compensate for the loss of SecA1, suggesting that 
their function is non-redundant. The ∆secA2 mutant was highly susceptible to sodium azide, routinely 
used to inhibit protein secretion. Thus, it was suggested that similar to SecA1, SecA2 could also 
participate in protein secretion. Using the alkaline phosphatase (AP) reporter system, it was shown that 
the ∆secA2 mutant accumulated unprocessed AP, a good indication that protein secretion was inhibited. 
In order to identify specific SecA2-mediated secreted proteins, proteomics studies were subsequently 
performed to determine differences in the protein profile of CF obtained from WT Mtb or the ∆secA2 
mutant [184]. Despite an unremarkably similar protein profile between both strains, the superoxide 
dismutase A (SodA) was the most significant protein to be underrepresented in the CF of the ∆secA2 
mutant strain. Conversely, increased SodA levels were detected in the mutant’s cell wall, suggesting that 
it was not being efficiently secreted. Interestingly, the SodA protein lacks a signal peptide in its N-




Rv0390, also present in reduced amounts in the CF of the ∆secA2 mutant strain. Interestingly, in M. smeg 
it was later shown that SecA2 could also mediate secretion of signal peptide-containing lipoproteins 
(Msmeg1712 and Msmeg1704) [185]. Secretion of these lipoproteins through the M. smeg SecA2 
pathway seems to be the exception rather than the norm as mutating secA2 did not affect other 
lipoproteins. In contrast to M. smeg, no defect in lipoprotein secretion has been identified in the Mtb 
∆secA2 mutant. However, a similar secretion defect was observed for Msmeg1704 after heterologous 
expression in the Mtb ∆secA2 mutant. Thus, Mtb and M. smeg SecA2 seem to recognize similar features 
in proteins being secreted through this pathway. Finally, in regards to the protein’s biochemical 
characterization, it has recently been suggested that SecA1 also participates in the secretion of SecA2 
dependent proteins [186]. Site directed mutagenesis of the SecA2 ATPase motifs abrogated its activity 
and led to a dominant negative mutant that even seemed to affect the SecA1 pathway. Conversely, 
conditional mutants for SecA1 also affected secretion of the SecA2-dependent lipoprotein Msmeg1704. 
The current dogma for SecA2-mediated protein secretion is the following: proteins both with and without 
signal peptide are recognized by the SecA2 pathway. Once the protein is bound to SecA2, it’s delivered to 
the SecYEG translocon and secreted with the help of SecA1.  
 In the context of host-pathogen interaction, it was shown that the ∆secA2 mutant failed to thrive 
in BMMOs [187]. In the murine model of TB, reduced bacterial burden was obtained in the lungs and 
spleens of mice infected with the mutant strain [184, 187]. However, the mutant strain did persist in the 
chronic stage of the disease, albeit at lower levels. Furthermore, after an aerosol infection with the mutant 
strain, prolonged survival for both WT and SCID mice was observed [184, 187]. This result with SCID 
mice suggested that attenuation of the ∆secA2 mutant strain was principally associated with a defect in 
counteracting the host innate immune system. Consistent with this hypothesis and in stark contrast to 
infecting BMMO with virulent Mtb strains, infection with the ∆secA2 mutant led to higher nitric oxide 
and inflammatory cytokines production [187]. Similarly, the mutant strain failed to down regulate the 




assumed that the lack of SecA2-mediated SodA secretion could explain the mutant’s phenotype. 
Surprisingly, the mutant strain was also compromised during in vitro infections of BMMOs obtained from 
phox mice lacking the ability to produce reactive oxygen species [187]. Thus, mutating secA2 has a 
greater impact in Mtb physiology beyond SodA secretion. Recent studies have determined that the 
∆secA2 mutant is defective in preventing phagosome-lysosome fusion [188]. Indeed, pharmacologically 
blocking phagosome-lysosome fusion with bafilomycin restored the secA2 mutant’s ability to reside in 
BMMOs. It has been suggested that the ∆secA2 mutant could have cell wall alterations that not only 
explain the activation of BMMO, but also its impotency in blocking phagosome-lysosome fusion. 
Interestingly, Listeria ∆secA2 mutants have dramatic alterations in their cell wall as evidence by rough as 
opposed to the smooth colony morphology associated with virulence [189]. Specifically, Listeria’s altered 
colony morphology has been attributed to SecA2-mediated secretion of autolysins that cleave 
peptidoglycan [190]. It remains to be determined if this is the case in Mtb.  One interesting aspect that has 
emerged from studying Mtb SecA2 pathway is the possibility of using the ∆secA2 mutants as a vaccine 
[191]. As mentioned, this mutant strain is attenuated both in vitro and in vivo, including in 
immunocompromised mice. Furthermore, the ∆secA2 mutant potently stimulates the innate immune 
system, which is critical in activating the adaptive immune system. Significantly, when the ∆secA2 
mutant was used as a vaccine, an enhanced CD8 T cell response was observed. This was attributed to 
antigen cross-presentation associated with the ∆secA2 mutant’s ability to induce apoptosis. More 
importantly, vaccinating with the ∆secA2 mutant significantly reduced bacterial burden and lung 
pathology in both infected mice and guinea pigs. In conclusion, the identification and characterization of 








1.6.1.3 Twin-arginine transporter (Tat) pathway. 
 The field of horticulture discovered the Tat pathway in the mid 1990’s when a SecA-independent 
protein secretion system was identified in the chloroplast’s thylakoid membrane [192].  This alternate 
secretion system was not inhibited by sodium azide, known to block SecA-mediated protein transport. 
Instead, protein secretion by this new pathway could be abrogated with valinomycin or nigericin which 
dissipate the proton motif force (PMF) [193]. Taking in consideration that secretion through the SecA 
pathway requires signal peptides in the protein’s N-terminus, it was considered that the two secretion 
pathways could mechanistically diverge because of significantly different signal peptides. However, 
signal peptides for both types of secreted proteins were remarkably similar, only differing in the 
conserved presence of an arginine-arginine (RR) motif in the signal peptide of proteins secreted by this 
new pathway. Thus it was suggested that the RR motif specifically targeted proteins being secreted by 
this alternate pathway. Indeed, mutagenesis experiments targeting the RR motif abrogated secretion 
through this new pathway [194]. Finally, while characterizing a maize mutant with defective protein 
transport into the chloroplast, a novel group of transporters was sequenced and shown to participate in 
this alternate secretion pathway [193]. Surprisingly, homology searches determined that similar proteins 
were encoded in the genomes of bacteria such as E. coli, Mtb and M. leprae. The term Tat (twin-arginine 
transporter) system was coined after confirming that mutating E. coli’s homologues abrogated secretion 
of some periplasmic proteins [194].  
 While the Tat system was being identified in chloroplasts, sequencing of Mtb genome was being 
completed. Probably due to the incipient body of knowledge in the Tat system, during the initial genome 
annotation this system was not included as a member of the ‘protein and peptide secretion’ subcategory 
[181]. The driving force to characterize Mtb Tat system came from several observations linking this 
pathway to virulence mechanisms in bacteria such as Legionella pneumophila, Pseudomonas aeruginosa 
and some strains of E. coli [195]. Using the amino acid sequence for E. coli’s Tat system, homologues for 




proteins have similar roles as their counterpart in E.coli: TatA oligomers form the translocation pore, 
whereas TatB and C seem to recognize and tether the target proteins. The genetic organization for Mtb tat 
genes was found to be conserved in M. leprae, M. bovis, M. avium and even M. smeg [195]. Furthermore, 
bioinformatics analysis suggested that at least 31 proteins could be secreted through the Tat system, 
including BlaC (a β-lactamase) and PlcA and B (phospholipases), previously shown to be important for 
Mtb, Legionella and Pseudomonas virulence [196]. However, this number of proteins seem to vary 
according to the algorithm and stringency applied during the analysis, and different studies have reported 
anywhere from 11 to almost 90 proteins putatively secreted through the Tat system [197-199]. Initial 
mutagenesis studies determined that in contrast to Mtb, the Tat system is not essential in M. smeg [195, 
197, 198]. Thus, most studies have been performed in the latter microorganism. Consistent with the 
bioinformatics analysis suggesting that BlaC is a Tat-secreted protein, the ∆tatC M. smeg mutant was 
susceptible to β-lactams [195]. Complementation with WT BlaC was able to restore resistance to β-
lactams, however mutating the RR motif or forcing BlaC secretion through the SecA pathway did not 
restore the WT phenotype. An additional study in M. smeg confirmed these results and furthermore, 
characterized a functional succinate transporter (DctP) that was secreted through the Tat pathway [197]. 
Interestingly, bioinformatics analysis performed in this and other studies, suggested that some Mtb 
lipoproteins also have Tat-compatible signal peptides containing the RR motif [198, 200].  Unfortunately, 
no experimental evidence has been obtained in Mtb or M. smeg confirming lipoprotein secretion through 
the Tat pathway.  
 Additional studies were performed to identify other Mtb proteins that could be secreted through 
the Tat pathway. Using stringent bioinformatics analysis 11 Mtb, putatively Tat-secreted proteins were 
identified [198]. Out of these 11 proteins, only Rv2525c is conserved in M. leprae. Taking in 
consideration the massive genomic decay present in M. leprae, conservation of an Rv2525c homologue is 
a good indication that it could have an important role in pathogenesis.  Similar to the phenotype observed 




slowed its replication rate in axenic cultures. Paradoxically, the ∆rv2525c Mtb mutant replicated faster in 
BMMO and was more virulent in the murine model of TB. The authors suggested that Rv2525c could 
have a role in cell wall metabolism, as a ∆rv2525c Mtb mutant had increased susceptibility to β-lactams. 
In agreement with this line of thought, structural homology with a transglycosidase was identified for 
Rv2525c using the Phyre secondary structure matching software [199]. In turn, the altered cell wall 
structure present in the ∆rv2525c Mtb mutant could increase the release of immunomodulatory molecules. 
Finally, a recent study reported that Ag85A and C are bona fide Tat-secreted proteins [201]. For these 
proteins, secretion through the Tat pathway depended on the oxidative potential in the cytoplasm. As 
occurs for AP, increased cytoplasmic oxidative conditions might assist in the folding of Ag85A and C. 
Interestingly, Ag85B does not seem to be secreted through the Tat pathway, instead being secreted 
through the conventional SecA pathway [202]. The reason why similar proteins would be secreted 
through different secretion systems is not known.  
 In conclusion, the Mtb Tat pathway is an essential, specialized protein secretion system that has a 
significant, yet not fully understood role in pathogenesis. Several Tat-secreted proteins like the 
phospholipases and Ag85A or C could have a direct immunomodulatory activity affecting the outcome of 
an infection. Alternatively, this dedicated protein secretion system could have an important role in cell 
wall remodeling, as suggested by the enzymatic activity present in Tat-secreted proteins such as Ag85A, 
Ag85C, Rv2525c and BlaC. The identification of additional Tat-mediated secreted proteins might 
enhance our understanding of this secretion system.  
 
1.6.2 Specific Mtb products 
1.6.2.1 PDIMs 
 Studies in the early 1900’s identified the presence of waxy-like material that could be extracted 
from Mtb using organic solvents. Importantly, when inoculated intraperitoneally in rabbits, this material 




epitheliod cells [203]. Anderson developed a protocol to isolate four waxes (A-D) based on their 
differential solubility in different organic solvents [204]. It was determined that prolonged incubations 
with potassium hydroxide were required to saponify wax A into two optically active components [205]. 
The alcohol and acid components were named phthiocerol [205], and mycocerosic acid [206] 
respectively, in order to reflect their origin and composition. The structures of phthiocerol [207] and 
mycocerosic acid [208] were elucidated in the late 1950’s using mass spectrometry and some interesting 
features were identified for both compounds. For instance, two alcohol groups were identified in the 
middle of the aliphatic chain of phthiocerol [207]. Mycocerosic acid was reported to contain 4 methyl 
groups [208], an unusual modification in fatty acids. Based on the structure of each individual component, 
it was suggested that both alcohol groups present in phthiocerol were esterified with a mycocerosic acid, 




Figure 1.1 Structure of PDIM. PDIM consists of two mycocerosic acids covalently linked through an 








individual components present in PDIM. The presence of alcohol and methyl groups in this molecule 
suggested that biosynthesis was performed by a polyketide synthatase. Adapted from reference [213]. 
  
In the 1960’s initial studies evaluating PDIM’s biosynthesis suggested that both radiolabeled 
propionate and acetate could be incorporated into phthiocerol [204].  Similarly, in a cell free assay it was 
shown that methylmalonate could be incorporated into the mycocerosic acids [209].  Interestingly, 
enzymes synthesizing mycocerosic acid were identified in the cytoplasm [209] as opposed to the cell 
membrane where fatty acid synthesis had generally been detected. Furthermore, efficient incorporation of 
methylmalonate into mycocerosic acids required the presence of a fatty acid ‘primer’ with 18-20 carbon 
atoms [209]. The enzyme synthesizing mycocerosic acid was eventually purified [210], subjected to N-
terminal sequencing and the resulting amino acid sequence was used to identify the mas (mycocerosic 
acid synthase) gene [211]. Additionally, it was determined that the MAS protein had a high homology to 
polyketide synthatases present in other organisms. Involvement of a polyketide synthatase in PDIM’s 
biosynthetic pathway could explain the aforementioned observations regarding its metabolic labeling with 
radiolabeled acetate, propionate, and methylmalonate, the cytoplasmic localization for the enzymatic 
complex and the requirement for a fatty acid priming the reaction. Inactivation of the mas gene indeed 
confirmed that it encoded for a protein participating in both PDIM biosynthesis and phenolic glycolipid 
(PGL) [212]. Interestingly, during Mtb genome annotation, it was observed that the mas gene was 
localized in a region encoding other polyketide synthatases [181]. This genetic organization suggested 
that PDIM and PGL had common biosynthetic steps. Furthermore, the fact that >1% of the Mtb genome 
was devoted for PDIM/PGL biosynthesis suggested that these products had an important role in 
pathogenicity. Then in 1999, a transposon mutagenesis study identified three PDIM-deficient mutants in 
which the transposons had integrated into this genomic region [213]. From these studies, it was suggested 
that the mmpL7 gene encoded for a PDIM transporter as this product accumulated in the Mtb cytoplasm 




polyketide synthatases, was the presence of genes encoding for FadD proteins with high similarity to fatty 
acid synthases [181]. It was shown that these proteins activate fatty acids via an acyl-adenylate 
intermediate and are subsequently transferred to the polyketide synthatase [214]. The stage was ready to 
complete the description of PDIM biosynthesis. Briefly, mycocerosic acid is synthesized by the concerted 
action of FadD28 and Mas [215, 216]. The former protein activates C14-C16 fatty acids and transfers 
them to Mas. Mas catalyzes the incorporation of methylmalonate into the fatty acid [209, 215], generating 
this methyl-branched polyketide. Phthiocerol biosynthesis also starts with an equivalent fatty acid 
activation by FadD26 [216], which is then transferred to the Pps proteins. These proteins mediate the 
incorporation of malonate or methylmalonate [215]. In contrast to other fatty acid synthases, the modular 
organization of PpsA and PpsB is unique in that it lacks an enoylreductase and dehydratase domain, but 
conserves the ketoreductase domain. Thus, during the incorporation of malonate, the β-keto group is only 
reduced to a hydroxyl group and the subsequent generation of an alkyl chain is not completed [181, 215]. 
These phthiocerol hydroxyl groups are subsequently esterified with mycocerosic acid, a step catalyzed by 
PapA5 [217]. 
 PDIM’s critical role in virulence was identified early on by Goren [218], when they isolated an 
Mtb strain that despite producing large quantities of SL, was avirulent. Animals infected with this strain 
had reduced numbers of pulmonary granulomas and less bacterial burden. However, mutant bacteria were 
not cleared out from the tissues but persisted at lower numbers. Similar results have been reported for all 
the engineered PDIM mutants [213, 219]. An important observation made by Domenech was the 
spontaneous loss of PDIM during in vitro culturing of Mtb and this occurred both in laboratory strains and 
clinical isolates [220]. The authors recommended that before legitimately claiming that other Mtb 
products are important virulence determinants, the absence of PDIM should be ruled out. Despite multiple 
studies highlighting the importance of PDIM as a major virulence determinant, the mechanism is still 
unclear. Cell biology studies using purified PDIM have suggested that the product is rather inert in 




with PDIM mutants lead to increased inflammatory cytokine production. Additionally, mutant strains fail 
to thrive in activated macrophages and this has been attributed to an enhanced susceptibility to RNis 
[219]. Recently, it was reported that PDIM could participate during the initial Mtb-macrophage 
interaction [221]. It was observed that PDIM could alter the macrophage’s membrane fluidity, including 
the fluidity of cholesterol-rich lipid rafts which are important during phagocytosis. A PDIM-less mutant 
was phagocytosed through a CR3 and MR-independent pathway and was not able to efficiently block 
phagosome-lysosome fusion. Furthermore, as determined by the altered hydrophobicity, it has been 
suggested that PDIM could have an important role in the structure of the Mtb cell wall [222]. Further 
studies are required to completely elucidate PDIM’s role in TB pathogenesis, however its importance has 
opened several lines of research into the pharmacological inhibition of Mtb polyketide synthatases. 
 
1.6.2.2  Capsule and Glucan/glycogen. 
 The presence of an electron transparent zone (ETZ) surrounding mycobacteria had been reported 
since the 1950s [223-225]  when electron microscopy was applied to study mycobacteria obtained from 
both axenic cultures or from infected tissues. Even though it was suggested that this ETZ could be 
attributed to a mycobacterial ‘capsule’, this hypothesis created significant controversy as the ETZ could 
simply represent an artifact during sample fixation for electron microscopy [225]. Furthermore, the ETZ 
could represent a host derived product as opposed to a mycobacterial product. Subsequently, several lines 
of evidence suggested that the ETZ was actually a microbial product as it could only be observed 
surrounding live bacteria but not dead bacteria [226, 227]. In addition, microscopic characterization of the 
‘capsule’ identified that it was composed of fibrils not present in host tissues and mycobacterial waxes 
were obtained during preliminary biochemical characterization of the fibrils [226]. In the 1980s, Rastogi 
determined that the mycobacterial ETZ/capsule could easily be stained with ruthenium red and it was 
present in both virulent and avirulent Mycobacterium spp [228]. Interestingly, the ‘capsules’ width was 




performed by Daffé after purifying it from the surface of live Mtb and M. bovis, after gentle mechanical 
disruption [229].  The capsule was reported to account for approximately 2-3% of dried bacteria and be 
constituted predominantly of polysaccharides and protein (94-99%), as opposed to lipids (1-6%). Further 
characterization of the sugars present in the polysaccharides identified arabinose and mannan (from 
arabinomannan), but predominantly glucose residues forming a polymer which shared several of 
glycogen’s chemical and biophysical properties. Similar to glycogen, mycobacterial capsules were shown 
to be repeating units of glucose residues in 14 linkage with short 16 branching occurring at the 
glucose residue in position 4 (Fig. 1.2) [54].  Glucan was not only present on the surface of mycobacteria, 
but it was also present in the CF suggesting that constant capsule remodeling was taking place [230]. 
Finally, a second glucose-containing polymer was found to be present inside mycobacteria and this 




Figure 1.2 Structure of M. bovis capsular glucan. Mycobacterium glucan consists of a polymer of 
glucose residues in a α14 linkage. Some glucose residues are also derivatized at position 6 with short 
oligomers of α14 linked glucose residues, constituting the branches present in glucan. Adapted from 
reference [54]. 
 






 Multiple experiments have been performed at the cell biology level to understand glucan’s role in 
the host-pathogen interaction. Serendipitously, glucan was purified as the molecule responsible for BCG’s 
anti-neoplastic activity [232]. It had been known for a while that BCG inoculation into different types of 
cancer induced tumor regression. In fact, BCG is still being used therapeutically against bladder cancer. 
As occasionally BCG has important side effects, it was decided that purification of the molecule(s) 
responsible for this activity could circumvent using a live bacteria. Glucan was purified from BCG 
extracts obtained after boiling and shown to mediate the anti-neoplastic effect. The mechanism involved 
in mediating this effect was not determined. However, subsequent studies with purified glucan have 
suggested that it has a detrimental effect in the activation of the immune response. Specifically, glucan 
has been shown to affect the differentiation of monocytes into dendritic cells [233]. In the presence of 
glucan, monocyte-derived dendritic cells have reduced levels of the co-stimulatory molecule CD80. 
Furthermore, these cells are devoid of CD1 and do not activate CD1 restricted T cells. Additional studies 
showed that glucan activated the dendritic cell receptor DC-SIGN which is known as being targeted by 
mycobacteria in order to affect antigen processing and presentation [234]. The immunosuppressive 
cytokine IL-10 was induced in dendritic cells stimulated with glucan. Alternatively, glucan’s role in the 
host-pathogen interaction has been evaluated by mechanically removing the capsule from live 
mycobacteria and comparing it to encapsulated bacteria. Initial experiments evaluated this interaction in 
the context of CR3. When the non-phagocytic CHO cells were transfected in order to express CR3, 
encapsulated as opposed to non-encapsulated bacteria were uptaken [235]. The interaction between 
transfected CHO cells and encapsulated Mtb could be blocked with either purified glucan or commercial 
glycogen, further confirming the interaction’s specificity. However, using macrophages as opposed to 
transfected non-phagocytic CHO cells suggested that the glucan capsule was actually inhibiting Mtb 
phagocytosis [236]. Capsule removal via sonication, increased the number of bacteria being uptaken by 
macrophages through a CR3-independent mechanism. It was suggested that this enhanced uptake was 




receptors besides CR3 could be mediating faster Mtb uptake, but the capsule was actually slowing down 
the process by targeting CR3 which is known not induce a respiratory burst.  
 In order to extrapolate the cell biology results to an in vivo animal model, Mtb mutants were 
engineered so as to disrupt genes putatively involved in glucan and/or glycogen biosynthesis [237]. As 
Mtb glucan and glycogen have a similar structure, mutations targeted Mtb genes with homology to 
E.coli’s glg involved in glycogen biosynthesis. In E.coli, glycogen biosynthesis starts with the glgC-
mediated glucose activation via an acyl phosphate. The main chain consisting of glucose in 14 linkage 
is performed by the polymerizing activity of glgA and the 16 linkage present in the branches by glgB. 
Homologues for these three genes were indeed identified in Mtb genome and the following observations 
were made in the mutagenesis experiment. At least two distinct biochemical pathways seem to be 
involved in glucan’s biosynthesis as compensation for a glgA mutation could be compensated by rv3032c, 
an additional glycogen synthase encoded in Mtb genome. However, double mutations were not successful 
suggesting that glycogen/glucan production is essential.  Interestingly, the branching enzyme glgB 
(rv1326c) was the only essential gene and it was hypothesized that a toxic polymer accumulated in its 
absence. As glgC involved in glucose activation was not shown to be essential, it was suggested than an 
additional redundant pathway could be present. Finally, and in contrast to the cell biology results 
highlighting glucan’s importance in the host-pathogen interaction, glucan’s absence did not affect the 
outcome of macrophage infections with mutant strains. In vivo studies, however, suggested that glucan 
could play a role in the persisting stage of chronic infections as reduced bacterial loads were observed for 
these mutants. As mentioned, the fact that glgC was not essential for glucan biosynthesis suggested that 
an additional pathway leading to glucose activation was present. Indeed, it was shown that a completely 
different pathway involved in glucan biosynthesis was present in mycobacteria and is dependent on the 
gene glgE (rv1327c) [238]. This enzyme was shown to transfer an activated glucose residue from maltose 
1-phosphate (maltose is a glucose disaccharide consisting of 14 linkage). The gene pep2 (rv0127) 




for the activation step. As occurred with the glcB mutant, glgE mutation also essential. Both genes seem 
to be in an operon and it was postulated that the reason for their essentiality was the accumulation of a 
toxic product. Thus, inhibiting GlgE has become an exciting drug target.  
 Altogether, an initial observation of a capsule-like material surrounding mycobacteria, led to the 
characterization of two glucose polymers present in this bacterial genus: capsular glucan and intracellular 
glycogen. Redundant pathways leading to glucan/glycogen biosynthesis were identified and in 
combination, shown to be essential. Despite all the cell biology studies suggesting that glucan played an 
important role in the host-pathogen relationship, it is currently hypothesized that glucan/glycogen could 
have a more important role either as a glucose depot and/or a trehalose sink. 
 
1.6.2.3 Mycobactin and Iron. 
Iron is an essential micronutrient required by all microorganisms. However, ferric iron is highly 
insoluble and microbial acquisition requires dedicated molecules collectively called siderophores, which 
essentially ‘solubilize’ iron [239].  For pathogenic bacteria the situation is even more precarious as free 
iron inside the host is even scarcer, instead being associated with the host proteins lactoferrin, transferrin 
and ferritin. In addition, the acute phase response occurring in inflammation significantly lowers iron 
concentration further more [239]. Thus, it has been postulated that pathogen iron acquisition could be an 
alternative drug target. Conversely, it has been shown that iron overload in humans, increases the risk 
factor for Mtb morbidity and mortality [240].  
In the early 1900’s, a simple yet transforming observation initiated the field of study in Mtb iron 
procurement: in vitro growth of the until-then non-culturable M. johnei, was achieved by supplementing 
egg media with Mtb extracts (referenced in [241]). Using extracts from M. phlei, the molecule responsible 
for this effect was identified by Snow et al in 1953 and the name “mycobactin” was coined [241]. 
Mycobactin was obtained after subjecting M. phlei to organic extractions followed by adsorption to 




was shown to bind other metals such as copper. The structures of M. phlei [242] and Mtb mycobactin 
[243] were elucidated by Snow in 1965 and the presence of hydroxamic acids previously known to 
coordinate iron binding, suggested that mycobactin was an iron siderophore . During mycobactin’s 
biochemical analysis it was observed that alkali treatment cleaved the molecule into two fragments: 
cobactin and mycobactic acid [243]. In turn, cobactin and mycobactic acid could be broken down to its 
basic constituents via acid hydrolysis. Mycobactic acid was shown to be composed of salicylic acid, a 
serine (Ser) residue, 2-amino-6-hydroxyaminohexanoic acid and fatty acids of different length. Instead, 2-
amino-6-hydroxyaminohexanoic acid and butyrate were shown to be cobactin’s constituents. Lysine 
residues were proposed to be modified to generate the 2-amino-6-hydroxyaminohexanoic acids 
containing the hydroxamic acids that mediate iron binding. From the N-terminus, mycobactin’s unusual 




Figure 1.3 Structure of mycobactin. The structure of mycobactin was deduced from initial studies using 
alkali and acid hydrolysis. Alkali hydrolysis cleaved mycobactin at the ester bond between butyric acid 
and the modified lysine residue, yielding two fragments: mycobactic acid and cobactin. In turn, acid 
Salicylic acid








hydrolysis cleaved mycobactic acid into its constituents: salicylic acid, a cyclized form of Ser, a modified 
lysine residue and a fatty acid that could vary in length. Cobactin was hydrolyzed in acidic conditions into 
butyric acid and a cyclized form of a modified lysine residue. The modified lysine residues provide iron-
binding properties. Adapted from reference [238]. 
 
This oxazoline ring is also covalently attached via an amide bond to a modified lysine residue. At 
the ε-amino group, the lysine residue is substituted with both a hydroxyl group and a fatty acid, 
generating acylated 2-amino-6-hydroxyaminohexanoic acid.  Both modifications generate one of the 
hydroxamic acids participating in iron binding. The modified lysine (acylated 2-amino-6-
hydroxyaminohexanoic acid) is attached to keto-butyrate via an ester bond, which is the target for the 
aforementioned alkali-mediated mycobactin fragmentation into mycobactic acid and cobactin. Finally, an 
amide bond covalently links the keto-butyrate to the second modified lysine residue (2-amino-6-
hydroxyaminohexanoic acid) which is also cyclized and provides the second hydroxamic acid. As 
mentioned, one of the initial findings during mycobactin characterization was the presence of fatty acid of 
varying lengths attached to the lysine residue [241]. It was later shown that long fatty acids are present in 
mycobactins, whereas shorter fatty acids ending with either a carboxy or a methyl ester are present in 
carboxy-mycobatins [244]. This structural difference accounts for the fact that mycobactins are only 
soluble in organic solvents whereas carboxy-mycobactins are soluble in both organics and aqueous 
conditions. As will be discussed below, this structural difference correlates with significantly different 
physiological roles during iron acquisition.  
Once mycobactin and carboxy-mycobactin’s structure had been determined, the field’s focus was 
shifted to determine their biosynthesis and function.  In agreement with the chemical groups characterized 
in mycobactin, initial metabolic labeling experiments determined that both radioactive lysine and acetate 
could be incorporated into the molecule at the 2-amino-6-hydroxyaminohexanoic acid and keto-butyrate, 




suggested that mycobactin could be synthesized by a mixed poliketide/non-ribosomal synthetase. In fact, 
a mixed poliketide/non-ribosomal synthetase had been shown to participate in the synthesis of 
yersiniobactin, another siderophore highly resembling mycobactin (referenced in [246]). Thus, in 1998 
Walsh et al performed bioinformatics analysis to characterize a putative mixed poliketide/non-ribosomal 
synthetase involved in mycobactin’s synthesis [246]. The criteria applied to the bioinformatics analysis 
consisted of finding genes that contained several A domains involved in amino acid activation, a 
poliketide-like module synthesizing and ligating keto-butyrate, but most importantly, the first module had 
to be able to activate and carry or ligate an aryl group such as salicylate. Indeed, a 24 kb 10-gene cluster 
named mbt, was shown to encode proteins putatively having these enzymatic activities. The first 
biochemical characterization of proteins involved in mycobactin biosynthesis was also performed, and 
MbtA and MbtB were shown to activate and carry salicylate, respectively. Subsequently, mutagenesis 
studies targeting mbtB effectively abrogated mycobactin’s production, further substantiating this locus’ 
role in mycobactin synthesis [247].  However, it was noticed that the mbt locus did not encode proteins 
required for lysine hydroxylation and acylation [248]. Thus, transcriptional studies were performed to 
identify other genes induced in iron-limiting conditions, a stimulus known to induce genes in the mbt 
locus. This strategy successfully lead to the identification of a second locus named mbtII, which was 
biochemically characterized and confirmed to modify lysine’s ε-amino group via hydroxylation and 
acylation. Finally, MbtE and MbtF were recently confirmed to participate in mycobactin synthesis by 
activating and inserting the modified lysine residues [249]. Despite some minor controversies, the 
pathway leading to mycobactin biosynthesis is pretty much defined.  
As mentioned above, identification of hydroxamic acids in mycobactin’s structure as well as its 
ability to chelate metals, suggested that mycobactin could be an iron siderophore. This was supported by 
the fact that iron deprivation led to increased mycobacterial mycobactin production [250]. Pioneering 
work by Ratledge et al in the 1970’s and Horwitz in the 1990’s, significantly contributed to understanding 




solubility in organic solvents, Ratledge determined that mycobactin was exclusively present in the 
mycobacterial cell wall but not in the cytoplasm or secreted in the media [251]. Furthermore, detailed 
kinetic analysis showed that after pulsing mycobacteria with radiolabeled iron, it initially bound to and 
was extracted with mycobactin, however, at later time points this was not the case. Thus, it was 
hypothesized that mycobactin’s role was to transport iron across the hydrophobic mycobacterial cell wall. 
A reductase dependent mechanism would then unload iron from mycobactin to finalize iron 
incorporation. Taking in consideration mycobactin’s insolubility in aqueous buffers, it was unclear how 
insoluble iron or iron ligated to host proteins could gain access to mycobactin embedded in the 
mycobacterial cell wall. While evaluating this discrepancy, Ratledge identified a group of water soluble 
mycobacterial siderophores that could solubilize precipitated iron and transfer it to mycobactin [252]. 
These mycobacterial water soluble molecules were collectively named exochelins. However, subsequent 
work has determined that exochelins obtained from avirulent vs. virulent mycobacteria have substantially 
different structures [253] and it has been proposed that the name exochelin and carboxy-mycobactin be 
used in reference to siderophores from avirulent vs. virulent mycobacteria, respectively. Both exochelins 
and carboxy-mycobactins were shown to extract iron from ferritin [244, 253], the host iron storage 
protein. After chelating iron, these molecules would maintain its aqueous solubility and could diffuse so 
as to relay iron to mycobactin. Finally, it was shown that carboxy-mycobactins could also extract iron 
from transferrin and lactoferrin [254], host iron transport molecules. Altogether, the widely accepted 
model for mycobacterial iron acquisition starts with carboxy-mycobactins removing iron from host 
proteins [253, 254]. After diffusing to the mycobacterial cell wall, iron would be transferred to 
mycobactin and shuttled across the cell wall. An ABC-type transporter encoded in the mbtII locus has 
recently been reported to mediate mycobactin transport across the cell membrane [255].  Interestingly, 
conditional mutants in the mycobacterial esx-3 protein secretion apparatus [256] had a similar phenotype 
as mutants in the mycobactin ABC-type transporter. Not only are mutants compromised to grow in iron 




exogenous mycobactin is not able to reverse the defect. Thus, an uncharacterized link between esx-3 and 
the mycobactin ABC-type transporter has been suggested.  
Several lines of evidence suggest that mycobactin is essential for Mtb physiology and 
pathogenesis. Initial transposon mutagenesis studies revealed that several genes of the mbtI locus are 
essential [257]. Even though alternative roles besides mycobactin import have not been defined for the 
esx-3 secretion apparatus, this secretion system is also essential [256]. In addition, mutation of non-
essential genes such as mbtB results in Mtb failure to thrive inside macrophages [247]. Finally, mutation 
of the mycobactin ABC-transport system is not only deleterious for Mtb in vitro growth inside 
macrophages, but more importantly during in vivo growth in mice lungs [255]. Thus, pharmacological 
inhibition of mycobactin synthesis is actively being pursued as an alternative drug target [258].   
 
1.7 Research Objectives. 
 After infection, the initial host-pathogen interaction is mediated by surface and secreted 
molecules. Characterization of the bacterial molecules participating in this initial interaction can lead to 
novel interventions aimed at reducing bacterial growth or minimizing tissue damage. Specifically for Mtb, 
the initial interaction with host pulmonary macrophages can lead to three principal outcomes: Mtb can 
replicate and induce host cell death, Mtb can be eradicated or alternatively, Mtb can persist in a dormant 
stage.  
The first outcome of the host-Mtb interaction is intracellular replication leading to the host cell 
demise. Multiple rounds of Mtb replication and host cell death are presumed to lead to necrotic 
granulomas, a hallmark of human TB. Furthermore, dying macrophages provide a nutrient-replete milieu 
in which Mtb has been suggested to thrive.  As macrophage cell death is a critical component of Mtb 
infection, understanding this event at a molecular level is warranted. In Chapter II, CF from virulent Mtb 




modulate macrophage cell death. Furthermore, the underlying mechanisms that participate in host cell 
death were also determined.   
In Chapters III and IV, the biosynthesis and role in pathogenesis of α-L-polyGln was evaluated. 
α-L-polyGln is a cell wall associated product that has been reported to be exclusively present in Mtb and 
M. bovis. The presence of this molecule in virulent Mycobacterium spp, suggests that it could have an 
important role in pathogenesis. The identification of a pathway leading to α-L-polyGln synthesis could 
provide tools to evaluate its role in pathogenesis. In Chapter III, the biochemical characterization of an 
Mtb enzyme participating in α-L-polyGln biosynthesis was performed. In Chapter IV, Mtb mutants for α-
L-polyGln biosynthesis were biochemically characterized and evaluated in the murine model of TB. The 
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Stable Extracellular RNA Fragments of Mycobacterium tuberculosis Induce Human Monocyte 





2.1  Introduction 
Apoptosis mainly occurs following activation of the caspase cascade by the mitochondrial or 
apical pathways [1, 2]. Mitochondrial release of organelle constituents such as cytochrome c and other 
macromolecules [3], activates the caspase cascade via pro-caspase-9. Alternatively the apical pathway is 
mediated by activation of pro-caspase-8 after cross linking of cell surface receptors belonging to the 
Tumor Necrosis Factor Receptor (TNFR) super family [4]. Both pathways converge to activate the 
executioner caspase-3 [1, 3]. Other alternative pathways designated as “type II” that do not rely on 
caspase 3 activity were described recently [5].  Cell death ensues after cleavage of the cell’s cytoskeleton 
and intracellular enzymes involved in cellular homeostasis, leading to apoptosis hallmarks such as 
exposure of PS in the cell membrane, DNA fragmentation, and cell shrinkage [1, 2]. 
Apoptosis is a process associated with multiple infectious diseases including tuberculosis [6]. 
Several lines of evidence suggest that apoptosis is an important process occurring during mycobacterial 
infection [7]. Recently, caspase activation and TUNEL staining demonstrated that apoptosis is a major 
event occurring in the caseous necrosis of granulomas from Mtb-infected humans [8]. More importantly, 
sst-1 and slca11 (formerly nramp-1), the best characterized murine genetic loci determining 
susceptibility/resistance to mycobacterial infections, were associated with the degree of macrophage 
apoptosis [9-11].  It also is known that macrophage infection with live Mtb  or stimulation with PPD 
activate both the apical and mitochondrial apoptotic pathways by inducing TNF-α production, caspase 
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activation and calcium influx, [11-15]. In contrast dead Mtb and ManLAM inhibit these pathways by 
inducing IL-10, activating Akt and blocking calcium influx [14-18]. 
Several mycobacterial molecules of diverse chemical nature were reported to induce apoptosis in 
various types of host cells. In particular, the 19 kilodalton (kDa) lipoprotein was shown to trigger murine 
and human macrophages apoptosis through TLR-2 via nitric oxide dependent and independent pathways 
[19-22]. Glycolipids such as TDM and LM from Mtb also activate apoptosis [23-25]. TDM induces 
apoptosis of murine natural killer and naïve T cells [23, 24], while LM targets human macrophages [25].  
Contrary to the consistent finding that macrophage apoptosis requires infection with live, metabolically 
active mycobacteria [11], the aforementioned mycobacterial molecules are cell wall associated products 
purified from inactivated cells. However, a systematic purification of secreted products released by 
actively growing Mtb that promote apoptosis has not been performed. 
To further address this issue we purified the major apoptosis-inducing product released by 
virulent Mtb strain H37Rv, and unexpectedly discovered this primary apoptotic factor was stable 
mycobacterial RNA fragments and not a protein or lipid.  Additional experimentation revealed the nature 
of these stable RNA molecules and that their induction of apoptosis was via a caspase-8 dependent, and 
TNF-α and caspase-1 independent mechanism that affected the ability of human monocytes to control 
mycobacterial infection.   
 
2.2  Materials and Methods 
2.2.1  Growth of Mtb. 
To prepare bacilli for monocyte infections, Mtb H37Rv (kindly provided by Laboratorio de 
Micobacterias, Instituto Nacional de Salud, Bogota, Colombia) was grown as a pellicle in Middlebrook 
7H9 medium (Becton Dickinson, Sparks, MD) supplemented with glycerol (Promega, Madison, WI), 
oleic acid-albumin-dextrose-catalase (OADC) (Becton Dickinson), and Tween 80 (Becton Dickinson).  




bacterial clumps, Mtb was suspended in RPMI-1640 with 20% glycerol and probe sonicated (Model 
CV33 Sonics Vibra Cell, Newtown, CT) five times at 2.5 W output for 1 min at 4º C.  The cell 
suspensions were stored at -70
o 
C until use.  CFUs were determined prior to monocyte infections by 
plating 100 μL of serial dilutions of an Mtb stock on Middlebrook 7H10 agar (Becton Dickinson) 
supplemented with glycerol and OADC. Colonies were counted after two weeks of incubation at 37º C. 
 
2.2.2  Isolation of Extracellular RNA. 
For isolation of biologically active fractions, Mtb strain H37Rv was grown in glycerol alanine 
salts (GAS) medium under constant rotation in roller bottles for two weeks at 37C and culture filtrate 
(CF) was obtained as previously described [26]. Similarly, CF was obtained from Mtb HN878, H37Rv 
∆RD-1 (obtained from Dr. Jacobs) in order to evaluate if RNA release also occurred in different strains 
including clinical isolates. Lyophilized CF was suspended overnight at 4C at 1 mg/ml protein 
concentration in ConcanavalinA (ConA) binding buffer [27], and passed over a ConA-Sephadex column 
(Sigma-Aldrich, St. Louis, MO) to remove mannosylated glycoproteins and lipoglycans (LM and LAM). 
The flow-through fraction was collected, concentrated, and washed three times with 20 mM Tris (pH 8.1). 
The CF depleted of mannosylated glycoconjugates (25 mg) was applied to a 1 x 10 cm column packed 
with 5 ml of DEAE-Sepharose (Amersham Biosciences Corporation, Piscataway, NJ) equilibrated with 
Tris 20 mM (pH 8.1).  The column was washed with 20 mM Tris 20 (pH 8.1) and eluted with stepwise 
increases (25 to 1000 mM) of NaCl in 20 mM Tris (pH 8.1). Each fraction was concentrated and dialyzed 
against 10 mM ammonium bicarbonate, filtered sterilized, lyophilized and stored at -20C until used.  
Initial biochemical analysis of mycobacterial RNA was accomplished by digesting fraction 7 for 
increasing periods of time at 37°C with either RNaseA, RNaseT or RNaseVI (Ambion, Austin, TX). 
To prepare highly purified RNA, the material eluted from DEAE-sepharose with 500-1000 mM 
NaCl was suspended in 0.1 ml of 10 mM ammonium bicarbonate, 1 mM MgCl2 to a final concentration of 




free Proteinase K (Sigma-Aldrich) for 8 h at 37°C at a final concentrations of 0.04 mg/ml. The digested 
material was partitioned with an equal vol of phenol:chloroform:isoamyl alcohol (25:24:1) followed by an 
equal vol of chloroform:isoamyl alcohol (24:1).  RNA was precipitated from the final aqueous phase with 
0.1 vol of 3 M sodium acetate (pH 5.3) and 2.5 vol of ethanol, and collected by centrifugation (13,000 x 
g, 30 min).  Final purification was performed by preparative gel electrophoresis using a denaturing urea 
poly-acrylamide gel [28].  RNA preparations were suspended in PBS, and filter sterilized. The gel 
purified RNA was incubated overnight at 37 C with or without 0.1 U/μl RNaseV1 (Ambion) and 
lyophilized.  Endotoxin contamination was determined using the Lymulus Amebocyte Lysate assay (Bio-
Whittaker, Walkersville, Maryland).  RNA concentration was determined by densitometry using Quantity 
One software (Version 4.1.1 Bio-Rad, Hercules, CA) after resolving the Mtb RNA and standards by 
denaturing urea poly-acrylamide gel electrophoresis and staining with ethidium bromide.  To assess for 
the presence of LAM, samples (1 g) were subjected to Western blot analysis using the LAM specific 
monoclonal antibody CS-35 as the probe [29].  As an alternative and faster method to obtain 
mycobacterial RNA, lyophilized CF was directly extracted with organic solvents and precipitated with 
ethanol as described above. 
To evaluate the kinetics of mycobacterial RNA release into the CF, low passage Mtb H37Rv was 
centrifuged at 3,000 rpm and washed three times with medium. Bacterial pellets were suspended in GAS 
medium and used to inoculate 400 ml cultures. CF was collected at different time points of incubation and 
processed.  Alternatively, CF was precipitated overnight at -20C with three volumes of ice cold acetone.  
The precipitated material was collected by centrifugation and analyzed by SDS-PAGE [30].   
 
2.2.3  RNA cloning and sequencing. 
Gel purified RNA was cloned as described by Elbashir and Lau for small interfering (si)RNA [28, 
31]. Briefly, the RNA was dephosphorylated and ligated to the 3’adaptor [5’ phosphorylated uuu AAC 




(Dharmacon, Lafayette, CO)]. The ligation products were gel purified, phosphorylated at the 5’ end with 
T4 polynucleotide kinase (New England Biolabs, Beverly MA) and ligated to the 5’ adaptor sequence [5’ 
TAC TAA TAC GAC TCA CT aaa 3’ (Dharmacon)].  Synthesis of cDNA from adaptor-ligated RNA was 
accomplished using the Thermoscript kit (Invitrogen) and the reverse primer (5’ GAC TAG CTG GAA 
TTC AAG GAT GCG GTT AAA-3’).  Double stranded DNA was generated by PCR amplification with 
the reverse primer, and the forward primer (5’CAG CCA ACG GAA TTC ATA CGA CTC ACT AAA-
3’).  An aliquot of the PCR products was digested with EcoRI (New England Biolabs) and ligated to form 
concatemers that were resolved by agarose gel electrophoresis and extracted.  Overhangs of poly-A were 
added with Taq Platinum polymerase in the presence of dNTPs.  The DNA fragments were ligated with 
pCR 2.1 TOPO vector (Invitrogen), transformed into TOP10 E. coli (Invitrogen) and individual clones 
grown for plasmid isolation. The cloned DNA fragments were sequenced through Macromolecular 
Resources Facility (Colorado State University).   Plasmid sequences were analyzed with the Vector NTI 
software (BioExchange, San Francisco, CA) to identify the 5’ and 3’ adaptor sequences, and the 
intervening regions were searched against the Mtb genome, via BLAST analysis. 
 
2.2.4  Monocyte infection and stimulation. 
 Venous blood (120 ml) was obtained from healthy volunteers after signing an informed consent 
form describing the protocol for human subjects, which was approved by the Ethics Committee of the 
Facultad de Medicina, Universidad de Antioquia.  The blood was defibrinated by continuous agitation 
with glass beads, centrifuged, and the buffy coat suspended in 3 vol of PBS.  Mononuclear cells were 
separated on Histopaque, density 1.077 g/ml (Sigma-Aldrich) by centrifugation at 400 x g, and cell 
viability determined by trypan blue exclusion.  Cells were suspended at 1x10
6
 cells/ml in RPMI-1640 
medium (Gibco BRL) without antibiotics and supplemented with 0.5 % heat-inactivated autologous 
serum (AS). The ratio of monocytes was determined by flow cytometry with anti–CD14-PE staining 
(clone M5E2, Becton Dickinson-Pharmingen). CD14+ cells (2x10
5




bottomed culture plates (Corning, Corning, NY) for 4 h at 37º C, and non-adherent cells removed by 
repeatedly washing with prewarmed PBS with 0.5% AS. RPMI-1640 supplemented with 10% AS (1 ml) 
was added to each well. The number of adherent cells was determined by mechanical removal and 
counting in a haemocytometer.  
Adhered monocytes were infected with viable Mtb at a multiplicity of infection of 5:1 for 4 h. 
Extracellular bacilli were removed by repeatedly washing with prewarmed PBS. RPMI-1640 
supplemented with 10% AS (1 ml) was added to each well.   The CF and RNA preparations were added at 
1 μg/ml protein or nucleic acid concentration, respectively. Cultures were incubated at 37º C, 5% CO2 for 
96 h, and the number of viable bacilli determined by plate counting after lysis of host cells with water 
containing 0.1% saponin [12].    
For analysis of apoptosis induction or cytokine production the CF, individual CF fractions, and 
purified mycobacterial RNA or rabbit mRNA (Sigma) were added at 1 μg/ml protein or nucleic acid 
concentration, respectively. PPD was used as a control at 10 g/ml.  Induction of human monocytes with 
anti-CD95 was performed by incubating 10
6
 cells with 2 g/ml of anti-human CD95 (BD Pharmingen).  
 
2.2.5  Determination of intracellular TNF and IL-10 by flow cytometry. 
Evaluation of intracellular cytokines was based on previous methods [14]. Briefly, cells were 
cultured for 18 h with mycobacterial products at 37°C and 5% CO2. Brefeldin A (1 g/ml) was 
subsequently added and the cultures were incubated for 6 h. Cells were washed twice with PBS, fixed 
with 2% paraformaldehyde in 0.1 M NaH2PO4 for 20 min at room temperature, and harvested. 
Intracellular cytokine labeling was achieved by washing the cells once with permeabilization buffer [PBS 
(pH7.4) containing 1% PHS, 1% BSA, 0.1% sodium azide and 0.1% saponin], and incubating in 200 l of 
permeabilization buffer containing 2.5 g mAb anti-TNF--FITC and 2.5 g anti-IL-10-PE, or IgG2a-
FITC and IgG2b-PE as isotype controls for  30 min at 4ºC. Cells were washed three times with PBS 




non-permeabilized cells were stained with the TNF-α and IL-10 specific antibodies. Thereafter cells were 
analyzed by flow cytometry with a FACS EPICS XL (Coulter, Hialeah, FL).  The percentage of positive 
cells and the mean fluorescence intensity were determined using Windows Multiple Document Interface 
2,8 software (WinMDI, Scrips Research Institute, La Jolla, CA). 
 
2.2.6  Determination of cell death by flow cytometry using annexinV and propidium iodide. 
Cells were cultured for 48 h in the presence of the mycobacterial products and incubated for 30 
min at RT in darkness with 5 l of FITC-labeled annexinV (Molecular Probes, Invitrogen), 10 l of 
propidium iodide at 1 µg/ml (ICN Biomedicals, Costa Mesa, CA), and 100 l of PBS.  Cells were washed 
with PBS and analyzed by FACS [11].  
To assess whether apoptosis was dependent on TNF-α signalling, monocytes were incubated for 1 
h with purified anti–TNF-α (MAb11, Becton Dickinson-Pharmingen), followed by the addition of the 
different stimuli for 36 h. Thereafter, annexinV staining was evaluated. 
 
2.2.7  Caspase activation.  
Caspase activation was measured at 48 h post addition of Mtb products to the adhered monocytes.  
The activation of caspase-1, 3, and 8 was determined by flow cytometry as previously described [12].  To 
evaluate whether caspase activation was required for apoptosis, monocytes were incubated with 10 nM of 
caspase-1 (YVAD.fmk), caspase-3 (DEVD.fmk), or caspase-8 (IEMD.fmk) specific inhibitors (Sigma-
Aldrich) for 1 h prior to the addition of mycobacterial products.  Dimethylsulphoxide and trichloroacetic 
acid were also assessed as buffer controls.  Exposure of PS was then evaluated by staining with annexinV. 
 
2.2.8  Statistical analysis.  
Experiments were performed a minimum of three independent times. Data were analyzed with 




performed by one-way ANOVA. Statistical significance was tested at p < 0.05 as the critical value. Data 
are presented as the mean  SEM. 
 
2.3  Results 
2.3.1  Purification and identification of apoptosis inducer.  
Infection of human derived monocytes for 48 h with live, virulent Mtb (MOI of 5:1) induces early  
apoptotic events that are defined by annexinV positive and propidium iodide negative staining [12].  
However, apoptosis does not occur with formaldehyde-fixed or heat-killed Mtb.  Thus, it was 
hypothesized that induction of apoptosis in human monocytes was due to a secreted product of Mtb [11].  
Towards purifying the responsible mycobacterial product(s), the CF from in vitro cultures of Mtb H37Rv 
was shown to induce monocyte cell membrane damage similar to the live infection [12].   As a first step 
in the purification scheme the ManLAM, previously shown to inhibit macrophage apoptosis [15, 17, 18], 
was removed by ConA-affinity chromatography to give Man-LAM depleted CF (CF-Man). This material 
was further resolved on DEAE-Sephadex with a stepwise gradient of sodium chloride from 0-1000 mM, 







Figure 2.1 Fractionation of CF by chromatography. A. SDS-PAGE and silver staining of fractions of 
CF after ConA affinity (CF-Man) and DEAE-Sepharose chromatography (F1 to F7). B. Western blot with 
CS35 anti-LAM showing that ConA chromatography efficiently removed ManLAM from the CF. Mw 
denotes the molecular mass standards.     
 
Evaluation of each fraction for induction of apoptosis via annexinV staining, demonstrated that 
fraction 7 induced the strongest response with nearly 70% of human monocytes displaying early cell 
membrane damage (Fig. 2.2) (a small percentage of cells was dually labeled with annexinV and 
propidium iodide, data not shown). Considerable activity was also associated with fraction 5 and 6.  
However, further purification and characterization was targeted to fraction 7 as it was the most potent.  
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Figure 2.2 Apoptosis-inducing activity of CF fractions. Separation of CF by ConA affinity 
chromatography and DEAE-Sepharose chromatography yielded a fraction with potent apoptotic activity 
in human monocytes. Apoptosis induced by DEAE-Sepharose fractions 1 to 7 (F1 to F7) and 
unfractionated CF was measured by flow cytometry and presented as percentage of human monocytes 
that stained annexinV positive *** significance p<0.001, ** significance p<0.01, * significance p<0.05 as 
compared to unstimulated control.  
 
The chemical nature of the apoptotic-inducing mycobacterial molecule(s) present in fraction 7 
was initially determined by assessing the loss of stimulation after differential enzymatic digestion with 
Proteinase K, DNaseI, or RNaseV1.  Unexpectedly, the apoptosis-inducing activity of fraction 7 was 
completely abrogated by treatment with RNaseV1, as there was a 95% reduction in the number of 
annexinV positive cells.  Digestion with DNaseI had no impact, whereas Proteinase K treatment increased 
the number of monocytes in early apoptosis (80% of monocytes), but was not statistically significant (Fig. 
2.3).  Treatment of monocytes with enzymes alone had a negligible effect on apoptosis (data not shown).  



























Figure 2.3 RNA in DEAE-Sepharose Fraction 7 induces apoptosis in human monocytes. Apoptosis 
induced by DEAE-Sepharose Fraction 7 (F7), F7 treated with proteinase K (F7+ProtK), F7 treated with 
DNase1 (F7 + DNase1), F7 treated with RNaseV1 (F7 + RNaseV1), CF, CF treated with RNaseV1 
(CF+RNaseV1), CF-Man, CF-Man treated with RNaseV1 (CF-Man+RNaseV1). Apoptosis was measured 
by flow cytometry and presented as percentage of human monocytes that stained annexinV positive. *** 
significance p<0.001, ** significance p<0.01 as compared to unstimulated control or between treated 
samples.  
 
Evaluation of fraction 7 by SDS-PAGE and ethidium bromide or silver staining pre and post 
enzymatic digestions confirmed the presence of nucleic acids in fraction 7.  These nucleic acids migrated 
at < 20 kDa by SDS-PAGE and were only eliminated by digestion with RNaseV1 (Fig. 2.4A and B). It 
was also noted that Proteinase K, but not RNaseV1 or DNaseI treatment resulted in the elimination of 
proteins present in fraction 7.  
 
































Figure 2.4 Fraction 7 is enriched with RNA. A. SDS-PAGE with ethidium bromide staining and B. 
silver staining of F7 and F7 treated with proteinase K, DNase1, or RNaseV1. By silver staining, it 
appeared like proteinase K treatment digested the majority of molecules present in fraction 7. Instead, 
ethidium bromide staining confirmed that RNA was present in significant concentrations in fraction 7, 
remaining after incubating with proteinase K or DNaseI but not with RNaseV1.  
 
To obtain structural information about the Mtb RNA, it was subjected to enzymatic digestion with 
RNases targeting single or double stranded RNA. As observed in Figure 2.5, the Mtb RNA was extremely 
susceptible to RNaseV1, which cleaves double stranded bases. In contrast, the Mtb RNA displayed 
intermediate to high resistance when enzymatically digested with RNaseA and RNaseT1 respectively, 
which cleave single stranded bases. Altogether, these results suggested that the Mtb RNA was 
predominantly double stranded. 
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Figure 2.5 Treatment with RNaseV1 efficiently digested RNA present in fraction 7. Ethidium 
bromide staining of a SDS-PAGE, showed that enzymatic digestion with RNaseV1, led to rapid and 
complete digestion of the RNA present in fraction 7.  
 
Furthermore, RNaseV1 treatment was additionally performed on CF and CF-Man to determine 
the RNA’s contribution to monocyte cell membrane damage induced by these complex fractions. As 
determined by evaluating the samples pre- and post-RNaseV1 digestion, the RNA was responsible for 
almost 70 and 90 % of the biological activity from CF and CF-Man, respectively (Fig. 2.3). 
 
2.3.2 Definition of Biologically Active RNA.  
To confirm that RNA was responsible for the biological activity, fraction 7 was digested with 
DNaseI and Proteinase K, extracted with phenol/chloroform/isoamyl alcohol (25:24:1) to remove 
contaminating lipids and undigested proteins and the resulting RNA was gel purified from a denaturing 
urea-polyacrylamide gel  (Fig. 2.6A). 
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Figure 2.6 Human monocyte apoptosis is specifically induced by gel purified mycobacterial RNA. 
A. SDS-PAGE with ethidium bromide (left) and silver stained (right) RNA gel purified from F7 (gpRNA) 
and treated with RNaseV1 (gpRNA+RNaseV1). B. Monocyte apoptosis induced by gpRNA untreated or 
treated with RNaseV1, anti-CD95 untreated or treated with RNaseV1 (anti-CD95+RNaseV1) and rabbit 
mRNA. Significance as described above.  
  
Gel purified RNA was subjected to RNaseV1 treatment and compared to untreated RNA in the 
biological assay with human monocytes.  The apoptotic activity of the gel purified RNA was retained 
after purification (72% apoptotic monocytes), and this activity was abrogated by RNaseV1 treatment 
(7.5% apoptotic monocytes) (Fig. 2.6A and B). As a control to ensure RNaseV1 was not modulating 
monocyte apoptosis via a different mechanism, we evaluated cell membrane damage induced by the well 
characterized anti-CD95 pathway in the presence or absence of RNaseV1.  No difference in AnnexinV 
positive cells was observed when monocytes were co-incubated with anti-CD95 and RNaseV1 versus 
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induced by other sources of exogenous RNA, monocytes were incubated with rabbit mRNA; no induction 
of monocyte apoptosis was observed (Fig. 2.6B). These results confirmed that fraction 7 obtained from 
Mtb H37Rv CF is enriched in RNA, which was the sole inducer of human monocytes cell membrane 
damage.  
To further define the RNA present in the CF the same strategy utilized to clone siRNA was 
adopted [28, 31]. From a library of cDNA clones plasmids were purified from a total of 33 clones. 
Sequence analyses of the plasmid inserts revealed that the Mtb RNA present in the CF predominantly 
consisted of tRNA and rRNA with lengths between 30 to 70 bases (Table 2.1).   
 









Cloned RNA Number of Clones2
Table 2.1 Sequence analysis of cloned extracellular mycobacterial 
RNA fragments present in Mtb CF 
1The specific regions of the RNA sequences represented by each clone are depicted in Figure 2.7




Of the 17 tRNA sequences, a majority corresponded to tRNA
Asp
 fragments and a total of 15 
clones represented 16S or 23S rRNA fragments, indicating selectivity in the RNA species released into 
the CF.   Sequence alignments for both the 16S and 23S rRNA showed that the majority of fragments 
originated from different regions of the mature rRNA and only occasionally did two fragments 
correspond to the same region (Fig. 2.7A and B). Alignment of the cloned tRNA fragments determined 







Figure 2.7 Contig alignments between sequenced RNA fragments and 16S rRNA, 23S rRNA or 
tRNA
Asp
. Contigs were generated using Vector NTI software to align sequences from the cloned RNA 







contigs obtained for 16S rRNA (A), 23S rRNA (B) or tRNA
Asp
 (C). For each sequenced fragment, 
numbers represent the nucleotide position in the respective gene.  
 
2.3.3  Kinetics of RNA Release.  
As tRNA and rRNA are highly abundant intracellular constituents, kinetic studies were 
performed to evaluate when the Mtb RNA started to accumulate in the CF and if its presence was 
attributable to the CF being harvested from late logarithmic (14 day), presumably autolytic, cultures . 
After extensively washing cells with GAS medium, CF was collected at different time points (0 to 28 
days) and analyzed by SDS-PAGE and ethidium bromide staining. Interestingly, the presence of Mtb 
RNA paralleled Mtb protein secretion into the CF.  Specifically, the RNA began to accumulate between 





Figure 2.8 Extracellular mycobacterial RNA accumulate in the CF with similar kinetics as the rest 
of the mycobacterial secretome.  Low passage Mtb H37Rv was thoroughly washed three times in GAS 
media and cultured in roller bottles. At different days (indicated below Figure) CF was harvested, filter 















sterilized and concentrated. CF was analyzed by SDS-PAGE plus silver (left gel) or ethidium bromide 
(right gel) staining.  
 
Similar results were obtained when the CF was immediately precipitated with acetone after 
harvesting, to rule out the possibility that higher molecular weight RNA species were being degraded to 
30 to 70 bases during the protracted processing of CF (not shown).  These results suggest that in addition 
to secreted proteins, Mtb H37Rv actively releases rRNA and tRNAs into the CF and these accumulate as 
stable products starting in early log phase. 
 
2.3.4  Different Mtb strains also release RNA into the CF.  
To rule out that RNA release by Mtb was not an isolated event occurring only in a laboratory 
strain, CF was generated from the Mtb clinical isolates HN878 and CDC1551. Additionally, H37Rv and 
H37Rv∆RD1strains obtained from Albert Einstein Institute, Bronx, NY (kindly provided by Dr. Jacobs) 
were also evaluated to determine if RNA release was a characteristic of CSU-adapted strains. As can be 
observed in Figure 2.9, after 14 days of culture, CF obtained from all the strains contained RNA 
migrating at approximately 20 kDa (CDC1551 not shown). Thus it was concluded that RNA release into 







Figure 2.9 RNA is also released by other strains of Mtb. CF was generated from a clinical isolate 
(HN878), an H37Rv mutant (∆RD1) and the lab strain H37Rv obtained from two different sources (CSU 
and Albert Einstein Institute, AE). Lyophilized CF was extracted or not with organic solvents and 
precipitated with ethanol. After resolving by SDS-PAGE and visualization by silver or ethidium bromide 
staining, RNA migrating <20 kDa was detected in the CF of all the strains 
 
2.3.5  Mechanism of RNA Induced Apoptosis. 
 In order to assess the mechanism by which RNA induced apoptosis, TNF-α and IL-10 production 
was evaluated since the balance between these two cytokines is a factor in modulating cell death [12-14, 
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induced by the positive control, PPD (Fig. 2.10A).  However, in contrast to PPD, the cell membrane 




Figure 2.10 Human monocyte apoptosis induced by extracellular Mtb H37Rv RNA is TNF-α 
independent.  A. TNF-α (open bars) and IL-10 (closed bars) induced in human monocytes treated with 
DEAE-Sepharose Fractions 7 (F7), gel purified Mtb H37Rv (gpRNA) and purified protein derivative 
(PPD) from Mtb were measured by flow cytometry. B. Treatment of monocytes with anti-TNF-α for 1 h 
prior to stimulation with  F7, gpRNA, or PPD demonstrated no alteration in annexinV staining for 
monocytes incubated with F7 or gpRNA, but did result in decreased annexinV staining for monocytes 
incubated with PPD (closed histogram). The open histograms with a solid line correspond to unstimulated 
monocytes.  
 
Given the importance of caspase activity in TNF-α dependent and independent apoptotic 











































performed to determine whether Mtb H37Rv RNA activates caspases.  Mtb RNA strongly activated 
caspase-8 (LETD-FMK), intermediately activated caspase-3 (DEVD-FMK) and had negligible effect on 
caspase-1 (YVAD-FMK), as determined by flow cytometry (Fig. 2.11A).  In contrast, PPD activated 
caspase-1, 3 and 8 to similar extents.  Consistent with these data, only caspase-8 inhibitor abrogated the 
RNA induced cell membrane alterations, whereas all the caspase inhibitors significantly abrogated PPD’s 
activity (Fig. 2.11B). These findings provide evidence that Mtb RNA activates apoptosis via a caspase-8 
signaling mechanism and that this route of activation differs from those observed for other mycobacterial 




Figure 2.11 The Mtb RNA’s activity is caspase-8 dependent. A. Flow cytometry demonstrated Mtb 



















Mtb H37Rv RNA gpRNA (open histogram with dotted line) or PPD (open histograms with solid line) for 
48 h and caspase activity was determined by flow cytometry after staining with FLICA-YVAD-FMK 
(caspase-1), FLICA-DEVD-FMK (caspase-3), or FLICA-LETD-FMK (caspase-8). Tissue culture 
medium without RNA or PPD was used as the control (closed histogram). B. Stimulation of apoptosis 
based on annexinV staining was measured for monocytes stimulated with gpRNA or PPD (top histogram) 
and when the monocytes were pretreated  for 1h with 10 nM caspase-1 (YVAD-FMK), caspase-3 
(DEVD-FMK), or caspase-8 (LETD-FMK) inhibitors (lower histograms). 
 
Lastly, the ability of RNA to alter monocyte’s control of mycobacterial growth was examined by 
treating Mtb infected human monocytes with purified RNA.  Determination of colony forming units 
(CFUs) after four days of incubation revealed a greater than two fold increase in the number of bacilli 
associated with RNA treated vs. untreated monocyte cultures (Fig. 2.12). Furthermore, digestion with 




Figure 2.12 Mtb H37Rv RNA altered human monocyte’s ability to control Mtb infection.  CFUs were 
determined for human monocytes infected with Mtb H37Rv and incubated for four days in the presence of 
















1 µg/ml of Mtb H37Rv CF, purified RNA (gpRNA), or purified RNA digested with RNaseV1 (gpRNA + 
RNaseV1).  The presence of CF or gpRNA resulted in a significant increase in CFUs as compared to the 
untreated infected monocytes (Control).  Data represent the mean ± SEM of 3 replicates of the same 
experiment (*p<0.03). 
 
2.4  Discussion. 
Understanding apoptosis at a molecular level is critical to elucidating the pathogenesis of 
tuberculosis. Recent in vivo evidence suggests that apoptosis is an active mechanism in necrotic 
granulomas [8], a pathological hallmark of tuberculosis that is widely accepted as being key to the 
bacterium’s persistence and transmission [33]. Our search for a Mtb product that replicated the apoptotic 
activity observed with a live Mtb infection [11], led to the surprising discoveries firstly that low molecular 
weight RNA fragments were secreted into the CF, long known as a source of major Mtb  protein antigens, 
and secondly that these RNA fragments were major apoptotic factors. The role of mycobacterial RNA in 
the pathogenesis of tuberculosis was initially proposed by Youmans and colleagues in the 1960s and 70s 
[34, 35].  In their studies, ribosomal RNA obtained from whole cells increased bacterial burden when 
introduced into infected animals. Our experiments demonstrated that apoptosis induced by RNA 
significantly altered the ability of the monocytes to control Mtb growth.   Although these studies did not 
assess in vivo growth of Mtb in a manner similar to Youmans and colleagues, they do provide support and 
a potential explanation for the early observations.     
The activation of specific caspases is central to the induction of apoptosis and classically 
differentiates between the mitochondrial and apical pathways [1, 5].  The strong induction of caspase-8 
activity with the Mtb RNA fragments and the prevention of apoptosis with a caspase-8 inhibitor provided 
convincing evidence for the induction of apoptosis via the apical pathway.  The Mtb RNA fragments also 
stimulated the production of TNF-α and although TNF-α is primarily recognized as a mediator of 




anti-TNF-α antibodies did not inhibit the induction of apoptosis by Mtb RNA fragments.  Our previous 
work as well as that of others also indicated a potential role for caspase-1 in Mtb mediated apoptosis [14, 
15]; however, the current studies demonstrated that Mtb RNA induction of apoptosis was caspase-1 
independent.  This  lack of caspase-1 involvement also suggests that the Mtb RNA is not inducing an 
inflammasome response [36].  We did not, however, investigate whether the RNA fragments inhibited 
caspase-1 activity as has been recently reported to occur with Mtb infections [37]. In the apical pathway 
of apoptosis, caspase-3 is defined as the effector caspase and is downstream of caspase-8 [1, 5]. Our 
studies unexpectedly revealed that treatment of monocytes with Mtb RNA fragments only resulted in a 
modest increase in caspase-3 activity, as compared to that induced by PPD, and inhibition of caspase-3 
failed to prevent Mtb RNA induced apoptosis.  Thus, while the caspase-8 data suggest that the excreted 
Mtb RNA fragments stimulate monocyte apoptosis via the apical pathway, the non-essentiality of TNF-α 
or caspase-3 indicated an alternative mechanism of induction. One potential mechanism is that described 
for the “type II” apoptotic cells where capase-8 activation directly induces a mitochondrial pathway of 
apoptosis and is associated with FAS or TNF-related apoptosis-inducing ligand (TRAIL) mediated 
signaling [5]. Future work will assess the specific apoptotic pathway and signaling events stimulated by 
excreted Mtb RNA.  
As evidenced by susceptibility to RNaseV1, the RNA fragments characterized in this study 
possess numerous dsRNA hairpin structures. Studies with other viral and bacterial dsRNAs demonstrate 
that interactions with TLR-8 or cryopyrin led to caspase activation [32, 38, 39]. Interactions between 
dsRNA and TLR-8 result in caspase-8 activity [38, 39] and TLR-8 polymorphisms are associated with 
increased susceptibility to tuberculosis [40]. Thus, activation of host monocytes via TLR8 would fit the 
data presented for the Mtb RNA fragments.  In contrast, bacterial RNA interactions with cryopyrin 
activate caspase-1 [32], an event that did not occur with the Mtb RNA fragments.   It must also be 
considered that tRNA and rRNA undergo multiple species specific modifications [41, 42] that could alter 




mammalian mRNA which is known to possess different modifications [42], did not activate monocyte 
apoptosis as the mycobacterial RNA fragments. Therefore, other PRRs for the Mtb RNA fragments need 
to be considered in future studies such as Protein Kinase R (PKR) that is activated in macrophages 
infected with M. bovis BCG [43], the endosomal TLR-3 and TLR-7 [44, 45], and cytoplasmic receptors  
Rig-1, MDA-5, DAI and Nod [46].   
Multiple classes of pathogen derived macromolecules are defined as modulators of innate 
immunity, including RNA and DNA [47].  However bacterial nucleic acids typically are not described as 
being extracellular products. Thus, the isolation of the small RNA fragments from the CF of Mtb as the 
primary apoptotic factor was unexpected.  The possibility that release of RNA fragments is due to lysis of 
Mtb was investigated by following the kinetics of RNA release.  Such analyses revealed that 
accumulation of the secreted RNA fragments paralleled the kinetics of Mtb protein secretion.  RNA was 
observed in the CF as early as 2 days, the same point in time used to distinguish truly secreted proteins 
from those resulting from autolysis [48].  Additionally, there did not appear to be a massive accumulation 
of extracellular RNA during late log-phase that would imply cell lysis as the underlying mechanism.  
Although a specific mechanism of active transport of the RNA fragments was not identified, there are 
suggestions by others that the ESX (Type VII) secretion apparatus of Mycobacterium spp. is involved in 
DNA transfer or conjugation [49].  Accumulation of mycobacterial RNA was also observed in the CF of 
H37Rv∆RD-1, ruling out the specific ESX apparatus encoded by this region. Nevertheless, there are 
multiple ESX like secretion modules encoded on the Mtb genome [50] and investigation into whether one 
or more of these is involved in  secretion of the RNA fragments is on-going.  An additional, novel 
secretion mechanism that could be responsible for RNA release was recently unveiled in mycobacterial 
species [51]. It was demonstrated that mycobacteria release vesicles with potent immunomodulatory 
activity both in vivo and in vitro. Even though most of this activity was attributed to lipoprotein 
enrichment in these vesicles, it was also shown that cytoplasmic components such as DnaK (and possibly 




bacterial lysis or cell division contributed to RNA release. It is well known that other intracellular 
molecules such as heat shock proteins, strongly activate the host immune system during in vivo 
mycobacterial infections [52, 53].  It is possible that early bacterial lysis allows for the release of 
significant quantities of mycobacterial proteins and RNA in host granulomas where it could induce host 
cell apoptosis leading to necrotic granulomas. It was originally expected that bacterial lysis only occurred 
during the chronic phase of in vivo infection. However, recent studies using plasmid loss as a “replication 
clock”, revealed that bacterial lysis is an ongoing event during the log phase of bacterial replication [54]. 
Thus mycobacterial RNA could also be accumulating and modulating the environment as granulomas are 
developing, in order to favor bacterial survival.  In this context, it was interesting to observe that 
mycobacterial RNA fragments affected the monocyte’s ability to control infection despite stimulating 
TNF-α production.  TNF-α production is required for both granuloma formation and bacterial control but 
alone is not sufficient [33]. The anti-inflammatory cytokine IL-10 which was also induced by the RNA 
fragments could be counteracting TNF-α.  Alternatively, it was recently observed that intranasal delivery 
of the synthetic RNA poly-IC, increased bacterial counts in tuberculosis infected animals by stimulating 
type-I IFNs [55]. Even though we did not evaluate this family of cytokines, we obtained similar enhanced 
monocyte “permissiveness” to Mtb infection when stimulating with mycobacterial instead of a synthetic 
RNA.  The stability of the Mtb RNA fragments must also be considered with respect to accumulation 
within the host.  The complex secondary structure of the tRNA and rRNA might protect against host as 
well as bacterial RNase activity, and allow for its stable accumulation in the granuloma. Experiments with 
TLR-9 KO mice have suggested that mycobacterial DNA is being sensed by the host immune response 
[56], thus it is not  unconceivable to expect a similar situation occurring with mycobacterial RNA.  
A hallmark of Mtb is the bacterium’s ability to interact with the host immune response in a 
manner that allows for its own survival and at the same causes active disease in only a relatively small 
percentage of the individual it infects.  With this perspective it is not surprising that this pathogen has 




involvement in this process of a bacterial product that is released or secreted only during active growth is 
not surprising.   Thus, the continued elucidation of the exact signaling mechanisms exploited by Mtb to 
induce apoptosis as well as the process the bacterium utilizes to release RNA fragments will allow further 
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Characterization of Rv2394, a homologue of the γ-glutamyltranspeptidase CapD 
 
3.1 Introduction. 
In higher eukaryotes, γ-glutamyltranspeptidases (GGTs) were initially described to participate in 
the glutathione (GSH) cycle, a term coined by Meister [1-3]. GSH is a tri-peptide consisting of a Glu, 
cysteine (Cys) and glycine (Gly) residues. In contrast to the conventional peptide link between the alpha-
carboxyl and amino groups of two adjacent amino acids, the Glu and Cys residues of GSH are covalently 
linked via a γ-linkage between a Glu γ-carboxyl group and a Cys amino group.  In turn, the Cys is linked 
to the Gly residue by a conventional peptide bond. GSH is critical for maintaining intracellular redox 
homeostasis due to the reducing power of Cys thiol group [3]. GSH is also released extracellularly where 
it participates in detoxification of endogenous products such as leukotrienes or foreign products such as 
xenobiotics.  Detoxification begins with the enzyme glutathione-S-transferase which covalently links 
GSH’s free thiol group to a wide array of compounds. After GGT removes the γ-linked Glu residue, 
dipeptidases cleave the C-terminus Gly and finally the free N-terminus of the thiol-linked Cys is 
acetylated [3]. Mercapturic acids are the end products of this detoxification reaction and are readily 
excreted by the body. Any remaining extracellular GSH that is not used for detoxification is recovered 
through a process that also starts by the GGT-mediated cleavage of the γ-linked Glu residue. This is of 
upmost importance specially for recovering Cys which is in limited intracellular concentration [1].   
 Several different functions have been attributed to conserved, extracellular bacterial and lower 
eukaryote GGTs. In E. coli it was shown by a simple yet elegant study that several amino acid auxotrophs 
could survive in medium supplemented with a di-peptide of Glu linked via its γ-carboxyl group to the 
essential amino acid [4]. In contrast, auxotrophs in which the extracellular GGT had been mutated did not 
thrive under these same conditions suggesting that uptake of the essential amino acid was dependant on 




in Glu uptake when presented with substrates such as GSH and glutamine (Gln) [5]. H. pylori does not 
seem to encode for a Gln transporter and instead has a functional Na
+
-dependant Glu transporter. Thus, 
when using Gln as the Glu source, the GGT performs a hydrolysis reaction generating Glu and ammonia 
[5]. In contrast, Saccharomyces cerevisiae and Francisella tularensis (F. tularensis) GGT participate in 
the GSH cycle required for sulfur and Cys uptake, thus resembling the role of GGT in higher eukaryotes 
[6, 7]. Finally, two novel roles were recently attributed to extracellular GGTs in H. pylori and H. 
capsulatum. H. pylori GGT was identified as a protein inducing gastric epithelial cell apoptosis [8, 9]. 
This was confirmed by showing that recombinant H. pylori GGT expressed in E. coli recapitulated the 
native GGT’s apoptosis-inducing activity. Furthermore, gastric epithelial cell apoptosis was attributed to 
the GGT-mediated catabolism of GSH into Glu and Cys-Gly [9]. This latter product is highly reactive and 
led to increased oxidative stress of gastric epithelial cells. Similarly, the increased reactivity of Cys-Gly 
generated by H. capsulatum GGT was harnessed to reduce insoluble ferric ion to the more soluble and 
acquirable ferrous ion [10].  Therefore, it can be concluded that despite sharing significant homology 
between different species, GGTs are rather promiscuous in terms of substrate specificity and function. In 
essence, GGT can accomplish multiple functions by targeting the γ-linkage between Glu and other 
functional groups as diverse as ammonia (in Gln), amino acids (as in the auxotrophs), peptides (GSH) or 
any GSH-modified compound (lipids and xenobiotics) targeted for excretion as mercapturic acids. 
 A completely different role was identified for CapD, a GGT present in Bacillus anthracis (B. 
anthracis). In addition to the hydrolysis reactions described above, CapD was shown to mediate a 
significantly more important transpeptidase reaction participating in B. anthracis capsule biosynthesis 
[11]. B. anthracis capsule consists of poly-γ-D-Glu, a polymer of D-Glu residues linked through a γ-
linkage [11-14]. CapD was shown to link poly-γ-D-Glu to diamino pimelic acid residues (DAP) present in 
B. anthracis cell wall [11]. Furthermore, it was suggested that CapD could participate in the elongation of 
poly-γ-D-Glu by crosslinking γ-D-Glu oligopeptides. Interestingly, Mtb has been shown to synthesize a 




further discussion of Mtb α-L-poly-Gln) [15]. In line with CapD’s role in B. anthracis poly-γ-D-Glu 
synthesis, it was reasoned that Mtb could have a homologous GGT participating in α-L-poly-Gln’s 
biosynthesis. Indeed, bio-informatic analysis confirmed that two capD homologues are present in Mtb 
genome (rv2394 and rv0773c). The experimentation presented in this Chapter provides several lines of 
evidence to demonstrate the function of Rv2394 as a CapD homologue. This represents the first 
biochemical characterization of Rv2394, as a Mtb GGT with enzymatic activity that could participate in 
the biosynthesis of α-L-poly-Gln by crosslinking α-L-Gln oligopeptides through a γ-linkage.  
 
3.2 Materials and Methods. 
3.2.1 Bioinformatic analyses. 
The amino acid sequence of Rv2394 was obtained from Tuberculist webpage and was analyzed 
using the following bioinformatic analyses tools: BLAST® from NCBI (http://blast.ncbi.nlm.nih.gov/), 
SignalP (http://www.cbs.dtu.dk/services/SignalP/), LipoP (http://www.cbs.dtu.dk/services/LipoP/) and 
NetOGlyc (http://www.cbs.dtu.dk/services/NetOGlyc/) available at the Expasy Proteomics Server 
website. Multiple sequence alignments were performed using Invitrogen VectorNTI (Invitrogen, 
Carlsbad, CA). Genome organization for the different genes was performed using the genome region 
comparison tool at JCVI comprehensive microbial resource webpage. 
 
3.2.2 PCR and cloning. 
rv2394 was amplified by PCR using Platinum Pfx DNA Polymerase (Invitrogen). Briefly, 100 ng 
of Mtb H37Rv genomic DNA was incubated with 1X Amplification Buffer, 0.3 mM dNTPs, 1 mM 
MgSO4, 0.3 µM forward and reverse primers (see Table 3.1), and 1 U of Pfx DNA Polymerase in a final 
volume of 50 µl. The thermocycler was programmed to amplify the DNA by a two-step cycling as 
follows: initial DNA denaturation for 5 minutes at 95°C, followed by 30 cycles of 1 min at 95°C and an 




for 1.5 h. The gel was stained with SYBR green 1/10,000 in 1X TAE for 30 min, visualized under UV 
light using GelDoc System (BioRad, Hercules, CA), and bands of expected size were excised and 
extracted using Qiagen Gel Extraction kit (Qiagen, Valencia, CA) in a final volume of 30 µl of EB buffer.  
 
Table 3.1 PCR Primers for Rv2394 constructs 
 
 
A’ overhangs were incorporated into the gel purified rv2394 PCR product with Taq polymerase 
(GE Health Systems, Waukesha, WI) for 60 min at 72°C and subsequently introduced into the pGEM-T 
Easy cloning system (Promega, Madison, WI) following the manufacture’s protocol. This cloning system 
was used to clone all PCR products.  After incubating overnight at 4°C, 1 µl of the cloning reaction was 
used to transform chemically competent TOP10 E. coli cells (Invitrogen) following the manufacture’s 
recommendations. Bacteria were plated on LB agar containing 100 µg/ml of ampicillin and incubated 
overnight at 37°C.  
Single colonies were picked up and grown overnight at 37°C in LB medium containing 100 
µg/ml of ampicillin with constant agitation at 200 rpm. Plasmids were then purified from E. coli cells 
Table 3.1 PCR Primers for Rv2394 constructs
Primer Sequence
For Rv23941 CAT ATG AGT GTT TGG TTG CGA GCG GG
Rev Rv23942 AAG CTT GGC ATC GTC GCC CAT GAC CGC
For Rv2394 TA3 CCG CCA GTG CCT GAG CAT GGC GCC AGC CAC CTC AGC GTC GTC GAT TCG
Rev Rv2394 TA CGA ATC GAC GAC GCT GAG GTG GCT GGC GCC ATG CTC AGG CAC TGG CGG
For Rv2394 TS4 CCG CCA GTG CCT GAG CAT GGC AGC AGC CAC CTC AGC GTC GTC GAT TCG
Rev Rv2394 TS CGA ATC GAC GAC GCT GAG GTG GCT GCT GCC ATG CTC AGG CAC TGG CGG
For Rv2394 SP-I5 GGT GGC TGC AGT GAT GCT GTC GGC GAA CGC AGA TCC CGG CTT CCA CGC GGG TGC GCC
Rev Rv2394 SP-I GGC GCA CCC GCG TGG AAG CCG GGA TCT GCG TTC GCC GAC AGC ATC ACT GCA GCC ACC
For Rv2394 -20SP1,6 CAT ATG TGT GGC GGC TTC CAC GCG GG
1NdeI site is underlined.
2HindIII site is underlined.
3Thr to Ala substitution (TA). Mutated base is underlined.
4Thr to Ser substitution (TS). Mutated base is underlined.
5Enforced signal peptidase-I mediated secretion (SP-I). Mutated bases are underlined.




using the Qiagen Mini Prep Isolation kit. Plasmids were subjected to restriction enzyme digestion in order 
to confirm the inserted PCR product. Briefly, 4 µl of each plasmid were incubated at 37°C for 3 h with 
0.5 µl of 10X buffer and 0.25 µl of NdeI and HindIII (New England Biolabs, Ipswich, MA). Digested 
plasmids were analyzed by agarose gel electrophoresis and SYBR green staining as described above. 
Plasmids containing inserts of expected molecular weight were submitted for sequencing at 
Macromolecular Lab Resources, Colorado State University.  Sequences were analyzed using VectorNTI 
(Invitrogen). Table 3.2 describes the plasmids that were engineered for this Chapter.  
 
Table 3.2 Plasmid names and description 
 
 
For protein expression, the shuttle vector pVV16 was obtained from the NIH, NIAID N01-AI-
40091 program at Colorado State University. To insert rv2394 or the engineered mutants into pVV16, 40 
µl of both pVV16 and the pGEM-T Easy plasmid containing the construct were simultaneously digested 
for 4 h at 37°C with 5 µl of 10X buffer and 2.5 µl of NdeI and HindIII (New England Biolabs). Digested 
pVV16
Shuttle plasmid for protein expression in mycobacterium spps. Contains a His-Tag at the carboxyl terminus.
pVV16.2394 Expression of WT Rv2394.
pVV16.2394TS
Expression of a mutant Rv2394 in which the Thr residue at position 446 is replaced by a Ser.
pVV16.2394TA Expression of a mutant Rv2394 in which the Thr residue at position 446 is replaced by an Ala.
pVV16.2394-20SP
Expression of a mutant Rv2394 lacking the signal peptide corresponding to the first 20 amino acids.
pVV16.2394-20SP TA Expression of a double mutant Rv2394 lacking the signal peptide and the Thr residue at position 446 is
replaced by an Ala.
pVV16.2394 SP-I Expression of a mutant Rv2394 in which the acylated cysteine is replaced in order to inhibit lipoprotein
processing. Engineered so that the signal peptide of Rv2394 is removed by SP-I as opposed to SP-II.
pVV16.2394 SP-I TA
Similar to pVV16.2394 SP-I with an additional mutation consisting of replacing Thr residue at position 446 with
Ala.
Plasmids Description




pVV16 and cloned gene were purified using a Gel Extraction Kit (Qiagen) and ligated O/N at 14ºC with 
400 U of T4 DNA ligase (New England Biolabs). Thereafter, ligated expression vectors were transformed 
into chemically competent E. coli TOP10 cells and transformed bacteria were plated on LB agar plates 
with 50 and 100 µg/ml of kanamycin and hygromycin, respectively. Plates were incubated O/N at 37ºC, 
colonies and plasmids were analyzed as described above. Once again, sequencing was performed to 
corroborate that no mutations had been introduced during the cloning process. 
 
3.2.3  Site Directed Mutagenesis. 
Site directed mutagenesis of rv2394 was accomplished following the SiteDirected Mutagenesis 
Kit (Stratagene, La Jolla, CA) protocol with minor variations. Briefly, 100 ng of the plasmid to be 
mutated was incubated with 1X Reaction Buffer, 125 ng of each mutated primer (see Table 3.1), 1 µl of 
dNTPs and 2.5 U of Pfu Turbo DNA polymerase in a final volume of 50 µl. The desired mutation was 
introduced by performing the following PCR: an initial DNA denaturing step of 30 sec at 95°C, followed 
by 18 cycles of 30 sec at 95°C and elongation for 8 min at 68°C. Thereafter, 10 U of DpnI were added to 
the PCR product and incubated for 1h at 37°C to digest the initial unmutated plasmid. Finally, the 
mutated plasmid was transformed into XL-1 Blue Supercompetent E. coli as described in the protocol and 
selected on LB agar plates containing 100 µg/ml of ampicillin. See Table 3.2 for a description of the 
Rv2394 mutants that were engineered for this Chapter.  
 
3.2.4 Generation and Transformation of Electrocompetent M. smeg mc
2





was grown at 37°C in 7H9 medium (BD Difco) supplemented with 0.05% 
Tween 80 until reaching an OD between 0.4-0.6 at an absorbance of 600 nm. Bacteria were harvested by 
centrifugation at 3000 x g for 10 min at 4°C. After decanting the supernatant, bacteria were washed twice 
with ice cold water by inverting the cells and centrifuging as before. Finally, M. smeg was washed with 




resuspended in 5 ml of 10% glycerol in water and 500 µl aliquots were stored at -80°C [16]. 
Electrocompetent M. smeg was thawed in ice and 60µl aliquots were incubated with 100 ng of plasmid 
for 5-10 min in ice. Cells were then added to 340 µl of water that had been dispensed into 0.2 mm 
electroporation cuvettes (BioRad). Electroporation was performed at 2000 Volts. Thereafter, cells were 
recovered from the electroporation cuvettes, added to 600 µl of 7H9 medium and incubated for 4 h at 
37°C. Bacteria were then recovered by centrifugation at 3000 x g for 5 min, and after decanting, were 
plated on 7H11 agar plates containing 50 and 100 µg/ml kanamycin and hygromycin, respectively. Plates 
were incubated at 37°C for 5-7 days and individual colonies were used to inoculate 5 ml of 7H9 liquid 
medium with the same antibiotics as the selection plates. After growing bacteria for 5 days at 37°C on an 
orbital shaker at 100 rpm, 1 ml of bacteria was harvested to determine recombinant protein production as 
indicated below (Western blotting section). Colonies producing a His-Tag reactive band corresponding to 
the protein’s predicted molecular weight, were harvested by centrifugation as described above and 
inoculated in 100 ml of 7H9 plus 50 µg/ml Kanamycin. After 5 days at 37°C on an orbital shaker, cells 
were harvested and used to inoculate Fernbacks containing 900 ml of 7H9 medium plus 50 µg/ml 
Kanamycin. Finally, bacteria were harvested by centrifugation and pellets were stored at -80°C until 
performing protein purification. 
 
3.2.5 Protein Purification.  
Bacterial pellets of recombinant M. smeg were thawed in ice and washed once with binding 
buffer (500 mM sodium chloride, 10 mM Tris-Hydrochloride, 5 mM Imidazole, pH 7.9). Binding buffer 
containing 1% TritonX-100 [17] and 1 tablet of Complete EDTA-free protease inhibitors (Roche Applied 
Sciences, Mannheim, Germany) in 50 ml of buffer, was added to bacterial pellets and cells were sonicated 
in ice for 5 cycles of 1 min intermittent pulsing in a Vibra Cell VCX750 Sonicator (Sonicator and 
Materials, Inc, Newton, CT). Bacterial slurries were then passed 7 times through a French Press at 1800 




for 5 min, supernatants were clarified by centrifuging at 4°C for 30 min at 27,000 x g. Thereafter, 
clarified supernatants were subjected to nickel affinity chromatography by binding to 1 ml of charged 
HisBind resin (EMD Chemicals, Gibbstown, NJ), at 4°C using gravity. The flow through fraction was 
collected and after washing with 10 column volumes of binding buffer containing 1% Triton X-100 [17], 
elution was performed with binding buffer containing a stepwise increase of 10, 15, 20, 30, 40, 60 and 
1000 mM imidazole.  Fractions were then analyzed by SDS-PAGE and silver staining (see below) to 
determine which fractions contained protein of the expected molecular weight, with the least amount of 
contaminating bands. These fractions were pooled and concentrated by centrifuging at 3500 x g, in an 
Amicon with 10 kDa molecular weight cutoff (Millipore, Billerica, MA). Finally, the concentrated 
fraction was dialyzed in 10 mM ammonium bicarbonate and stored at 4°C. The concentration of purified 
proteins was determined by the BCA protein Assay (Pierce, Rockford, IL) using the manufacturer’s 
procedure. After incubating at 37°C for 30 min, optical density was determined at a wavelength of 500 
nm using a Bio-Rad plate reader. Protein concentration was determined by extrapolating the optical 
density of samples with the optical density of a standard curve containing known concentrations of bovine 
serum albumin (BSA) (Pierce). 
 
3.2.6 Western Blotting.  
One µg of purified protein was resolved by SDS-PAGE in 4-12% Tris-Glycine gels (Invitrogen) 
by running in 1X MES buffer (Invitrogen) at 200 Volts for 45 min. Thereafter, gels were either silver 
stained as described before [18] or transferred to a nitrocellulose membrane (Bio-Rad) at 50 Volts for 1 h.  
For Western blotting, membranes to be probed with antibodies were blocked at RT for 1 h with 
1% BSA in 1X TBS, whereas membranes to be probed with ConA  were blocked with 1 % BSA diluted 
in PBS [19].  BSA-blocked membranes were incubated with either 1/10,000 mouse anti-His antibody 
(Qiagen) diluted in 1X TBS or biotinylated-ConcavalinA (Sigma, St. Louis, MI) at 1 µg/ml in PBS. 




0.5 % Tween-20 in TBS or PBS. After washing, Western blots were developed with NBT/BCIP (Sigma) 
as recommended by the manufacturer. For lectin blotting, washed membranes were incubated with 1 
µg/ml peroxidase-labeled streptavidin for 1 h. Finally, lectins blots were developed with chloronapthol 
(Sigma) as recommended by the manufacturer.  
 
3.2.7 N-Terminal Sequencing.  
For N-terminal sequencing, 10 µg of protein were resolved by SDS-PAGE using 4-12% Tricine 
gels (Invitrogen). Proteins were electroblotted onto PVDF nylon membranes at 50 volts for 1 h. 
Thereafter, blotted membranes were stained with Coomassie blue for 30 min and destained in methanol 
[20]. Membranes were submitted to the Proteomics Facility at UC-Davis for N-terminal sequencing. 
 
3.2.8  Mass Spectrometry analysis.  
Protein Identification and Detection of glycopeptides. Five µg of protein was resolved by SDS-
PAGE using 4-12% Tris-Glycine gels and in-gel digestion was performed as described before [21].  
Peptides were separated by applying to a C18 chip column with 5µm particle size, a 40 nL trap, 
and dimensions of 75µm X 43 mm (Agilent, Santa Clara, CA). Peptides were eluted with an increasing 
linear gradient (15 to 80%) of acetonitrile in 0.1% formic acid over 17 min, using an Agilent 1260 
capillary HPLC system at a flow rate of 4 µl/min. Eluted peptides were introduced in a qTOF Agilent 
C520 (Agilent).  
Peptide identification was determined using Mascot (Matrix Science Ltd, 
www.matrixscience.com) software. Peptide identities were accepted if a 95% or higher probability was 
obtained using the Peptide Prophet algorithm. To identify glycopeptides, the MS/MS data was searched 
for a neutral loss of m/z 162 corresponding to a hexose. Analysis was performed using the XCalibur 





3.2.9 GGT Enzymatic Assay.  
The GGT assay was performed as previously described [2]. Briefly, enzymes were incubated with 
1 mM of the donor L-γ-glutamyl-ρ-nitroanilide (L-Glu-γ-ρNA, Sigma) and 20 mM of the acceptor 
glycylglycine (Gly-Gly, Sigma) in a 0.1 M Tris-HCl, pH8 buffer. Alternatively, Gly-Gly was replaced 
with a dipeptide of Glu residues (Glu-Glu, Sigma), oligopeptide of Glu residues (polyGlu, Sigma), a 
dipeptide of Gln residues (diGln, Pi Proteomics, Huntsville, AL), or a pentapeptide of Gln residues 
(pentaGln,Pi Proteomics) to evaluate other acceptors. The plate was kept on ice until the reaction was 
started and then incubated in a spectrophotometer plate (Bio-Rad) at 37°C for 15-30 min. OD readings at 
an absorbance of 405 nm were recorded every 3-5 min. GGT from equine kidney (Sigma) was used as a 
positive control.  
 
3.3  Results  
3.3.1 Bioinformatics analyses. The B. anthracis capA-capE operon located in the pX02 plasmid has 
been shown to encode for proteins involved in the biosynthesis of poly-γ-D-Glu, a capsule product 
essential for its virulence [12, 13]. Interestingly, virulent Mycobacterium such as Mtb uniquely synthesize 
α-L-poly-Gln, a similar peptidic polymer which could also have a role in Mtb virulence [11]. Taking in 
consideration that CapD is probably the best characterized protein encoded in the capA-capE operon, as a 
first approach to studying the biosynthesis of Mtb α-L-poly-Gln we decided to determine if capD 
homologue(s) are encoded by the Mtb H37Rv genome, The CapD sequence was obtained from the NCBI 
protein database and used for homology searches by BLAST analysis in the Tuberculist webpage 
(http://genolist.pasteur.fr/TubercuList/).  As can be observed in Figure 3.1, Rv2394 was identified as the 
protein with highest homology to CapD. Specifically, both proteins were 26% identical, had 41% 
conserved amino acids and overall e-value of 5
-36





Rv0773c (annotated as ggtA) was identified as a second mycobacterial protein with significant 
homology to both CapD and Rv2394 (not shown).  Analysis was limited to Rv2394 as it has higher 
homology to CapD than Rv0773c. Furthermore, additional bio-informatic analyses suggested that similar 
to CapD, Rv2394 would also be localized to the extracellular space. In contrast, Rv0773c seems to be 
localized in the cytoplasm as it lacks a conventional or a lipoprotein signal peptide (not shown). Finally, it 
was determined that virulent Mtb as opposed to avirulent Mycobacterium have a conserved genomic 
organization in the rv2394 locus (see below). This could suggest that rv2394 participates in a unique 







Figure 3.1 Amino acid alignment between B. anthracis CapD and Mtb Rv2394. The amino acid 
sequence for CapD was obtained from B. anthracis str. Ames ancestor and compared to Mtb proteins 
using the BLAST tool in the Tuberculist webpage http://genolist.pasteur.fr/TubercuList/. As can be 
observed, Rv2394 was identified as a CapD homologue with a high percent of identical and conserved 




Initial bio-informatic analysis was focused on predicting whether Rv2394 could have GGT 
activity similar to CapD [11]. The amino acid sequence for Rv2394 was obtained from Tuberculist 
(http://genolist.pasteur.fr/TubercuList/) and analyzed using BLAST
®
 tool from NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). As can be observed in Figure 3.2, BLAST
®
 analysis determined 






Figure 3.2 Rv2394 has a putative GGT domain. The amino acid sequence for Rv2394 was obtained 
from Tuberculist data base and analyzed with the BLAST
®
 tool from NCBI. As can be observed, a 
putative GGT domain was predicted to be present in Rv2394.  
 
The catalytic motif amongst GGTs is highly conserved and consists of a Thr residue located at the 
N-terminus of the enzyme’s catalytic domain [22, 23]. Interestingly, this Thr residue is not the mature 
protein’s N-terminal amino acid. An autocatalytic intra-chain cleavage splits the pre-protein into two 
subunits that remain non-covalently associated: the large (L) and small (S) subunits originate from the 
protein’s N and C-terminal regions, respectively [24]. The catalytic Thr residue becomes the N-terminus 
of the cleaved S subunit. Usually the L subunit remains anchored to the extracellular leaflet of the cell 




biochemically characterized GGTs, multiple sequence analysis was performed using VectorNTI 
(Invitrogen).  In Figure 3.3, it can be observed that similar to other GGTs, Rv2394 possess a conserved 
Thr residue (position 446) present in the catalytic motif. Additional amino acids surrounding this Thr 





Figure 3.3 Rv2394 has conserved amino acid residues present in the catalytic motif of GGTs. Using 
VectorNTI’s multiple sequence alignment tool, the sequence of Rv2394 was aligned with other 
biochemically characterized GGT sequences.  Similar to other GGTs, a Thr residue that is critical for 
enzymatic activity and autocatalytic cleavage (marked with an arrow) is also present in Rv2394. As 
depicted in the consensus sequence, additional amino acids surrounding the catalytic Thr are also 
conserved in Rv2394. 
 
B. anthracis CapD has been localized to the extracellular compartment, consistent with the 
subcellular localization of its substrate poly-γ-D-Glu [11]. Even though it hasn’t been determined 
experimentally, secretion of CapD to the extracellular space is probably determined by a putative N-
terminal signal peptide identified in our own bio-informatic analysis (not shown). Similar to B. anthracis 
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poly-γ-D-Glu, sub-cellular fractionation has also suggested that Mtb  α-L-poly-Gln is located outside the 
mycobacterial cytoplasmic membrane [11]. Thus, it was predicted that Rv2394 could have a signal 
peptide similar to CapD and this was evaluated by subjecting the amino acid sequence of Rv2394 to bio-
informatic analysis using SignalP 4.0 Server tool ([25], http://www.cbs.dtu.dk/services/SignalP/), and 
applying the algorithm for Gram positive organisms and both neural networks and hidden Markov 
models. This analysis indicated the presence of a possible signal peptide that would be cleaved between 
amino acids 28 and 29 by signal peptidase I (SP-I) (Fig. 3.4). Thus the Pro residue located at position 29, 
would become the mature protein’s N-terminus after being translocated outside the cytoplasmic 
membrane. However, it is noted that the score for the SP-I cleavage site at amino acid 28-29 is relatively 




Figure 3.4 Signal peptide prediction in Rv2394 using the tool SignalP 4.0. The protein sequence for 




algorithm for Gram-positive organisms and Markov method were used. A putative cleavage site was 
predicted to occur between alanine (Ala) at position 28 and proline (Pro) at position 29.  
 
Alternatively, some bacterial proteins containing signal peptides are post-translationally modified 
with acyl groups at an N-terminal Cys residue exposed after cleavage by SP-II [26, 27].  Once again, B. 
anthracis CapD hasn’t been experimentally shown to be anchored to the cell membrane through acyl 
groups but our own bio-informatic analysis highly suggests this (not shown). In order to evaluate if 
Rv2394 could be acylated as suggested by the annotation found in the Tuberculist webpage, its sequence 
was analyzed using the LipoP tool ([26], http://www.cbs.dtu.dk/services/LipoP/) available in Expasy (Fig. 




Figure 3.5 Cleavage of Rv2394’s signal peptide is putatively mediated by signal peptidase II (SP-II). 
The amino acid sequence for Rv2394 was obtained from the Tuberculist data base and analyzed with 
LipoP tool. In addition to the presence of a putative signal peptide already predicted by SignalP, LipoP 
predicted that cleavage of Rv2394’s signal peptide is probably mediated by SP-II between amino acid 20 




Instead of the putative SP-I-mediated cleavage site occurring between amino acids 28-29 (score: 
14.5), LipoP predicted a greater probability that Rv2394’s signal peptide could be processed by the SP-II 
pathway (score: 18). Compatible with the well characterized mycobacterial acylation pathway [27], SP-II-
mediated cleavage between amino acids 20 and 21 would leave Cys 21 as the new N-terminus. In turn 
this N-terminal Cys could become acylated.  
As described in Chapter IV, a CapA homologue (Rv0574c) was identified in M. tuberculosis but 
no homologues to the other cap genes seem to be present. In bacteria, genes involved in a metabolic 
pathway tend to cluster and form operons. Therefore, genome organization analysis of the rv2394 locus 
was performed to determine if neighboring genes could be involved in the biosynthesis of α-L-poly-Gln. 
Interestingly, in Mtb and M. bovis, the sulfite metabolism and Cys transport loci are split by the insertion 




Figure 3.6 Comparison of the genome organization for the rv2394 locus in different Mycobacterium 
spp.  In Mtb and M. bovis, rv2394 is located between the sulfite reductase and Cys transport loci. In 



























contrast, M. smeg, M. avium and M. paratb these two loci are contiguous without additional genes 
inserted in between. 
 
In contrast, these loci are contiguous and face each other in the saprophytic M. smeg and the 
opportunistic M. avium and M. paratuberculosis.  Thus, this unique genome organization only present in 
virulent Mycobacterium could suggest that these genes are involved in a unique pathogenesis mechanism 
that isn’t present in avirulent bacteria. Rv2395 was identified as a putative oligopeptide transporter from 
the Opt family, whereas Rv2396 was determined to be a member of the PPE family. Even though it could 
be envisioned that Rv2395 participates in the transport of poly-Gln oligopeptides, a specific role in the 
biosynthesis of α-L-poly-Gln for these two proteins would require additional experimentation.  
Altogether, results obtained from bio-informatic analyses suggested that Rv2394 is a putative 
lipoprotein with GGT activity dependent on a conserved Thr residue. This lipoprotein would be located in 
the extracellular compartment where M. tuberculosis α-L-poly-Gln has been identified by subcellular 
localization [15]. These results are in agreement with those obtained with B. anthracis poly-γ-D-Glu and 
CapD. Thus, it was hypothesized that Rv2394 could be involved in a GGT reaction putatively occurring 
during α-L-poly-Gln biosynthesis (see Chapter IV). CapD’s enzymatic activity, protein motifs and post-
translational modifications are well characterized [12]. Further evaluation of Rv2394 was therefore 
performed using recombinant protein constructs produced in M. smeg., to evaluate the likelihood that 
Rv2394 could be CapD’s ortholog.  
 
3.3.2 Recombinant expression of rv2394 constructs and evaluation of the resulting products.  
To further explore Rv2394’s enzymatic activity as well as post-translational modifications, 
Rv2394 was PCR-amplified from H37Rv genomic DNA (gDNA) and cloned into the mycobacterial 




The pVV16 expression vector encodes for a C-terminus hexa-Histidine tag (His-Tag), enabling 
purification by nickel affinity chromatography. Correct subcellular localization would be mediated by an 
N-terminus signal peptide. Additional Rv2394 constructs were engineered to evaluate the protein’s 
enzymatic activity after: a) mutating the conserved catalytic Thr residue (Fig. 3.7A), b) forcing secretion 
through the SP-I pathway to abrogate N-terminus acylation (Fig. 3.7B) and c) mistargeting Rv2394 to the 
cytoplasmic compartment (Fig. 3.7C).  
By site-directed mutagenesis, the catalytic Thr residue was modified to either a conserved amino 




Figure 3.7 Site directed mutagenesis of additional Rv2394 constructs. Additional Rv2394 constructs 
were engineered to evaluate: A) Enzymatic activity after site-directed mutagenesis of the catalytic Thr 
residue (position 446, codon ACC), to either Ser (TS, codon AGC) or Ala (TA, codon GCC). B) Forced 
secretion through the SP-I pathway. By site-directed mutagenesis, sequence 15-MLSLSGCGG-23 was 
converted to 15-MLSANADPG-23. This new sequence affecting the 3 most C-terminus amino acids of 
the signal peptide and the 2 most N-terminus amino acids of the mature protein, would abrogate Cys 
acylation and force SP-I mediated secretion instead of the default SP-II pathway. C) Protein 
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mislocalization by removing the signal peptide. The first 20 amino acids encoding for Rv2394’s signal 
peptide were removed by PCR. Cys 21, corresponding to the putatively acylated amino acid during SP-II 
mediated secretion, would instead represent the second, non-acylated amino acid of a mistargeted, 
cytosolic protein. New constructs were verified by DNA sequencing as shown in Figure 3.7. 
 
Site-directed mutagenesis was also used to force Rv2394’s secretion through the SP-I pathway as 
opposed to the expected SP-II pathway (construct Rv2394 SP-I, Fig 3.7B). For this purpose, the sequence 
LSGCG was replaced with the sequence ANADP. This mutation removes the putatively acylated Cys 
(bold and underscored), corresponding to the first amino acid of the mature Rv2394. Furthermore, the 
new sequence ANADP (obtained from MPT-32 or 45-kDa glycoprotein), conforms to the rule A-X-A-D-
P which has been used in algorithms to predict mycobacterial protein secretion [29]. Signal peptide 
cleavage at the N-terminus of the aspartic acid residue (D) would leave the sequence DP as the mature 
protein’s 2 most N-terminal amino acids. A third construct was engineered to mistarget a putative 
extracellular protein like Rv2394 to the cytoplasmic compartment (Fig. 3.7C). For this, the DNA 
sequence encoding for the signal sequence was removed by PCR to generate the construct Rv2394-20SP. 
Finally, both Rv2394 SP-I and Rv2394-20SP were subjected to a second mutation affecting the catalytic 
Thr residue to generate constructs RV2394 SP-I/TA and Rv2394-20SP/TA, respectively. After 
confirming by DNA sequencing that these modifications had been achieved (Fig. 3.7), plasmids were 
electroporated into M. smeg and proteins expressed as previously described.  
 Anti-His Western blots targeting the C-terminal histidine-tag were performed in order to evaluate 
expression of Rv2394 constructs. Rv2934’s expected molecular weight is 66.5 kDa, but autocatalytic 
cleavage should result in a C-terminus histidine-tagged S domain with an expected molecular weight of 
23 kDa. Consistent with this, a 23 kDa anti-His reactive band was detected by Western blot A when 
expressing both wild type Rv2394 and Rv2394 SP-I constructs (Fig. 3.8). A similar result was observed 




apparent effect on the enzyme’s autocatalytic activity. In contrast, a band migrating between 73-75 kDa 
was detected in all the constructs containing the TA mutation (Rv2394 TA, Rv2394 SP-I/TA and 
Rv2394-20SP/TA), suggesting that this mutation abrogated the enzyme’s autocatalytic activity regardless 




Figure 3.8 Expression of Rv2394 constructs in M. smeg. M. smeg was electroporated with the different 
Rv2394 constructs. Protein expression was evaluated for three different colonies each, by anti-His 
Western blot as all the constructs have a C-terminus His-Tag. A anti-His reactive 23 kDa band was 
observed for constructs Rv2394 WT, Rv2394 TS, Rv2394 SP-I. In contrast, a 70 kDa anti-His reactive 
band was observed for all the constructs having the TA mutation. Unexpectedly, Rv2394 – 20SP also 
migrated at 70 kDa despite having a WT catalytic site. By protein expression, it seemed that both 
constructs lacking a signal peptide were expressing less efficiently, therefore there were not pursued 
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Notably, despite encoding for the wild type enzymatic motif, expression of the construct Rv2394-
20SP had a similar effect to the TA mutants and no autocatalytic processing was detected. Thus, at least 
for this construct, sub-cellular localization affected the protein’s enzymatic activity. As low expression 
levels were detected by Western blot for both cytoplasmic-localized constructs, they were not pursued 
further as protein yield could be limiting. In contrast, removal of the acylation site and forcing secretion 
through the SP-I pathway, had the opposite effect and resulted in increased band intensity. Thus, further 
biochemical analyses were mainly performed on Rv2394 SP-I and the TA version with abrogated 
autocatalytic activity (some experiments were also performed with the putatively acylated WT or TA and 
TS mutants). 
 
3.3.3 Purification of Rv2394 SP-I.  
Ni
+
 affinity chromatography was used to purify Rv2394 SP-I and Rv2394 SP-I/TA via interaction 
with the recombinant proteins’ C-terminus His-Tag. For Rv2394 SP-I, analysis by SDS-PAGE and silver 
staining revealed the expected presence of two predominant bands migrating at approximately 23 and 50   
(Fig. 3.9). 
As previously observed during protein expression checks, Western blots confirmed that the band 
migrating at 23 kDa was responsible for the anti-His reactivity present in the S subunit. No anti-His 
reactivity was observed for the L subunit migrating at 50 kDa. In contrast and in accordance with 
Rv2394’s SP-I/TA predicted size after abrogation of the autocatalytic activity, a band migrating at 
approximately 73 kDa was observed both on the anti-His Western blot and silver stained gel (Fig. 3.9). 
The protein’s identity was confirmed by mass spectrometry analysis of in-gel digested bands. In addition, 






Figure 3.9 Rv2394 consists of two non-covalently associated subunits. Silver stained gel (left panel) 
revealed that Rv2394 SP-I (lane 2) consists of two subunits migrating at 50 and 23 kDa approximately 
(thin arrow and arrow head, respectively). In contrast, Rv2394 SP-I/TA (lane 1) lacking autocatalytic 
activity, migrates at approximately 70-73 kDa (thick arrow). For Rv2394 SP-I, anti-His reactivity (middle 
panel) is restricted to the 23 kDa band (arrow head). In contrast, reactivity using the mannose-binding 
lectin ConA (right panel), is restricted to the 50 kDa band (thin arrow). As expected, anti-His and ConA 
blots react with the 70-73 kDa Rv2394 SP-I/TA (thick arrow) resulting from both subunits remaining 
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Table 3.2 N-terminal sequencing of Rv2394 constructs 
 
 
As predicted by bio-informatic analyses comparing other GGTs (Fig. 3.4), Thr 446 was 
unequivocally identified at the 23 kDa band’s N-terminus. Data obtained from N-terminus sequencing of 
the 50 and 73 kDa bands of Rv2394 SP-I and its TA version respectively, resulted in several signals 
suggesting that signal peptide cleavage of Rv2394 SP-I was heterogeneous. Alternatively, additional 
trimming of N-terminal amino acids by other proteases could have occurred after SP-I cleavage. 
Nevertheless, the predominant signal obtained from N-terminal sequencing of these bands corresponded 
to Gly-Ala-Pro-Ser-Thr, which is located four amino acids away from the carboxy terminus of the 
engineered cleavage site.  
Despite multiple attempts to obtain pure protein, this was not completely successful for several 
reasons. Non-denaturing conditions were used during purifications to conserve the protein’s enzymatic 
activity (see below). The protein did not bind strongly to the Ni
+
 resin, thus it started eluting during the 
wash steps. In turn, this resulted in low protein yields. Furthermore, GroEL1 a 60 kDa mycobacterial heat 
shock protein containing a histidine-rich motif, was routinely found as a contaminating band (Fig. 3.9, 
asterisk in left panel). Enzymatic assays were therefore performed with enriched Rv2394 and mass 
spectrometry analysis was done from gel extracted, SDS-PAGE-separated proteins.   
 
Rv2394 SP-I S-subunit Thr-Ser-His-Leu
Rv2394 TA Blocked
Rv2394 SP-I TA Gly-Ala-Pro-Ser-Thr
Rv2394 SP-I L-subunit Gly-Ala-Pro-Ser-Thr
Table 3.3 N-terminal sequencing of Rv2394 constructs




3.3.4 Identification of post-translational modifications present in Rv2394 SP-I.  
As mentioned above, bio-informatic analyses suggested that during secretion through the SP-II 
pathway, Rv2394 could be post-translationally modified with acyl groups on the N-terminus Cys residue. 
Two indirect approaches were taken to evaluate if the WT Rv2394 could be acylated as predicted by 
LipoP (Fig. 3.6, see above). Initially, N-terminal sequencing of the purified protein was attempted (Table 
3.3, see above). In contrast to the constructs that were engineered to be secreted through the SP-I 
pathway, no sequencing was possible because the N-terminus was blocked possibly due to the acyl group. 
As N-terminal sequencing is abrogated by multiple amino acid modifications besides acylation, an 
additional technique of detergent phase partitioning with Tx-114 was performed [30]. After inducing 
partitioning at 37°C, lipoproteins are enriched in the detergent phase due to the presence of its acyl group. 
As can be observed in Figure 3.10, anti-His reactivity targeting the protein’s C-terminus of the S domain 




Figure 3.10 Detergent phase partitioning in Tx-114 suggest Rv2394 could be acylated. Whole cell 
lysate of M. smeg overexpressing WT Rv2394 (right lanes) or the vector control (pVV16, left lanes) were 
subjected to detergent phase partitioning in Tx-114. This is a common technique highly suggestive of 
Anti-His Blot









protein acylation. After acetone precipitation, proteins were resolved in SDS-PAGE and analyzed by anti-
His Western blot. As expected, no anti-His reactivity at 23 kDa was observed in lanes containing vector 
control. In contrast, anti-His reactivity was observed in the detergent phase of whole cell lysates of M. 
smeg overexpressing Rv2394 (asterisk). As acylation occurs in the N-terminal domain but the His-Tag is 
present in the C-terminal domain, this result suggests non-covalent interactions between both subunits are 
stronger than detergent hydrophobic forces separating them.  
 
As acylation occurs in the N-terminus domain, this result suggests that the non-covalent 
interaction between both domains was stronger than the hydrophobic forces during Tx-114 partitioning. 
More conclusive data suggesting that Rv2394 is acylated could be obtained if Tx-114 partitioning was 
attempted in Rv2394 TA. This construct should be acylated at the N-terminal Cys and as it has an 
abrogated autocatalytic activity, the full length protein (73 kDa) should partition in the detergent phase. 
Definitive evidence proving acylation of WT Rv2394 could be obtained by mass spectrometry techniques 
such as MALDI or lipid analysis by GC-MS. 
An additional post-translational modification commonly observed in secreted mycobacterial 
lipoproteins is glycosylation. Bio-informatic analyses using NetOGlyc tool 
(http://www.cbs.dtu.dk/services/NetOGlyc/) in the Expasy website [31], suggested some of the Thr 







Figure 3.11 Rv2394’s glycosylation prediction by NetOGlyc Rv2394’s sequence was obtained from 
Tuberculist and analyzed by NetOGlyc tool. The protein’s amino acid sequence is shown above, the 
putatively glycosylated Thr residues (T) are depicted below. In addition to detecting the previously 
recognized signal peptide (underlined), this tool also predicted that 9 T residues could be glycosylated. 
The majority of these T residues are clustered at the protein’s N-terminus in proximity to the acylated Cys 
residue (black circle). Interestingly, NetOGlyc did not predict glycosylation of T 446 (red box), the 
putative catalytic residue which cleaves itself from the preceding Gly residue (vertical black line). The 
green diamond shows a T residue predicted to be glycosylated and confirmed by mass spectrometry. The 
blue dotted line corresponds to a putatively glycosylated and phosphorylated peptide. 
    
Consistent with its putative catalytic function Thr 446 (Fig. 3.11, red box), was not predicted to 
be glycosylated. The majority of the predicted glycosylated Thr residues were clustered in the L subunit 
in proximity to the N-terminal acylated Cys (Fig. 3.11, circle). Initial evaluation to determine if Rv2394 
SP-I could be glycosylated was performed by Western blot with ConA as the probe. As observed in 
Figure 3.9 (right panel), ConA interacted with the 50 kDa L subunit but not with the anti-His reactive 23 




residues are present in the N-terminus L subunit. Furthermore, ConA also bound to the 73 kDa Rv2394 
SP-I/TA containing both the N-terminus (glycosylated L domain) and the C-terminus (His-tagged S 
domain). Definite confirmation that Rv2394 SP-I is glycosylated was performed by mass spectrometry 
analysis of in-gel trypsin-digested Rv2394 SP-I. Mass spectrometry data was analyzed for the neutral loss 
of 162.05 amu, corresponding to the mass of one hexose moiety. Identification of the de-glycosylated 
peptide was performed by MS/MS and compared to a theoretical MS/MS sequencing obtained from 
Protein Prospector (http://prospector.ucsf.edu/prospector/mshome.htm). As can be observed in Figure 
3.12, one of the identified peptides corresponds to the L subunit’s C-terminus generated after 
autocatalytic cleavage.  
   
 
 
Figure 3.12 Rv2394 SP-I is post-translationally modified with hexose residues. After in-gel trypsin 
digestion of Rv2394 SP-I, peptides were analyzed by mass spectrometry for neutral loss of 162.05Da, 
corresponding to one hexose residue. As can be observed in the right panel, a doubly charged peptide 
with an m/z of 939.9523 was converted to an 858.423 m/z peptide. The 81.52Da difference corresponds 
to a hexose on a doubly charged peptide. MS/MS of the 858.423 m/z peptide resulted in sequencing of the 






As predicted by bio-informatic analysis with NetOGlyc (Fig. 3.11, green hexagon), the only Thr 
residue present in this peptide could be the modified amino acid.  Longer versions of this peptide with 
additional amino acids at the N-terminus were also observed by mass spectrometry to have a neutral loss 
of 1 hexose residue (not shown). 
Serendipitously, two peptides with m/z of 1025 and 1054 were observed to undergo the loss of a 
hexose residue in addition to a neutral loss of 79.98 amu (Fig. 3.13). This neutral loss is characteristic of 




Figure 3.13 Mass spectrometry evidence that Rv2394 is phosphorylated. Two peptides with m/z of 
















additional neutral loss corresponding to a phosphate group with m/z of 39.99. The neutral loss of the 
hexose or phosphate group was consecutive but not simultaneous, suggesting that the phosphate group 
was not present on the sugar. The 1054.46 m/z peptide seems to represent a longer version of the 1025.95 
m/z peptide as suggested by the presence of similar ions (702.86 and 835.92 m/z, *) during ms/ms.  
 
These neutral losses were sequential but not simultaneous, indicating that phosphorylation 
occurred elsewhere besides the hexose residue. The peptide with m/z of 1054.46 seems to represent a 
longer version of the 1025.95 m/z peptide as similar ions with m/z of 702.86 and 835.92, were observed 
during MS/MS. Characterization of this glyco-phospho peptide has not been fully achieved probably 
attributed to additional modifications present in the surrounding amino acids.  Nevertheless, the ion with 
m/z of 702.86 was unequivocally identified as EVAPAAATENYLR from the parent MS where this ion 
was observed along with those for the modified peptide (Fig. 3.14). This peptide is located in the L 




Figure 3.14 Identification of the 702.85 m/z ion. Identification of the peptide previously observed in the 





mass spectrometry digest obtained from ProteinProspector. The peptide’s sequence is displayed on the 
left. 
 
Altogether, in addition to the observed auto-catalytic activity, the obtained experimental data is 
compatible with the bio-informatic analyses predicting that Rv2394 could undergo two additional post-
translational modifications associated with secretion: acylation of the N-terminus Cys residue and 
glycosylation of Thr residues. Furthermore, Rv2394 was also observed to putatively undergo 
phosphorylation. A summary of all the engineered Rv2394 constructs and possible post-translational 




Figure 3.15 Summary of the engineered Rv2394 constructs and putative post-translational 
modifications.  Diagram representing the Rv2394 constructs that were evaluated in this study. WT 
SP-II
Cys Gly Thr (446)
SP-II
Cys Gly Ser (446)
SP-II


















Rv2394 (pVV16.2394) has a SP-II motif (red box) at the N-terminus with a properly located Cys residue 
that might be acylated (zig-zag line). Autocatalytic activation results in cleavage between the Gly and Thr 
residues located at position 445 and 446 (vertical black line). This event is catalyzed by the Thr residue at 
position 446. Site directed mutagenesis of this amino acid was performed to change the catalytic Thr 
residue to a conserved Ser or non-conserved Ala residues. Furthermore, the SP-II motif was mutated so as 
to convert it to a SP-I motif (green box) which does not undergo acylation (pVV16.2394 SP-I). A third 
mutant was made in which the SP motif was completely removed to affect protein secretion (pVV16.2394 
-20SP). Double mutants were generated for pVV16.2394 SP-I and pVV16.2394-20SP, in which the 
catalytic Thr residue was mutated to an Ala residue. In addition to acylation Rv2394 also undergoes 
glycosylation (diamond) and possibly, phosphorylation (P ?). 
 
3.3.5 Enzymatic activity of WT and mutant Rv2394.  
Finally, Rv2394’s GGT activity was evaluated by performing enzyme kinetic assays as described 
elsewhere [33]. In this reaction, the donor’s γ-linked Glu moiety is transferred to either water (hydrolysis) 
or the N-terminus of an acceptor such as amino acids or peptides (transpeptidase).  For this assay, L-Glu-
γ-pNA was used as the donor and L-amino acids or peptides were used as acceptors [34]. GGT-mediated 
release of pNA was followed over time by measuring the absorbance at 405 nm, but unfortunately this 
method does not allow differentiating between a hydrolysis or transpeptidase reaction. Initial enzyme 
assays were performed to determine the effect of mutating the catalytic Thr residue to a conserved or non-
conserved amino acid such as Ser and Ala, respectively. Similar to a eukaryote GGT that was used as a 
positive control, WT Rv2394 was able to cleave L-Glu-γ-ρNA in the presence of Gly-Gly (Fig. 3.16), the 







Figure 3.16 WT Rv2394 has GGT activity as opposed to the TS and TA mutants. GGT activity was 
evaluated using the acceptor Gly-Gly and following the release of ρNA from the donor L-Glu-γ-ρNA. 
The WT Rv2394 had considerable enzymatic activity and similar kinetics as a eukaryote GGT used as a 
positive control. In contrast, both TA and TS mutants lacked any enzymatic activity. Similarly, no activity 
was observed in control (pVV16) M. smeg which was processed identically as the recombinant Rv2394 
clones.  
 
Surprisingly, despite having auto-catalytic activity (Fig. 3.8), Rv2394 TS lacked GGT activity 
and no increase in absorbance could be observed during the 30 min reaction. As expected from other 
reports evaluating TA mutants devoid of auto-catalytic activity, no detectable GGT activity was observed 
for Rv2394 TA. 
 Furthermore, acceptors mimicking the structure and amino acid composition of α-L-poly-Gln 
were additionally evaluated. Initially, the Glu oligomers α-L-Glu-Glu (Di-Glu) and α-L-poly-Glu (poly-
Glu) were used as they were readily available. Importantly, WT Rv2394 could also use Di-Glu and poly-
Glu as acceptors to a similar extent as Gly-Gly (Fig 3.17). In contrast, the commercial eukaryote GGT 
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As Gln oligomers resemble α-L-poly-Gln better than Glu oligomers, the former were 
subsequently evaluated. Rv2394 was able to use di or penta-α-L-Gln as acceptors for the GGT activity, in 
a similar fashion as the commonly used Gly-Gly (Fig. 3.18A). Once again and in comparison to Gly-Gly, 
the commercial GGT displayed minimal activity when using di or penta-α-L-Gln as acceptors (Fig. 
3.18B). Finally, the effect that bicarbonate might have on Rv2394’s enzymatic activity was evaluated. 
The rationale for including bicarbonate in the reaction buffer was the description that it enhances B. 
anthracis capsule formation [35]. Even though bicarbonate’s effect on capsule synthesis has been 
principally associated with increased expression of the cap genes [36], its effect on the enzymatic 
activities of the Cap proteins has not been considered. Interestingly, it was noted that bicarbonate 
containing buffers significantly enhanced Rv2394’s GGT activity towards all the acceptors. Furthermore, 
the presence or absence of bicarbonate in the reaction’s buffer didn’t significantly enhance the 
commercial GGT’s activity (Fig. 3.18B). For eukaryote GGTs, an allosteric effect had been previously 
reported for the non-physiological maleate [37]. Whether bicarbonate’s effect on Rv2394 activity is 







Figure 3.17 Glu di/oligopeptides can be used as acceptors by WT Rv2394. GGT activity was 
evaluated using different acceptors as depicted in the legend. WT Rv2394 could use short L-Glu-
containing peptides as acceptors. In contrast, eukaryote GGT and both Rv2394 mutants lacked enzymatic 
activity when including these acceptors. As shown in Figure 3.16, both Rv2394 mutants also lacked 

























Figure 3.18 Gln di or pentapeptides can be used as acceptors by Rv2394 and its activity is enhanced 
by bicarbonate containing buffers. A) As α-L-polyGln is composed of Gln residues, Gln di or 





























































































































































































































pentapetide was used as an acceptor to evaluate the GGT activity of Rv2394. In Tris containing buffers, 
these Glnd-based acceptors were used by Rv2394 as efficiently as Gly-Gly. Interestingly, the presence of 
bicarbonate in the reaction of buffer (as in ammonium bicarbonate, Ambic) as opposed to Tris, 
significantly enhanced Rv2394’s activity using all the acceptors. B) In contrast to its activity in the 
presence of the acceptor Gly-Gly, and as observed for Glu-based acceptors, the commercial GGT didn’t 
efficiently used Gln-based acceptors. In addition, the presence of bicarbonate (Ambic) didn’t have a 
major effect on the enzyme’s activity towards any of the evaluated acceptors.  
 
In conclusion, GGT activity was confirmed for Rv2394. In contrast to a commercial eukaryote 
GGT used as control, Rv2394 was capable of using Glu or Gln based di or oligo peptides as acceptors, 
which resemble the structure of α-L-poly-Gln.  
 
3.4  Discussion. 
 Since the discovery that transpeptidases are targeted by the widely used β-lactam antibiotics, 
these enzymes have become a major focus of study in the field of bacterial physiology and pathogenesis 
[38]. The classic transpeptidase/transglycosase penicillin-binding proteins were shown to mediate cross-
linking between the third and fourth amino acids of neighboring peptidoglycan pentapeptides (43 
linkage). Subsequently, three additional groups of bacterial transpeptidases have been characterized and 
interestingly, several of these enzymes have been involved in remodeling or modifying peptidoglycan 
through different mechanisms. L,D-transpeptidases (Ldts) were initially identified to catalyze a β-lactam-
resistant, non-classical 33 linkage present in Gram positive bacteria [39]. It has become evident that 
Ldts are not restricted to Gram positive bacteria as they were recently shown to participate in cross-
linking Braun lipoprotein to E. coli peptidoglycan [40]. Furthermore, Ldts were also shown to mediate 
33 linkages present in the peptidoglycan of stationary Mtb [41]. Inactivation of this enzyme was shown 




bacillus susceptible to a combination of β-lactam antibiotics and β-lactamase inhibitors. Sortases are an 
additional group of transpeptidases shown to covalently link proteins to peptidoglycan in Gram positive 
bacteria [43]. These enzymes mediate a transpeptidase reaction between the third amino acid of the 
peptidoglycan pentapeptide and a specific sequence in the protein to be cross-linked. Recently, CapD a 
GGT present in B. anthracis was included as an additional member of peptidoglycan-modifying 
transpeptidases [11, 14, 44]. CapD was shown to covalently link polymers of γ-D-Glu to meso-DAP and 
most importantly, genetic or pharmacological inhibition of B. anthracis CapD reduced lethality in the 
mouse model [14]. In our search for CapD homologs that could be involved in the bio-synthesis of Mtb α-
L-poly-Gln, Rv2394 was identified as the best candidate due to its high homology to CapD, putative 
extracellular localization and its presence in a highly conserved genomic locus only encountered amongst 
virulent Mycobacterium. Significantly and as described in Chapter IV, Mtb mutants for Rv2394 had 
reduced concentrations of Glu and ammonia in their cell wall, further substantiating its role in α-L-poly-
Gln biosynthesis.  
The major reason to characterize Mtb Rv2394 was its homology to CapD, the B. anthracis 
enzyme participating in poly-γ-D-Glu synthesis. The exact role of CapD in poly-γ-D-Glu biosynthesis had 
been controversial until recently. Initially, the enzyme was characterized as catalyzing a hydrolysis 
reaction leading to B. anthracis capsule depolymerization. Hence the protein was initially named Dep 
instead of CapD [45, 46].  CapD’s most straightforward evaluable activity still consists of incubating the 
enzyme with high molecular weight B. anthracis capsule [11, 47, 48]. By agarose gel electrophoresis and 
methylene blue staining, it can be observed that this incubation leads to progressive loss of the high 
molecular weight capsule with concomitant generation of smaller fragments that can even run out of the 
gel. Furthermore, incubation of B. anthracis with CapD or alternatively CapD overexpression, led to the 
accumulation of small γ-D-Glu capsule fragments in culture supernatants [47, 48]. Altogether, these 
results led to the hypothesis that CapD was involved in capsule degradation or turnover. In contrast to the 




accumulation of capsule γ-D-Glu oligopeptides in the culture supernatants [46]. Significantly, mutants 
were also devoid of capsule. This phenotype was also observed when incubating bacteria with capsidin, a 
CapD inhibitor [14, 44]. Thus, the hypothesis was modified and currently it is accepted that CapD 
participates in capsule anchoring to the cell wall. The controversy regarding CapD’s function was finally 
settled with the demonstration that in cell free assays, the enzyme could mediate a transpeptidase reaction 
cross-linking oligopeptides of γ-D-Glu to peptidoglycan’s meso-DAP [14]. In order for CapD to perform 
the GGT reaction, both the specific donor and acceptor had to be present. In the absence of acceptor 
(DAP-containing pentapeptides or muropeptides), CapD principally catalyzed a hydrolysis reaction. 
Therefore, in cell-free assays the aforementioned controversy involving CapD-mediated capsule 
hydrolysis was due to enzymatic reactions lacking CapD’s physiological acceptors [14]. A similar 
hydrolysis reaction has also been reported for a member of the SortC family of transpeptidases when the 
physiologically relevant acceptors are omitted during the enzymatic reaction.  
Using CapD as a model for a GGT involved in the biosynthesis of an amino acid polymer such as 
a B. anthracis poly-γ-D-Glu, a similar function was envisioned for Rv2394 during Mtb biosynthesis of a 
peptidic polymer such as α-L-poly-Gln. As discussed above, not only was CapD shown to cross-link 
poly-γ-D-Glu and peptidoglycan, but it also mediated an auto-transpeptidation reaction resulting in the 
elongation of higher molecular weight γ-D-Glu oligomer [14]. The fact that in contrast to eukaryote GGT, 
recombinant Rv2394 was able to catalyze a GGT reaction in the presence of acceptors mimicking α-L-
poly-Gln such as di-Glu, di-Gln, penta-Gln and oligo-Glu, supports this activity. Furthermore, reduced 
Gln and ammonia content in cell-walls of Mtb mutants for Rv2394, strongly substantiates the hypothesis 
that this enzyme participatates in α-L-poly-Gln biosynthesis (see Chapter IV). It should be kept in mind 
that Mtb α-L-poly-Gln was described as exclusively consisting of α-linkages [15]. In vitro modeling of 
poly-CAG extending diseases (the CAG codon encodes for Gln), has shown that Gln oligopeptides 
consisting of more than 40 α-linked residues are highly insoluble due to extensive β-sheet formation [49]. 




aggregating phenotype explaining the pathology of poly-GAG extending diseases, generation of such 
insoluble products could possibly present problems to Mtb. As an alternative during α-L-poly-Gln 
biosynthesis, smaller but soluble α-L-Gln oligopepeptides could be synthesized intracellularly. After 
being exported, the α-L-Gln soluble oligopeptides could be cross-linked by Rv2394 through a γ-linkage 




Figure 3.19 Role of Rv2394 in α-L-polyGln biosynthesis.  α-L-polyGln oligopeptides would be 
synthesized in the cytoplasm and transported extracellularly by the Rv0547c locus (see Chapter IV). In 
the extracellular compartment, Rv2394 would crosslink α-L-polyGln oligopeptides through a γ-linkage. 
Consistent with the currently proposed structure, most Gln residues would be in an α-linkage and only a 
minority of residues would be in a γ-linkage. Similar to CapD, Rv2394 could have a polymerizing or 




Detecting a minor population of γ-linkages in α-L-poly-Gln’s structure could thus be challenging, 
resulting in the erroneous assumption that this polymer exclusively consists of α-linkages [15].  
In B. anthracis, two distinct “populations” of poly-γ-D-Glu have been identified. The first 
“population” corresponds to the aforementioned poly-γ-D-Glu which is covalently linked to the cell wall 
[14, 46]. Furthermore, a significant amount of free poly-γ-D-Glu is present in the culture filtrate 
representing a second “population” [46]. In contrast, only cell wall-associated but non-covalently bound 
α-L-poly-Gln has been described in Mtb. The conclusion that α-L-poly-Gln is not covalently attached to 
the Mtb cell wall, was drawn by the fact that both products could simply be separated by a physical 
method such as density gradient ultracentrifugation [15]. It should be stressed that the cell wall 
purification method for B. anthracis poly-γ-D-Glu analysis is significantly more stringent than the 
equivalent for α-L-poly-Gln analysis in Mtb cell walls. Mtb cell wall purification basically consists of 
three 2% SDS extractions at 60°C for 2 h [15]. In contrast, B. anthracis cell wall purification includes 
boiling in 1% SDS, protease digestion for 12 h, extraction with 8M LiCl2, and finally, hydrolysis with 
hydrofluoric acid to remove polysaccharides [11]. Some of these procedures such as the extraction with 
8M LiCl2 and hydrofluoric acid treatment could be included during the extraction of Mtb cell wall in 
order to unequivocally conclude that α-L-poly-Gln is definitely non-covalently attached to the Mtb cell 
wall. Alternatively and as described for poly-γ-D-Glu, two “populations” of α-L-poly-Gln could be 
associated to the Mtb cell wall by both covalent and non-covalent bonds. Free α-L-poly-Gln would 
remain non-covalently associated to the Mtb cell wall, as its insolubility would preclude diffusion into the 
culture filtrate. Meanwhile and paralleling CapD’s activity, Rv2394 could be covalently cross-linking a 
second “population” of α-L-poly-Gln to the Mtb cell wall. If this is the case, then meso-DAP present at 
the third position of mycobacterial pentapeptides would be the most probable candidate. For all 
peptidoglycan-modifying transpeptidases (PBPs, Ldts, sortases and GGTs), the amino acid located at the 
third position seems to be the targeted “hot spot” [14, 38-41]. As with CapD, the likelihood of detecting 




that better resemble Mtb  peptidoglycan (such as DAP containing pentapeptides), as well as donors 
mimicking α-L-poly-Gln (such as di or penta-Gln).  
One major characteristic that was experimentally shown to be important in Rv2394 and is shared 
amongst GGTs is autocatalytic activation [24, 51]. In contrast to the other transpeptidases such as the 
Penicillin-Binding Proteins, sortases and Ldts, GGTs belong to the family of N-terminal nucleophile 
(Ntns) proteins [52, 53]. Ntns include proteins with diverse functions such as the proteasome, 
asparaginase, penicillin acylase, aspartylglucosaminidase, and Gln phosphoribosyl-pyrophosphate 
amidotransferase [52]. More importantly, Ntns share a three-dimensional structure characterized by the 
pre-protein’s autocatalytic loop lying in close proximity to the enzymes’ catalytic site, which facilitate the 
activation process [52-54]. Specifically for GGTs, the crystal structure for B. anthracis CapD, H. pylori 
and E. coli GGT crystal structures, has confirmed this [51, 55, 56]. In all GGTs described so far, 
autocatalytic activation is dependent on a conserved Thr residue. Ser and Cys are alternative nucleophiles 
in some members of the Ntn family [52]. Consistent with the characterized GGTs, mutating Rv2394’s 
conserved Thr residue to Ala completely abrogated its autocatalytic and transpeptidase activity.  In 
contrast, mutation of the Thr residue to a conserved amino acid such as Ser did not affect Rv2394’s 
autocatalytic activation. Interestingly, transpeptidase activity over a 30 min time frame was not observed 
for the Rv2394 TS construct. Similarly, despite the occurrence of autocatalytic activation for an E. coli 
GGT TS mutant, an altered Km and Vmax was reported for this mutant’s transpeptidase reaction [24]. E. 
coli’s TS mutant required days instead of minutes to perform the transpeptidase reaction [24]. 
Furthermore, some Ntns such as the proteasome are highly susceptible to a TS mutation [57]. Thus, as 
observed for Rv2394 TS, a conserved mutation affecting the catalytic Thr residue uncoupled the 
autocatalytic and transpeptidase reactions.  Uncoupling both reactions in GGTs has additionally been 
achieved pharmacologically. Whereas 6-Diazo-5-OxoNorleucine (DON) readily inhibited transpeptidase 
activity, GGT’s autocatalytic activity was preserved [24]. Finally, a rather unexpected finding was 




was expected to undergo autocatalytic activity. In contrast, an un-cleaved pre-protein form was observed 
during expression checks. Except for Neisseria meningitides GGT [58] and maybe Mtb Rv0773c which 
seems to lack a signal peptide, the remaining GGTs have been characterized as extracellular proteins.  
Thus, auto-catalytic activation might have evolved to occur only after the GGT has correctly folded once 
in the extracellular compartment. In Mycobacterium, one major post-translational modification occurring 
in the extracellular compartment is glycosylation [59]. Indeed, Rv2394 was shown to be glycosylated and 
in agreement with human GGT [60], the lack of this post-translational modification might affect its 
folding and autocatalytic activation. Alternatively, Rv2394 is unique amongst bacterial GGTs in having 
Cys residues in the extracellular domain. In eukaryote GGTs, it has been well established that these Cys 
residues participate in disulphide bond formation which are critical for proper folding and autocatalytic 
activation [61]. By remaining in the cytoplasm, Rv2394–20SP might lack disulphide bonds, thus the 
protein might not fold properly to support autocatalytic activation.   
Besides autocatalytic activation, three additional post-translational modifications including 
glycosylation, acylation and phosphorylation were putatively identified in recombinant Rv2394. Both 
glycosylation and acylation of Rv2394 were expected based on the accurate and high predictive value 
obtained when subjecting mycobacterial proteins to bio-informatics analyses such as NetOGlyc, SignalP 
and LipoP, respectively. Our own bio-informatic analyses suggest such modifications might also be 
present in CapD. The presence of hexose residues attached to Rv2394 was confirmed by ConA lectin blot 
and mass spectrometry analysis showing the characteristic neutral loss of 162.0528 m/z. Glycosylated 
peptides identified by mass spectrometry and ConA reactivity was limited to the L-subunit, whereas 
Rv2394’s S-subunit was not found to be glycosylated using either technique. As seen for other 
mycobacterial glyco-lipoproteins [62], Rv2394’s putative glycosylated Thrs/Ser residues clustered at the 
N-terminus (L subunit). In agreement with our result, ConA reactivity of Rv2394’s L-subunit had been 
reported in a study identifying glycosylated M. tuberculosis proteins obtained from culture filtrates[63]. 




Rv2394, to the best of our knowledge this is the first biochemical demonstration for a glycosylated 
bacterial GGT. The fact that most studies evaluating bacterial GGT activity and crystal structure have 
been performed with recombinant proteins expressed intracellularly in E. coli, could explain why 
glycosylation had not been previously reported for bacterial GGTs. In contrast to bacterial GGTs, there is 
ample evidence that higher eukaryote and fungal GGTs are heavily glycosylated [17, 60]. For human 
GGT, approximately one third of the protein’s molecular weight has been attributed to N-linked 
carbohydrates [60]. The S-subunit has also been shown to be glycosylated in eukaryote GGTs. 
Interestingly, a recent report with human GGT identified glycosylation as an essential step required for its 
auto-catalytic activity [60]. On the other hand, enzymatic de-glycosylation of the processed GGT did not 
affect its transpeptidase activity, further confirming that both enzymatic activities can be uncoupled [60]. 
Regarding Rv2394 acylation, this post-translational modification was evaluated by Tx-114 partitioning 
[30]. As reported for acylated proteins, Rv2394 partitioned to the detergent phase as determined by anti-
His reactivity against Rv2394’s S-subunit. It should be kept in mind that after Rv2394’s autocatalytic 
activation, the acyl groups responsible for detergent partitioning are present in the L-subunit. In contrast, 
the His-Tag is present in the S-subunit. Thus both subunits seemed to remain associated during 
partitioning despite only being non-covalently associated. The crystal structures of H. pylori, E. coli and 
B. anthracis GGTs have identified considerable interaction between both subunits and this could explain 
why they remained associated during detergent partitioning [51, 55, 56]. A comprehensive study 
evaluating putative mycobacterial lipoproteins by Tx-114 partitioning also detected Rv2394 in the 
detergent phase [64]. Furthermore, this study reported the detection by mass spectrometry of peptides 
from the S-subunit of Rv2394. Detection of peptides for the S-subunit of Rv2394 could be attributed to 
the presence of a minor population of immature Rv2394 at the pre-protein stage when both subunits are 
still covalently linked. Alternatively, the S-subunit of Rv2394 could have long hydrophobic domains that 
could be forcing its partitioning into the detergent phase. Using the Kyte/Doolittle algorithm at ProtScale 




30 amino acids each were present in the S-subunit ( not shown). As this subunit consists of 198 amino 
acids, the presence of 60 hydrophobic amino acids accounting for almost one third of the subunit could 
have a substantial impact during detergent partitioning. More conclusive biochemical evidence is required 
to definitely confirm the presence of acyl groups in Rv2394’s L-subunit. 
Unexpectedly, phosphorylation seemed to be an additional post-translationally modification 
present in enzymatically-active Rv2394. A neutral loss of 79.98 m/z corresponding to a phosphate residue 
[32], was clearly and consistently seen in several scans during mass spectrometry analysis of Rv2394. 
This serendipitous finding was even more remarkable as glycosylation was also present in the 
phosphorylated peptide. Consecutive neutral losses of 162.0528 and 79.98 m/z corresponding to a hexose 
and phosphate residue respectively, were detected for these peptides suggesting that the hexose residue 
isn’t the phosphorylated group. In Mycobacterium, glycosylation has been shown to occur in the external 
cell membrane leaflet during SecA-mediated export of secreted proteins and lipoproteins [59]. Thus, the 
presence of a sugar residue is a very good indicator that this glyco-phospho peptide has undergone the 
mycobacterial secretion pathway en route to its extracellular location.  If this is the case, then Rv2394 
would constitute the first extracellular mycobacterial protein proven to be phosphorylated. Unfortunately 
it was not possible to conclusively identify the glyco-phospho peptide, probably attributed to amino acid 
modifications occurring during protein purification and/or while perfoming trypsin in-gel digestion for 
mass spectrometry. Nevertheless, by analyzing the fragmentation of the glyco-phosphopeptide, it was 
possible to circumscribe it to longer versions of the peptide EVAPAAATENYLR. This peptide is 
localized in the L-subunit and was not predicted by NetOGlyc to be glycosylated. Longer versions of this 
peptide would have at least two Thr residues where both glycosylation and phosphorylation could co-
exist. The significance and extent of this putative phosphorylation is not known, but some of the 
mentioned enzymatic assays were performed with the same batch of Rv2394 that was subsequently 




The current dogma is that phosphorylation occurs intracellularly where ATP is synthesized, but 
the presence and concentration of extracellular ATP, as well as the function of extracellular kinases is 
currently unknown. It is envisioned that Rv2394 phosphorylation could occur either intracellularly before 
secretion through the Sec translocon or extracellularly after protein folding. In contrast to eukaryotes, 
bacterial secretion through the Sec translocon does not necessarily occur simultaneously with translation 
(co-translational translocation) [66]. Considerable folding has been known to occur before translocation. 
Furthermore, Mycobacterium do not have a SecB protein which mediates ribosome stalling until docking 
to a translocon [67]. Therefore, it is possible that Rv2394 could be phosphorylated during its brief 
intracellular stage, specially taking in consideration that the putative phosphorylated residue lays close to 
the protein’s N-terminus. Other alternative secretion mechanisms described in Mycobacterium spp, could 
be participating during Rv2394 secretion. The SecA2 pathway has been shown to mediate secretion of 
folded proteins lacking a signal peptide like superoxide dismutase and catalase [68]. Recently, this 
pathway was also shown to participate during secretion of specific lipoproteins containing a signal 
peptide and a lipobox [69]. Therefore it would be important to evaluate the SecA2-mediated secretion of a 
lipoprotein like Rv2394, which by folding intracellularly could become phosphorylated prior to secretion. 
An alternative secretion system that has been shown to mediate translocation of partially folded proteins 
is the twin-arginine transport (Tat) system. Interestingly, some mycobacterial β-lactamases involved in 
cell wall structure were recently shown to be exported by the Tat system [70], however Rv2394 does not 
have a Tat signal sequence. Finally, a previous report had documented PknB-mediated phosphorylation of 
Rv0016c, an extracellular penicillin-binding protein. Compatible with the requirements for tranlocation 
by the Tat system, our own bio-informatic analysis identified two arginines in the signal peptide of 
Rv0016c [71]. Interestingly, the phosphorylated residues are located extracellularly. This report did not 
address the mechanism of how extracellular residues become phosphorylaed.   
Besides a role in α-L-poly-Gln biosynthesis, Rv2394 could be participating in other biochemical 




between the sulfate reductase and Cys uptake loci of Mtb and M. bovis [28]. Sulfate acquisition by this 
intracellular bacteria could potentially be more complex that in other Mycobacterium spp., requiring the 
presence of these additional genes. As occurs during the GSH cycle, one possibility could be that Rv2394 
participates in sulfur uptake after cleavage of host GSH. A similar role was described for F. tularensis 
CapD homologue, whereas no role in capsule biosynthesis was identified for this protein [6]. In this 
regard, it should be mentioned that in Mycobacterium, a different operon encoded by rv1280c-rv1283c 
has already been characterized as a GSH or Cys-Gly uptake system [72]. Paradoxically, these two 
peptides are toxic to both Mtb and M. bovis and mutations to this operon abrogated their GSH 
susceptibility [72, 73]. Thus, it is currently thought that both Mtb and M. bovis only have one functional 
GSH uptake system and this could rule out the possibility that Rv2394 has this role. Nevertheless, an 
uncharacterized or alternative function in sulfate metabolism should be further pursued for Rv2394 and 
not disregarded. For instance, recombinant Rv2394 could be incubated with GSH and the appearance of 
Glu or Cys-Gly monitored over time.  
In conclusion, we report the first biochemical characterization of Rv2394, a Mtb GGT with 
significant homology to CapD. We believe the presence of transpeptidases in clinically relevant Gram 
positive and negative bacteria, and their involvement in critical aspects of bacterial pathogenesis, should 
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Chapter IV  
 
Mtb α-L-Polyglutamine: Biosynthesis and Role in Pathogenesis 
 
4.1 Introduction.  
Mtb is the causative agent of human TB, a disease annually affecting approximately 7-8 million 
people and causing almost 2 million deaths [1]. Even though much has been learned about this pathogen 
since its genome was sequenced, big gaps in knowledge are still present. During genome annotation [2], it 
was observed that approximately 16% of the open reading frames were hypothetical conserved proteins 
with unknown function. Furthermore, a precise biochemical function could only be attributed to 40% of 
the open reading frames and for the remaining 44% only a putative function could be suggested [2]. It is 
hoped that further biochemical characterization of Mtb’s proteome could lead to better understanding its 
virulence factors and how they contribute to pathogenesis. For instance, considerable proteome 
differences have been observed for several related Mtb clinical isolates causing outbreaks in New Jersey 
[3]. How and why proteome differences exist in a genetically conserved microorganism, is currently 
unknown.  
  One clearly identified Mtb virulence factor is its cell wall [4]. From a clinical point of view, the 
mycobacterial cell wall is a big challenge as its hydrophobicity represents a major barrier against 
antibiotic diffusion [5]. Furthermore, the cell wall is responsible for mycobacterial acid fastness which is 
conveniently used during routine microbiological staining. The mycobacterial cell wall is composed of 
extractable lipids, the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex and a cell membrane [6]. 
Altogether they constitute a remarkably different structure than Gram positive and negative cell wall. The 
major extractable lipids are PDIM, the mannosylated glycolipids PIMs, LM, ManLAM, and the trehalose 
based lipids TDM and SL, amongst others [7]. Starting from the outside, mAGP consists of mycolic acids 
covalently linked to the non-reducing end of the arabinogalactan chain [6]. Mycolic acids are long α-
alkyl-β-hydroxyl fatty acids with more than 60 carbon units and are considered the major hydrophobic 




which forms a covalent bridge between mycolic acids and peptidoglycan [6]. GlcNAc and MurNAc 
residues constitute the repeating disaccharide present in peptidoglycan and the MurNac residues are 
derivatized with a peptidic chain composed of L-Ala, D-Glu, mesoDAP and D-Ala [6].  This peptidic 
chain is crosslinked by PBPs forming the classical 34 linkage (DAPD-Ala) [9] and/or Ldts making a 
33 linkage (DAPDAP) [9-11].  
In comparison to other microorganisms, several chemical modifications have been documented in 
Mtb’s peptidoglycan and seem to be important for the bacterium’s physiology. For instance, it has been 
shown that the D-Glu residue could be amidated or modified with a Gly residue [6]. Addtionally, the 
MurNAc residue is glycolated [12] as opposed to the usual acetylation present in most bacteria. It has 
been well documented that the mycobacterial cell wall confers Mtb with some of the properties making it 
such a resilient microorganism. At the cell biology level, Mtb cell wall components have been shown to 
participate in blocking phagosome-lysosome fusion [13]. Furthermore, it has been suggested that the cell 
wall protects Mtb from the macrophage’s oxidative burst [14], and, in vivo studies have shown that cell 
wall components participate in granuloma formation [15] and immune response modulation [16]. Taking 
in consideration the importance of Mtb’s cell wall, its biosynthesis is currently a major antibiotic target. 
Specifically, INH and ethambutol are included in the first line of anti-TB drugs as they interfere with 
mycolic acid and arabinogalactan biosynthesis, respectively [5]. It is hoped that more targets can be 
identified by understanding the Mtb’s cell wall biosynthesis. This is exemplified by the recent observation 
that Ldt activity mediates a different peptidoglycan crosslinking pattern required for Mtb’s persistence in 
chronic infections [10]. Thus, Ldt inhibition has been considered a new antibiotic target [17].  
Several decades ago it was noticed that the cell wall obtained from virulent vs. avirulent 
Mycobacterium spp, differed in some immunomodulatory properties. For example, the cell wall of M. 
bovis BCG was shown to have adjuvant properties not present in M. smeg and this was particularly 
important as BCG but not M. smeg had therapeutic benefits in several types of cancer [18, 19]. Thus, it 




immunomodulatory properties and characterization of mycobacterial cell walls indeed confirmed 
biochemical differences [16]. SL and PDIM were identified in the pool of extractable lipids obtained 
exclusively from virulent Mycobacterium spp. TDM was also initially characterized from virulent Mtb 
and determined to confer its characteristic serpentine colony morphology, therefore it is also known as 
‘cord factor’. However, it was later shown that TDM was present in other avirulent Mycobacterium. In 
this case, biochemical differences between the TDM obtained from virulent vs avirulent strains is 
attributed to subtle chemical modifications such as in its mycolate chains. In addition to lipid 
modifications, it was reported that cell walls of virulent Mycobacterium also contained two polymers 
consisting of hydrosoluble glucan (a polymer of glucose) [20] and insoluble poly-Glu/Gln that was 
present in peptidoglycan preparations [21]. As a similar polymer consisting exclusively of Glu residues 
had been identified in B. anthracis capsule and shown to be important for its virulence [22-24], further 
studies were carried out to characterize Mtb’s poly-Glu/poly-Gln.  
 The initial observation that led to the eventual characterization of Mtb poly-Glu/poly-Gln was 
done by Migliore et al in 1966 [21], when his group identified high Glu concentrations in the cell wall of 
Mtb clinical isolates. The high Glu concentrations lead to a Glu/DAP ratio of more than 30:1, in contrast 
to the expected ratio of 1:1 (one Glu and one DAP residue per peptidoglycan chain). The high Glu/DAP 
ratio was present after delipidation, urea extraction and trypsin/chymotrypsin digestion of cell walls, 
suggesting the excess Glu did not originate from conventional cell wall proteins and was not present as 
free Glu [21]. Furthermore, cell walls obtained from Mtb H37Rv, H37Ra and M. bovis BCG had 
significantly less Glu but still the ratio of Glu/DAP was higher than the expected ratio of 1:1 [21]. Taking 
in consideration that during amino acid analysis peptide bonds are cleaved during acid hydrolysis, it was 
suggested that the excess Glu was covalently linked and constituted a polymer similar B. anthracis poly-
Glu [21].  Indeed it was subsequently shown that a Glu-containing polymer could be extracted from both 
Mtb and M. bovis cell walls after mild acid hydrolysis [25]. In contrast to B. anthracis poly-Glu, 




joined α-linkages [25-27].  Milder purification techniques of Mtb’s polymer resulted in the identification 
that some Glu residues could be amidated, corresponding to Gln residues instead [27]. Finally, 
purification of Mtb’s polymer by sucrose gradient ultracentrifugation without acid hydrolysis confirmed 
the polymer was composed entirely of L-Gln residues covalently joined by α-linkages [28], hence the 
name α-L-polyGln which will be used hereafter. 
 The capsule of B. anthracis is entirely composed of poly-γ-D-Glu and it’s essential for virulence 
[22, 29]. The biosynthetic machinery of B. anthracis capsule is well understood and is known to be 
encoded in genes of the pX02 plasmid [23, 24]. B. anthracis that loose this plasmid are not encapsulated 
and are avirulent [23, 24]. Conversely, introducing the pX02 plasmid into non-encapsulated Bacillus spp, 
led to bacterial encapsulation [23]. Capsule biosynthesis activity has been specifically mapped to the 
capA-capE operon in the pX02 plasmid [29]. Biosynthesis of poly-D-Glu starts in the cell’s cytoplasm 
where CapB activates the substrate in an ATP-dependent fashion [22, 30]. In concert with CapC, these 
two enzymes catalyze the covalent linkage of D-Glu residues via γ-linkages [30, 31]. CapA and CapE 
transport the elongating polymer to the extracellular space [30, 32], where CapD covalently links the 
capsule to DAP residues of B. anthracis peptidoglycan [33-35].  In contrast, biosynthesis of Mtb’s α-L-
polyGln has not been elucidated. It has been reported that reduced quantities of α-L-polyGln were 
obtained in Mtb’s cell wall after inhibition of Rv2220 [36], an abundantly secreted Gln synthetase present 
in the CF [37]. Despite the presence of three additional Gln synthetase encoded in Mtb’s genome, Rv2220 
accounts for the majority of the bacillus Gln synthetase activity [38]. Even though Rv2220 could have a 
direct role in α-L-polyGln biosynthesis, this would be highly unlikely taking in consideration that this 
enzyme is present and highly conserved in other Mycobacterium spp lacking α-L-polyGln [39]. Instead, 
inhibition of Rv2220 could have an indirect effect on α-L-polyGln as limiting intracellular Glu/Gln 
concentrations could be available for this polymer’s biosynthesis.  
 The main objectives of this Chapter were to identify genes participating in the biosynthesis of 




consideration the biochemical similarities between B. anthracis poly-γ-D-Glu and Mtb α-L-polyGln, 
homologs of B. anthracis capA-capE operon were sought for in Mtb’s genome. Rv0574c and Rv2394 
(discussed in Chapter III), were identified as proteins with significant homology to B. anthracis CapA and 
CapD, respectively.  Reduced concentrations of ammonia and Glu residues were present in the cell walls 
of Mtb mutants for both genes, a good indication Rv0574c and Rv2394 could participate in α-L-polyGln 
biosynthesis. Amino acid analysis of WT and complemented strains was unsuccessful as the WT and 
possible the complemented strains stopped accumulating α-L-polyGln in the cell wall. Nevertheless, 
preliminary studies in the murine model of TB suggested that mutants for α-L-polyGln grew and 
disseminated faster in the initial stages of disease, but this difference with the WT strain normalized 
thereafter. Despite the subsequent normalization of lung and spleen bacterial burden, it appears that 
mutants for α-L-polyGln biosynthesis induce more lung inflammation and consolidation throughout the 
course of the infection. Additional studies with mutant and complemented strains should be pursued in 
order to confirm these results.  
 
4.2 Materials and Methods. 
4.2.1 Bioinformatic analyses.  
The amino acid sequences for CapA, B, C, D and E were obtained from the annotated B. 
anthracis strain, ‘Ames Ancestor’ pXO2 plasmid (Accession number NC_007323). These sequences 
were individually analyzed by BLAST against the Mtb H37Rv proteome using Tuberculist. Rv0574c and 
Rv2394 were identified as CapA and CapD homologues, respectively. (Characterization of Rv2394 was 
discussed in Chapter III). The amino acid sequence for Rv0574c was obtained from Tuberculist and 
analyzed using the following bioinformatic analyses tools: BLAST® from NCBI and PROSITE scan, and 
ScanSite pI/Mw available at the Expasy Proteomics Server website. Genomic organization for the 





4.2.2 Genetic inactivation and complementation of rv0574c and rv2394.  
Inactivation of rv0574c and rv2394 was accomplished in Mtb H37Rv by a phage transduction 
system [40]. This system accomplishes an insertion/deletion event in which a substantial fragment of the 
open reading frame is removed and replaced by inserting a hygromycin resistance cassette (performed by 
Dr. Rainer Kalscheuer at Dr. William Jacobs’ lab, Albert Einstein College of Medicine, Bronx, NY).  
For complementation of the rv0574c mutant, two amplicons were obtained by PCR. The first 
amplicon consisted of rv0574c plus 500 bp upstream of the gene’s start codon in order to include the 
putative endogenous promoter. The second amplicon encompassed both rv0574c and rv0573c, plus 500 
bp upstream. This amplicon was engineered to circumvent the possibility that mutation of rv0574c also 
had a polar effect on the expression of the downstream gene rv0573c. A similar strategy was used for 
complementation of the rv2394 mutant. Both amplicons contained rv2394 plus 500 bp upstream of the 
gene’s start codon. The second amplicon contained rv2395 as well in case a polar effect had been 
introduced. Plasmids engineered in this Chapter are described in Table 4.1.  
 
Table 4.1 Plasmid names and description 
 
pGEM-T+rv2462c Plasmid used to clone rv2462c used to synthesize Southern blot probe
pMV306+rv0574c Integrative plasmid to complement the rv0574c mutant. Includes 500bp
upstream of rv0574c start codon in order to use endogenous promoter. *
pMV306+rv0574c_rv0573c Integrative plasmid to complement the rv0574c mutant. Also encodes for
the downstream gene, rv0573c, in order to complement polar effects.
pMV306+rv2394 Integrative plasmid to complement the rv2394 mutant.
pMV306+rv2394_rv2395 Integrative plasmid to complement the rv2394 mutant. Also encodes for the
downstream gene, rv2395, in order to complement polar effects.
Plasmids Description
Table 4.1 Plasmid names nd descriptio
* For all complementation plasmids, the constructs started 500bp upstream of the mutated gene’s start codon, in order to 




PCR primers for complementation studies are described in Table 4.2. PCR and cloning was performed as 
described in Chapter III. The PCR products were inserted in the XbaI and ClaI restriction sites present in 
pMV306, an integrative plasmid containing a kanamycin resistance cassette.   
 
Table 4.2 PCR and qRT-PCR primers 
 
A) PCR primers
a forRv2462c CAT ATG AAG AGC ACC GTC GAG CAG TTG AGC CC   
b revRv2462c AAG CTT CGT TGT CGC TTC GTC GGA CG
c forRv0574c ACT AGT GGC CGG GTG CAT CTC GCT GCT CGG
d revRv0574c ATC GAT TTA CTC CTT GCT CGT TAG GTT GGC AGC
d revRv0573c ATC GAT GTT CTA GGG TCG TTT GGC CTT CGC CCC G
c forRv2394 ACT AGT GCG TTG GTC ACC GGG TAC GCC AGG CCA GTG T
d revRv2394 ATC GAT TCA GGC ATC GTC GCC CAT GAC CGC GC
d revRv2395 ATC GAT TTA CCC AGG CAA ATC GGG CAG TGG CT
B) qRT-PCR primers
e rv0574c.14 CTG ATG TGG TGA CGG TGC TG
rv0574c.129 GGT CGC ATC CCG CAT ATA CC
rv0574c.366 GCT GGC CAA CAA CCA CAT TC
rv0574c.511 CAT GGC CAA CCG TGA CTA GC
rv0574c.1011 CTC CCA GAC CGA CAC CGA AT
rv0574c.1130 GTT AGG TTG GCA GCG GGA AC
rv0573c.75 CGA AAG AAT GTC GGG CAC AG
rv0573c.223 CAC GCA GGT AAC GCA GAT CC
rv1330c.732 CAC GCT GCT GGT GGA TAC CT
rv1330c.840 TAC CCC AAG CTC ACC GGA AT
rv2395.1093 GGT TAC ATG GCC GGG TTG AT
rv2395.1198 CCG GAC CAT ACG CAG TCT TG
rv2394.529 GGA CGG TCG ATC GGA GTA CC
rv2394.663 CCT GGC GCT GAT GTC AAA AC
rv2394.1382 TGA CGA CGA CGG TGG AAT CT
rv2394.1498 CCA CCG GTG ATC CGT CAG TA
rv0773c.1126 TTC ACT GTG GTG CCG AGA CA
rv0773c.1242 CAT CAC CCC GAA GCT CAT CA
Table 4.2 PCR and qRT-PCR primers.
a Underlined NdeI site
b Underlined HindIII site
c Underlined SpeI site
d Underlined ClaI site




4.2.3 Generating Electrocompetent Mtb.  
With minor modifications, electrocompetent Mtb was generated as described before [41]. Both 
rv0574c and rv2394 mutants were grown at 37°C in 7H9 (BD Difco) supplemented with OADC (BD 
Difco), 0.05% Tween 80 and 100 µg/ml of hygromycin (Invitrogen). When cultures reached an OD 
600nm between 0.4-0.6, bacteria were harvested by centrifugation at 3,000 x g for 10 min at 4°C. After 
decanting the supernatant, bacteria were washed twice with ice cold water by inverting the cells and 
centrifuging as before. Finally, mutant H37Rv was washed with ice cold 10% glycerol in water followed 
by centrifugation. After decanting, bacteria were resuspended in 5 ml of 10% glycerol in water and 500 µl 
aliquots were stored at -80°C.  
 
4.2.4 Transformation of mutant Mtb H37Rv.  
Except for minor modifications, transformation of electrocompetent mutant Mtb H37Rv was 
accomplished as described for M.smeg (Chapter III) [41]. After plasmid electroporation, transformed Mtb 
was allowed to recover for 24 h at 37°C in 7H9 media supplemented with OADC and 100 µg/ml of 
hygromycin. Bacteria were then plated in 7H11 agar plates supplemented with OADC and containing 50 
and 100 µg/ml kanamycin (Fisher) and hygromycin, respectively. Plates were incubated at 37°C for 3-4 
weeks until single colonies were obtained. Thereafter, single colonies for each mutant were grown in 10 
ml of 7H9 media supplemented with OADC and kanamycin plus hygromycin, as described above. After 
approximately 2 weeks at 37°C with gentle agitation, 5 ml of culture were harvested by centrifugation at 
3,000 x g for 10 min and after decanting supernatants, bacterial pellets were frozen at -80°C until 
genomic DNA was extracted for Southern Blots. The remaining 5 ml cultures were upscaled to 100 ml in 







4.2.5 g DNA extraction.  
Mtb H37Rv g DNA was extracted as described before with minor modifications [42]. After 
thawing frozen bacterial pellets, they were incubated O/N at 37°C in a solution consisting of 50% 
sucrose, 1 M Tris pH 8.0, 0.5 M EDTA pH 8.0 and 600 µg/ml of lysozyme. Thereafter, bacteria were 
incubated with 200 µg/ml of proteinase K (Sigma), 1% SDS for 4 h at 55°C and then extracted with an 
equal volume of 25:24:1 phenol:chloroform:isoamylalcohol (Sigma) for 30min at RT. After 
centrifugation at 13,000 x g for 10 min, the aqueous layer was transferred to a new tube and the DNA was 
precipitated O/N at -20°C after the addition of 1/10 the volume of 3 M sodium acetate pH 5.2 and 2 
volumes of 100% ice cold ethanol. Precipitated DNA was recovered by centrifuging at 13,000 x g for 30 
min, supernatants were discarded and the pellet was washed with 1 ml of 70% ethanol. Centrifugation 
was carried out as before, the supernatant was removed and the DNA was allowed to dry by evaporation. 
DNA was resuspended in 100 µl of TE buffer pH 8 and quantified with a NanoDrop (ThermoScientific).  
 
4.2.6 Southern Blot.  
To generate the probe for Southern blot, rv2462c was PCR amplified using the primers in Table 
4.2. As described in Chapter III, the PCR amplicon was inserted in pGEM-T Easy (Promega) and cloned 
into TOP10 E.coli (Invitrogen). Plasmids obtained from resulting colonies were confirmed by sequencing 
at PMF in CSU. A plasmid containing the correct insert was digested with NdeI and HindIII and the 
dropout consisting of rv2462c was gel-purified. Gel-purified rv2462c was used to generate a biotinylated 
probe, according to the manufacturer’s protocol (New England Biolabs). Briefly, 100 ng of gel purified 
rv2462c was denatured by boiling for 5 min and incubated with 1X labeling mix (containing biotinylated 
random primers), dNTPs (containing biotinylated ATP) and 5 U Klenow fragment (3’-5’ exo). The PCR 
reaction was allowed to proceed for 3 h at 37°C and after quenching with EDTA, DNA was precipitated 
with ethanol. Precipitated probe was pelleted by centrifugation at 13,000 x g for 30 min, supernatant was 




Five µg of Mtb H37Rv g DNA was digested O/N at 37°C with 20 U of AvrII (New England 
Biolabs). Digested DNA was resolved in a 0.8% agarose gel and depurination was peformed with 0.25 M 
HCl for 10 min. This reaction was stopped with 3 washes of 0.4 M NaOH for 15 min. The DNA was 
subsequently blotted O/N to an Amersham Hibond-N nylon membrane (GE Healthcare Life Sciences) by 
capillarity using 20x SSC buffer.  Using an UV Cross linker (Fisher), blotted DNA was cross-linked to 
the membrane with UV light at 1200  x 100 µJ/cm
2
. Thereafter, the membrane was prehybridized in a 
hybridization oven (VWR) at 68°C for 1h with 5 X Denhardt’s reagent, 0.5% SDS, 6X saline-sodium-
phosphate-EDTA (SSPE) and 100 µg/ml of Salmon Sperm DNA (Sigma).  Biotinylated probe was 
denatured by boiling for 5 min and after keeping in ice for 2 min, was added to the prehybridization 
solution. Hybridization was performed O/N at 68°C. The reaction was detected using the Phototope
®
-Star 
Detection Kit (New England Biolabs). Briefly, the membrane was blocked for 5 min with a solution 
containing 5% SDS, 25 mM sodium phosphate, pH 7.2. Thereafter, streptavidin to a final concentration of 
1 µg/ml was added to the blocking solution and incubated for 5 min. After washing two times, the 
membrane was incubated for 5 min with 0.4 µg/ml biotinylated alkaline phosphatase in blocking solution.  
Once again, the membrane was washed twice and incubated for 5 min with 0.25 mM CDP-Star Reagent 
in 1X CDP-Star Assay Buffer. Finally, the membrane was washed and exposed for 5 min to a fragment of 
clear blue X-ray film. The film was developed using an X-OMat Processor (Eastman Kodak, Rochester, 
NY). 
 
4.2.7 qRT-PCR.  
With some modifications mRNA was obtained as described before [43]. Briefly bacterial pellets 
were transferred to 1 ml of Trizol (Invitrogen) containing silica beads and stored at -80°C until analyzed. 
After thawing samples in ice, bacteria were broken by 3 cycles of bead beating at 4800 rpm for 3 min. 
Trizol was transferred to a tube with an equal volume of chloroform and after centrifuging at 13,000 x g 




phase was precipitated with an equal volume of isopropanol and centrifuged at 13,000 x g for 10 min to 
pellet the RNA. Thereafter, the RNA pellet was washed with 80% ethanol and DNA was digested with 
DNaseI (Fermentas) for 20 min at 37°C. DNaseI was removed by extracting with Phenol and 
centrifugation as described above. Finally, the aqueous layer was precipitated at -80°C with ammonium 
acetate and ethanol as described for the DNA.  RNA pellets were obtained by centrifugation, resuspended 
in RNase free water and quantified by spectrophotometry with a NanoDrop. 
RNA was converted to cDNA using the Superscript III First-Strand Synthesis for RT-PCR kit 
(Invitrogen) [43]. Briefly, RNA was incubated with 50 ng of random hexamers, 200 U of Superscript III, 
40 U of RNaseOut, 20 mM DTT, 6 mM MgCl2 and 1X RT buffer. cDNA synthesis mix was then 
incubated for 10 min at 25°C, and the reverse transcriptase step was performed for 50 min at 50°C. 
Finally, after cDNA synthesis, RNA was removed with RNaseH for 20 min at 37°C. cDNA was then 
normalized to 50 ng/ul for the qRT step.The mix was prepared with 50 nM forward and reverse primers 
(see qRT primers in Table I), 50 ng of cDNA and 1X SYBR green. The thermocycler was programmed to 
perform the following: step 1, 55°C for 2 min; step 2, 95°C for 2 min; step 3, 45 cycles of 95°C for 15 
sec, 60°C for 30 sec and 72°C for 45 sec; step 4, 72°C for 5 min. After the reaction was completed, 
specificity was evaluated by performing a melting curve between 30°-94°C. Data was analyzed using the 
iQ™5 Optical System Software Version 2.1 (Bio-Rad). To obtain mRNA concentration for each gene, 
CT values were extrapolated to curves containing 1, 10 and 100 ng of g DNA. Data was normalized to 
sigA or 16SrRNA (not shown). 
 
4.2.8 Bacterial culture for biochemical analysis.  
Mutant and complemented Mtb H37Rv were grown at 37°C with constant agitation in 100 ml of 
GAS medium containing 50 µg/ml of Kanamycin and 100 µg/ml of Hygromcyin. Thereafter, cultures 
were upscaled by transferring bacterial pellets to FB containing 900 ml of the same medium and grown 




plus antibiotics but cultures were left at 37°C without agitation (static cultures) to induce pellicle 
formation. Similar to Migliore et al [21], the starting material for the current cell wall analysis was 
bacteria harvested from pellicles. Approximately 30 days after inoculating the FB, a thick pellicle had 
grown on the surface of the media at the interphase between air and liquid. Bacterial pellicles were gently 
harvested with a cell scraper avoiding bacteria that had sedimented to the bottom of the FB instead of 
growing on the media’s surface. Bacteria were pelleted by centrifugation at 3,500 x g for 15 min, the 
supernatant was discarded and after freezing at -80°C, bacteria were inactivated by γ-irradiation. 
 
4.2.9 SDS-extracted cell wall.  
Cell wall extraction was performed as described by Hirschfield et al [28]. γ-irradiated Mtb was 
resuspended as a 2:1 weight: volume ratio in PBS containing 1 µg/ml of both DNaseI (Sigma) and 
RNaseA (Sigma). Probe sonication was performed with 3 cycles of 90 sec intermittent pulsing at 50% 
duty cycle in a Cole Palmer (Vernon Hills, IL) sonicator. The slurry was then passed seven times through 
a French Pressure Cell press (Spectronic Instrument, Rochester, NY) at 1200 psi to break cells. Unbroken 
cells were removed by centrifugation at 3000 x g for 5 min and the supernatant was centrifuged at 27,000 
x g for 1 h in order to obtain cell walls. Thereafter, the cell wall was extracted for 2 h at 60°C with 
constant stirring in PBS containing 2% SDS. After SDS extraction, cell wall was obtained by 
centrifugation at 27,000 x g for 30 min, supernatants were discarded and the SDS extraction procedure 
was repeated two more times.  
To remove SDS, cell walls were washed three times with water for 30 min with constant stirring 
and collected by centrifugation as described above. Finally, cell walls were extracted with 80% acetone 
for 30 min in constant stirring. After pelleting the cell wall by centrifugation, it was dried under a stream 






4.2.10 Cell wall amino acid analysis.  
Samples were analyzed as recommended by the manufacturer of the AccQ Tag amino acid 
analysis kit (Waters Corporation, Milford, MA). Briefly, cell wall was resuspended at 25 mg/ml in 6 N 
HCl and hydrolyzed under constant reflux for 20 h at 112°C in 13x100 glass tubes. After centrifuging 
tubes for 15 min at 3,000 x g to remove insoluble material, the supernatant was harvested. An aliquot of 
the hydrolyzates was diluted 60 fold in water so as to reduce the HCl concentration to 0.1 N. Samples 
were then filtered through at 0.2 µM filter to further remove any insoluble material. As internal standard 
(IS), α-aminobutyric acid (MP Biomedicals, Santa Ana, CA) was added to the samples. The sample’s pH 
was then neutralized by mixing the same volume of sample and sodium borate. Neutralized samples (20 
µl) were derivatized with 5 µl of the AccuTag reagent at 55°C for 10 min. Thereafter, 20 µl of derivatized 
sample was resolved on a 3.9 x 150 mm AccQ Tag Amino Acid Analysis Column using the Waters 
HPLC 2695 Separation Module System. The column was kept at 37°C and run at a constant rate of 1 
ml/min. Using this derivatization protocol, 500 pmols of IS would be present in the 20 µl of analyzed 
sample. Amino acid standards (Pierce) were analyzed the same way after addition of an equivalent 
concentration of DAP (Sigma) and IS. It should be noted that commercial DAP was obtained as meso-
DAP and in the amino acid analysis two peaks with similar intensity (250 pmol) were observed.  
Amounts of ammonia, Glu and Ala were determined as follows =    
 
 500 pmol x (area of the amino acid in the sample/area of the IS in the sample) 
       (area of the amino acid in the control/area of the IS in the control) 
Amount of DAP was determined as follows=  
250 pmol x (area of the amino acid in the sample/area of the IS in the sample) 
       (area of the amino acid in the control/area of the IS in the control) 
 






4.2.11 Cell wall lipid analysis.  
Whole lipids were extracted from 100 mg of γ-irradited cells, by an O/N incubation under gentle 
stirring with 5 ml of 2:1 chloroform:methanol [44]. Bacteria were pelleted by centrifugation at 3,000 x g 
for 10 min and supernatants were saved. Bacterial pellets were extracted two additional times following 
the same procedure. Supernatants from the three extractions were pooled and dried under a nitrogen 
stream. As described in the results section, lipids were analyzed by TLC in solvents with different 
polarities and developed by cupric sulfate spraying. 
Mycolic acids were extracted from 10mg of SDS-extracted cell wall core. Mycolic acids were 
hydrolyzed from mAGP by incubating with 15% tetrabutyl ammonium hydroxide for 2 h at 110°C [44]. 
Released mycolic acids were then methylated with dichloromethane and iodomethane by agitation at RT 
for 1hr. After centrifuging at 3,000 x g for 10 min, the organic layer was transferred to a new tube, 
resuspended in 1ml diethyl ether and the soluble material was transferred to another tube. After drying 
under a nitrogen stream, mycolic acid methyl esters (MAMEs) were resuspended in dichloromethane. 
Finally, MAMEs were analyzed by TLC using 95:5 petroleum ether:ether and visualized after spraying 
with cupric sulfate.  
 
4.2.12 Animal studies.  
Six to nine week female C57BL/6 mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). Mice were infected with the Glas-col (Terre Haute, IN) aerosol chamber and the target dose 
was 100 CFUs per animal [45]. At day 1 post-infection, three mice were euthanized by CO2 asfixiation, 
their lungs homogenized and plated on 7H11 plus OADC plates to enumerate bacteria. CFUs were 
counted 3-4 weeks after incubating plates at 37°C. 
At days 30, 90, and 180 post-infection, 5 mice per bacterial strain were euthanized. One lobe was 
perfused with 2% formalin and stored in 2% formalin until processed for histological analysis. The 




4.2.13 Histopathological analysis.  
 A stereology based analysis referred to as the Area Fraction Fractionator, was performed to 
determine the percent lung consolidation [46]. Representative slides were used to determine the lung and 




4.3.1 Bioinformatics analyses.  
Taking in consideration the similarities between Mtb and B. anthracis α-L-polyGln and poly-γ-D-
Glu respectively, it was reasoned that a common biosynthetic pathway could be present in both 
microorganisms. Thus, in the Tuberculist webpage, BLAST analysis was performed to identify Mtb 
homologues of the B. anthracis Cap proteins, which synthesize poly-γ-D-Glu. Whereas no homologues to 
CapB, C or E were detected to be encoded in the Mtb genome, Rv0574c (Fig. 4.1) and Rv2394 (see 
Chapter III) were identified as CapA and CapD homologues, respectively.  Specifically Rv0574c and B. 
anthracis CapA shared 25% identical amino acids with an e score of 7
-17
. Homology between these two 
proteins is mainly present at the protein’s N-terminus, but not at the C-terminus. As no additional 







Figure 4.1 Mtb Rv0574c is a homologue of B. anthracis CapA. The Cap proteins present in B. 
anthracis pXO2 plasmid have been identified to synthesize poly-γ-D-Glu. Thus, the CapA-E proteins 
were analyzed by the BLAST tool in Tuberculist web page to identify Mtb homologues that could be 
involved in α-L-polyGln biosynthesis. In addition to a CapD homologue (Rv2394, see Chapter III), 
Rv0574c was found to have high homology to CapA, specifically at the N-terminus. Several identical and 
conserved amino acids are depicted.  
 
 To identify conserved protein domains and additional Rv0574c homologues, the protein sequence 
of Rv0574c was analyzed by BLAST analysis using the non-redundant NCBI protein database. As can be 
observed in Figure 4.2, a CapA or PgsA domain (pfam09587) was identified in Rv0574c. The difference 






Figure 4.2 Rv0574c has a conserved CapA domain present in proteins involved in poly-Glu 
biosynthesis. The amino acid sequence for Rv0574c was obtained from Tuberculist and analyzed against 
non-redundant proteins, using the BLAST tool from NCBI. Domains present in CapA or PgsA proteins 
involved in poly-Glu biosynthesis were also identified in Rv0574c, suggesting that this protein could be 
CapA’s homologue. 
 
An Rv0574c homologue seems to be present in other Mycobacterium spp. As shown in Table 4.3, 
the genome for some members of the Mtb complex encodes for an identical protein with 99% identity (the 
only difference was in the start codon). An Rv0574c homologue with 91% identity is also present in M. 
cannetti, which also belongs to the Mtb complex. In Table 4.3 it can also be seen that some atypical 










Table 4.3 Identity between Mtb H37Rv Rv0574c and other Mycobacterium spp 
 
 
In B. anthracis the CapA protein is encoded in an operon encompassing capA-capE [29]. As 
described above, it was observed that Mtb rv0574c and rv2394, the homologues of capA and capD 
respectively, are not clustered in an operon. However, it was important to explore the genetic context 
around rv0574c to evaluate its conservation amongst other Mycobacterium spp encoding an Rv0574c 
homologue. Also, bioinformatic analyses might help determine if genes encoded in the rv0574c locus 
could participate in a putative pathway involved in α-L-polyGln biosynthesis. The genetic context of the 
Mtb H37Rv rv0574c locus is conserved amongst other Mtb strains, including clinical isolates, as well as 
in M. bovis and BCG which have Rv0574c homologues with the highest identity (Fig. 4.3). This locus is 
also present in M. cannetti and africanum, additional members of the Mtb complex. Interestingly, the 
locus is also conserved in M. kansassii and to a lesser degree in M. chubuense (not included in Fig. 4.3 
because the genomes for these later Mycobacterium spp, are not available for comparison in the 
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Figure 4.3 Genomic organization of the rv0574c locus is conserved in Mtb and M. bovis. Using the 
comparative genomic organization in the Comprehensive Microbial Resource page, the locus for Mtb 
H37Rv rv0574c was compared to other Mycobacterium spp. This locus was present in Mtb and M. bovis 
strains, including clinical isolates such as CDC1551. The same genomic organization was also observed 
in the attenuated Mtb H37Ra and M. bovis BCG. The region encompassing rv0575c-rv0571c was not 
present in M. smeg, M. avium, M. paratuberculosis, M. leprae or M. abscessus. However, it was also 
detected in M. cannetti, M. kansassi and with some variations, in M. chubuense (not shown).  
 
For the other proteins encoded in the rv0574c locus, it was not possible to definitely allocate a 
role in a putative pathway involved in α-L-polyGln biosynthesis. Bioinformatic analysis suggested that 











Figure 4.4 Rv0575c has an oxygenase domain. Rv0575c’s amino acid sequence was analyzed by 
BLAST analysis against the non-redundant database in the NCBI webpage. An oxygenase domain present 
in several oxidoreductases was detected.  
 
It has been previously reported that Rv0573c has a putative nicotinic phosphoribosyltransferase, 
similar to Rv1330c [47] (see discussion). Rv0572c is a hypothetical protein and during bioinformatics 
analysis, conserved protein domains were not detected (not shown). Finally, Rv0571c seems to be 
composed of two completely different domains: a phosphoribosyltransferase (COG1926) and a hydrolase 




Figure 4.5 Rv0571c has two domains: a hydrolyase and a phosphoribosyl transferase domain. 
Rv0571c’s amino acid sequence was analyzed by BLAST analysis against the non-redundant database in 




(denoted with arrow), whereas a hydrolase domain is present in the C-terminus (denoted with an 
arrowhead). 
Thus, if these proteins are in fact involved in α-L-polyGln biosynthesis, the biochemical pathway 
would be novel and completely different to the one involved in poly-γ-D-Glu biosynthesis. A plausible 
hypothesis is presented in the discussion (see below).  
 
 4.3.2 Mutation of rv0574c and rv2394 in Mtb H37Rv.  
The assumption that Rv0574c and Rv2394 could be involved in α-L-polyGln biosynthesis was 
based on homology to the Cap proteins and conserved genomic organization in virulent strains. In order 
to obtain biochemical data supporting this hypothesis, mutants in rv0574c and rv2394 were engineered in 
Mtb H37Rv. These genes were mutated by an insertion/deletion event using a phage transduction system 
in which part of the open reading frame is removed and replaced with a hygromycin resistance cassette 
[40] (Mutants were constructed by Dr. Rainer Kalscheuer at Dr. Jacobs lab). Mutants were evaluated by 
Southern blot hybridization at the Jacobs lab. In Figure 4.6, it can be observed that gene mutation 
correlated with a shift in the hybridization pattern (no additional information regarding the Southern blot 




Figure 4.6 Southern blot analysis of ∆rv0574c and ∆rv2394. Genomic DNA from the mutant strains 







inactivation. Mutants and WT strains were hybridized with probes against the respective genes 
(performed by Dr. Kalscheuer at Dr. Jacobs lab, Albert Einstein College of Medicine, Bronx, NY).  
 
4.3.3 Biochemical analysis of mutant strains.  
 Even though by transposon mutagenesis analysis it has been reported that Rv0574c and Rv2394 
are non-essential genes [48], it was important to determine if mutants had in vitro growth defects in the 
absence of selection pressures. If so, it would be difficult to ascertain if in vivo growth defects have 
significant physiological relevance. As observed in Figure 4.7, no difference was observed between the 




Figure 4.7 Growth curves of H37Rv WT, ∆rv0574c, ∆rv2394. H37Rv WT and mutant strains ∆rv0574c 
and ∆rv2394 were grown in 7H9 supplemented with OADC and 0.05% Tween-80. Bacterial growth was 
determined by following the OD 600nm over the indicated days. No significant difference in growth rates 























  Biochemical analyses were then performed on the cell wall core of mutant strains to determine 
amino acid composition. To obtain cell wall core, cell walls were extracted thrice with 2% SDS at 60°C 
as this protocol had been previously shown to remove mycobacterial proteins without affecting α-L-
polyGln structure and possibly its concentration [28]. SDS-extracted cell walls were subjected to acid 
hydrolysis in order to obtain free amino acids amenable to amino acid analysis. As observed in the 
representative chromatogram  obtained during amino acid analysis of cell wall cores, only Ala, Glu, DAP 
and ammonia were detected (Fig. 4.8, ammonia is also measurable with the AccuTag® amino acid 
analysis reagent). Thus, only the peptidoglycan-associated amino acids remained after cell wall 
extraction. Excess Glu and ammonia could be attributed to α-L-polyGln reported to remain associated 
with peptidoglycan during this extraction procedure. Interestingly, for both mutants significantly smaller 




Figure 4.8 Representative chromatograms obtained after amino acid analysis show reduced Glu 


















































































































































































































































































































































































































































































hydrolysates were analyzed with the AccuTag® amino acid analysis kit (Waters). An amino acid standard 
(Pierce) was used to determine retention times and the control area for quantitative analysis. In 
comparison to WT H37Rv, both ∆rv0574c and ∆rv2394 had smaller peaks for both Glu and ammonia. 
The other peaks observed during amino acid analysis of SDS-extracted cell wall core correspond to Ala 
and DAP.  α-aminobutyric acid is used the IS. 
Alternatively, data was normalized as the ratio between the amount of each amino acid or 




Figure 4.9 Reduced ratios of Glu/DAP and ammonia/DAP were detected for both mutants. Analysis 
of acid hydrolyzates of SDS-extracted cell wall core were performed after normalizing for the amount of 
DAP. As can be observed, Ala/DAP ratios were similar in mutants and WT H37Rv with an approximate 

















ratio of  2.2:1 as expected based on the mycobacterial cell wall structure. Ratios of Glu/DAP and 
ammonia (NH3)/DAP were reduced in both mutants in comparison to WT H37Rv. Interestingly, even in 
the mutants, the ratio of Glu/DAP was much higher than expected taking in consideration the presence of 
one Glu residue per peptidoglycan pentapeptide.  
 
As reported previously [21] and experimentally determined here, the Glu/DAP ratio in WT 
H37Rv is higher than the expected ratio of 1:1. Even though in both mutants the Glu/DAP ratio was still 
greater than 1:1, an almost 0.5-fold reduction was observed in comparison to WT cell wall. The reduction 
of ammonia/DAP ratio was proportional to the reduction of Glu/DAP, suggesting that this ammonia was 
originating from hydrolyzed Gln. In contrast, the ratio of Ala/DAP remained constant suggesting no 
peptidoglycan changes occurred for both the rv0574c and rv2394 mutants.  
Analyses of the total extractable lipids and the covalently linked mycolic acids were also 
performed on WT and mutants strains. No difference was observed for the mycolic acids, again 







Figure 4.10 Lipid analysis of H37Rv, ∆rv0574c and ∆rv2394 revealed differences in apolar lipids. 
A. Total lipids were extracted from whole cells with 2:1 chloroform:methanol and analyzed by TLC on 
silica plates using different mobile solvent systems, as depicted above. As noted by *, differences 
between WT and mutant Mtb, were only observed when resolving total lipids with an apolar solvent 
system (98:2, chloroform:methanol). Interestingly, a similar pattern was observed for both the rv0574c 
and rv2394 mutant.  
B. Mycolic acids methyl esters (MAMEs) were obtained from SDS-extracted cell wall core and analyzed 
after resolving in a silica TLC. No differences were observed for mycolic acids. TLCs were developed 
with cupric sulfate.  
 
The only noticeable difference was during TLC analysis of total lipids in an apolar solvent 
system, consisting of 98:2 chloroform:methanol (Fig. 4.10, third TLC, denoted with *). Unfortunately, 
this was not explored further and the identity of these lipids was not confirmed. However, others have 
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published that during apolar lipid analysis, the upper band corresponds to PDIMs whereas the lower band 
corresponds to triacylglycerols [49, 50] (see discussion).   
 
4.3.4 Evaluation of the mutant Mtb strains in the murine model of TB.  
C57BL/6 mice were infected with a low dose aerosol of WT H37Rv, ∆rv0574c and ∆rv2394. At 
the indicated time points, mice were euthanized and both lungs and spleens were harvested and plated in 
nutrient 7H11 agar. At day 30 and 180, mice infected with either mutant had higher bacterial burdens in 
the lungs (Fig. 4.11A). Additionally, higher bacterial burdens were also observed at day 30 in the spleens 
of mice infected with either mutant strain (Fig. 4.11B). At early time points, higher extra pulmonary 
bacterial count is a good indicator of increased dissemination. However, as disease progressed, tendencies 
reverted to the one observed for infections with the WT strain. In contrast, histopathological analysis 
suggested that lung lesions in mice infected with the mutant strains were more severe than in mice 
infected with the WT strain, and furthermore, this difference persisted throughout the infection (Fig. 









Figure 4.11 Increased lung and spleen bacterial burden, as well as lung lesion severity in mice 
infected with ∆rv0574c and ∆rv2394. C57BL/6 mice were infected with a low dose aerosol of WT 
H37Rv, ∆rv0574c and ∆rv2394. At the indicated time points, mice were euthanized and both lungs and 
spleens were harvested and plated in nutrient 7H11 agar. A. Mice infected with either mutant had higher 
bacterial burdens in the lungs at day 30 and day 180. B. Faster dissemination to the spleen was observed 
when mice were infected with either mutant. C. The severity of the lung lesions was increased in mice 
infected with mutant strains. Differences were not statistically significant.  
 
4.3.5 Genetic complementation of mutant strains.  
The integrative plasmid pMV306 (Fig. 4.12, left panel) was used to complement the mutant 
strains by cloning the mutated genes in the plasmid’s XbaI and ClaI site (Fig. 4.13B and C, only the 
vectors complementing rv0574c are shown). All the constructs included 500 bp upstream of the mutated 
gene’s start codon, in order to obtain expression of the complemented protein in a physiological context. 
As explained in the material and methods section (see above), two constructs were engineered for each 
mutant. Besides complementing the mutated gene rv0574c (Fig. 4.13B), the second construct also 
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included the downstream gene rv0573c (Fig. 4.13C). As rv0574c and rv0573c are only 9 bp apart, the 
second construct was used to circumvent the possibility that a polar effect had been introduced when the 




Figure 4.12 Maps of the integrative vector pMV306 and both constructs engineered to complement 
the rv0574c mutation. A. The pMV306 plasmid is an integrative vector that encodes for an integrase 
mediating a recombination event between the plasmids attP site and the attB site present in Mtb’s genome 
(Figure 4.13). Furthermore, it encodes for a Kanamycin resistance cassette which can be used as a 
selection marker. Two vectors containing the endogenous putative promoter (as described by D. 
Sherman), were engineered to complement the rv0574c mutation. B. The first construct only included the 
mutated gene rv0574c. C. The second construct included the downstream gene rv0573c in case a polar 
effect had been introduced when mutating rv0574c. Both constructs were inserted in pMV306’s ClaI and 
XbaI site. The AvrII site was used during Southern blot analysis of the complemented bacteria (see Figure 
4.14). 
 
pMV306 encodes for an integrase which performs a site-specific recombination event between 
the plasmid’s (Fig. 4.12A) and Mtb’s genome (Fig. 4.13) attP and attB site, respectively. Furthermore, it 








































observed in Figure 4.14, the Mtb’s attb site (denoted with an arrow head), is located within the gene 
encoding for tRNA
Gly




Figure 4.13 Schematic representation of a recombination event between Mtb’s chromosome and 
pMV306. The integrase encoded in pMV306 (top) mediates a recombination event between the attP and 
attB site present in the plasmid and Mtb chromosome (middle), respectively. In Mtb genome, the attB site 
lies in the tRNA
gly
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by 10,270 bp. This fragment contains the gene rv2462c which was used to generate the Southern blot 
probe. A second AvrII site is present downstream and is separated from the first one by 14,525 bp (red 
arrow and *). Integration of pMV306 inserts an AvrII site (bottom, dotted line), and rv2462c becomes 
embedded in a 7,456 bp fragment instead. During Southern blot analysis of WT and mutant strains using 
a probe against rv2462c, it was observed that AvrII digestion resulted in a fragment of approx. 14 kb (see 
Fig. 4.15). This probably reflects that AvrII digestion occurred in the last site (denoted by red arrow and 
*). After complementation with pMV306-based vectors (see fig. 4.13), Southern blot analysis confirmed 
the AvrII insertion and the rv2462c-reactive bands were proportional to the size of the different 
engineered constructs.  
 
It was decided that a general way to screen for a recombination event between all of the 
engineered pMV306-based complementation plasmids and Mtb’s genome, was to perform Southern blots 
targeting rv2462c.  Digestion of WT genomic DNA with AvrII should result in a 10,270 bp fragment 
hybridizing to a probe targeting rv2462c (Fig. 4.13 arrows point to the closest AvrII restriction sites 
flanking rv2462c).   
In contrast, a band migrating above 10 kb was observed (Fig. 4.14), suggesting that digestion 
occurred at the next downstream AvrII site, resulting in a 14,525 bp fragment instead (Fig. 4.13, denoted 







Figure 4.14 Southern blot analysis of complemented ∆rv0574c and ∆rv2394. Mutant complementation 
was achieved with pMV306-derived vectors. The attB site where pMV306 recombines is in close 
proximity to rv2462c which was used to synthesize the biotinylated probe used in this Southern blot. A 
higher than expected band was obtained for WT, ∆rv0574c and ∆rv2394. Bands for complemented strains 
were consistent with expected size (see Fig. 4.13). Lane 1, WT H37Rv, lane 2 ∆rv0574c, lane 3 ∆rv0574c 
complemented with pMV306 (vector control), lane 4 ∆rv0574c complemented with pMV306+rv0574c, 
lane 5 ∆rv0574c complemented with pMV306+0574_0573c. As rv0574c and rv0573c overlap, 
complementation of ∆rv0574c was also performed using a construct containing both genes (lane 5). Lane 
6, ∆r2394, lane 7 ∆r2394 complemented with pMV306, note the same hybridization pattern as lane 3 
corresponding to ∆rv0574c complemented with pMV306. Lane 8, ∆r2394 complemented with 
pMV306+2394. Note that complementation with rv2394 results in a smaller fragment than with vector 
alone, attributed to an additional AvrII site present in the gene’s promoter coding sequence. Lane 9, 













Digestion with AvrII consistently led to a bigger fragment than expected and currently the reason 
for this is unknown. One possible is point mutations which have been described to occur even within a 
same lab [51].  Despite this, several lines of evidence suggested that it was prudent to continue. First, the 
plasmid encoding rv2462c was sequenced. Second, the biotinylated probe was obtained from a gel-
purified rv2462c dropout obtained after restriction enzyme digestion. Third, during Southern blot analysis 
of the complemented strains, the rv2462c probe hybridized to a unique and very sharp band (Fig. 4.14). 
This is consistent with the fact that the Mtb genome does not encode for other homologues of rv2462c. 
Finally and most important, analysis of the bands resulting after complementation corresponded to the 
expected size. In Figure 4.14, it can be observed that recombination between Mtb’s DNA and pMV306 
would insert an AvrII site, resulting in a 7456 bp band during Southern blot analysis. The size of this band 
is in accordance to the one detected experimentally (Fig. 4.14, lane 3). Complementation with 
pMV306+0574c, or pMV306+0574c_0573c should generate bands corresponding to 9,099 and 10,503 
bp, respectively similar to the bands detected in the Southern blot (Fig. 4.15, lanes 4 and 5). For the 
∆2394 mutant, complementation with pMV306+2394 should result in a smaller band than 
complementation with empty vector, as rv2394's promoter encodes for an additional AvrII site (Fig. 4.14 
lane 7 vs lane 8).  When the ∆2394 mutant is complemented with pMV306+2394_2395, a band of 
approximately 10 kb should be observed taking in consideration that rv2395 is almost 2000 bp (Fig. 4.14, 
lane 9). 
 
 Finally, complementation of mutant strains was evaluated by qRT-PCR to determine that 
complemented genes were being expressed to similar levels as WT control. Several sets of primers were 
used to analyze each of the mutated genes (see Table 4.2 for qRT-PCR primers). Furthermore, qRT-PCR 
was also performed on the gene downstream of the mutation in order to evaluate polar effects. As rv2394 
(see Chapter III) and rv0773c both seem to encode a GGT, expression of rv0773c was evaluated in the 




rv1330c have been suggested to encode for redundant phosphoribosyl transferases [47], expression of the 
later gene was evaluated to determine compensatory mechanisms in case mutating rv0574c had a polar 
effect on rv0573c’s expression. As observed in Figure 4.15A, mutating rv0574c effectively abolished its 
expression as determined by the three sets of primers being evaluated. Complementation with both 
constructs restored the expression of rv0574c and in addition, this mutation didn’t seem to have a 
significant polar effect on the expression of rv0573c. No difference in rv1330c expression was observed 




Figure 4.15 qRT-PCR analysis confirming the lack of ∆rv0574c and ∆rv2394 expression in mutants 
and efficient complementation. mRNA was obtained for rv0574c and rv2394 mutants and 
complemented strains. qRT-PCR analysis was performed to evaluate the mRNA expression levels for the 








































































and complemented strains, respectively. Data is expressed as the ratio of mRNA for each respective 
gene/mRNA for SigA A. Primers 0574c-1 and 0574c-2 did not amplify any mRNA for ∆rv0574c and 
∆rv0574c complemented with an empty vector (+Int). In contrast, complemented strains including gene 
rv0574c or rv0574c_rv0573c restored mRNA expression levels. Levels of mRNA for rv0573c were 
enhanced when co-expressing both rv0574c_rv0573c in the integrative plasmid. No differences were 
observed for rv1330c, an rv0573c homologue suggesting that this gene was not being up-regulated to 
compensate for the lack of rv0573c. B. Expression levels for rv2394 were less than for rv0574c even in 
the WT H37Rv. Nevertheless it can be observed that for the ∆rv2394 mutant or the mutant complemented 
with an empty vector (Int), both primers amplified between 1000 to 10,000-fold less mRNA. Expression 
levels for rv2394 were restored to WT levels when complementing with either rv2394 or rv2394_rv2395. 
Interestingly, mutants and complemented strains had increased mRNA expression levels for rv2395, 
suggesting that mutation in rv2394 had a polar but positive effect on the expression of rv2395. Expression 
of rv0773c, an additional ggt was not affected by rv2394’s mutation. 
 
Similar to what was observed for the rv0574c mutant, mutating rv2394 abrogated its expression 
(Fig. 4.15B). Furthermore, no compensation was observed for rv0773c, the gene encoding a putative 
GGT homologue. Complementing the mutated gene restored rv2394’s expression to WT levels. 
Interestingly, mutating rv2394 had a polar but positive effect on the expression of rv2395, the 
downstream gene.  If this later gene has a role in α-L-polyGln biosynthesis, then the uncontrolled 
expression of rv2395 could affect the polymer’s concentration. This remains to be investigated.  
 
4.3.6 Amino acid analysis of complemented strains.  
 After confirming by both Southern blot and qRT-PCR that complementation of mutant strains 
had been achieved, amino acid analysis of SDS-extracted cell wall cores was performed (Fig. 4.16). 




Instead of obtaining a similar ratio of Glu/DAP of approx. 12 (see Fig. 4.9), the new ratio was approx. 6, 
very similar to the ratios previously obtained for the mutants.  These new results precluded further 
experimentation and require re-evaluating the phenotype of the mutant and WT strains. It is known that 
the Mtb genome accrues considerable number of mutations during in vitro culturing, which tend to 
abrogate its virulence [51, 52]. It has been suggested that in order to maintain Mtb virulence, bacterial 
strains should frequently be subjected to the selection pressure of in vivo conditions [51]. Future 




Figure 4.16 Amino acid analysis of SDS-extracted cell wall core in WT, mutant and complemented 
strains. Amino acid analysis was performed on SDS-extracted cell wall cores from WT, mutant and 






















complemented strains. Unfortunately, overall trends were different than observed in Fig. 4.9. The WT, 
mutant and complemented strains had similar ratios of Glu, NH3 and Ala to DAP.  
 
4.4 Discussion.  
 The presence of pathogen-specific products is a unique opportunity to understand virulence 
mechanisms. In the TB field, comparison between avirulent BCG and virulent M. bovis [53], led to the 
discovery that the RD1 encodes for a specialized protein secretion system. Other examples of virulence 
determinants present in Mtb and M. bovis as opposed to environmental Mycobacterium include the 
identification of PDIM and SL in the former strains. In contrast, no specific role in pathogenesis has been 
identified in some Mtb-specific products such as SL [54]. However, this could be attributed to problems 
in experimental designs or models. As genome reduction is a common theme in the evolution of 
pathogens [55], the fact that a metabolic pathway is preserved in a virulent microorganism should 
mandate its evaluation. Similar to B. anthracis, Mtb synthesizes an amino acid polymer that is present in 
the bacterium’s cell wall. Since B. anthracis requires poly-γ-D-Glu for its virulence [22], it was 
hypothesized that α-L-polyGln, an Mtb specific product, could also have a role in TB. In this Chapter, the 
identification of genes involved in the biosynthesis of the Mtb-specific α-L-polyGln was sought using the 
B. anthracis model of poly-γ-D-Glu biosynthesis. Rv0574c and Rv2394 were determined to be the most 
likely candidates involved in α-L-polyGln biosynthesis, as they share high homology to B. anthracis 
CapA and D, respectively. Mutants for both genes were generated and evaluated biochemically, as well as 
in animal models of TB.  
  As mentioned, the initial strategy to identify Mtb genes that could be involved in α-L-polyGln 
biosynthesis was based on the polymer’s similar structure and biochemical composition to B. anthracis 
poly-γ-D-Glu. Rv0574c and Rv2394 were identified as Mtb proteins with high homology to B. anthracis 
CapA and D respectively, which are involved in poly-γ-D-Glu biosynthesis. In the Bacillus model, CapA 




the peptidoglycan [33-35]. However, no Mtb homologues were identified for CapB, the actual protein 
involved in polymerizing D-Glu residues [22, 30]. Furthermore, initial bioinformatics analysis suggested 
that the proteins encoded in either the rv0574c or rv2394 loci could not perform an amino acid 
polymerization reaction. Other alternatives were therefore sought based on the following premises. The 
covalent polymerization of Gln residues to make α-L-polyGln requires the formation of an energy-
dependent peptide bond. Three major mechanisms have evolved in nature to catalyze covalent linkages 
between amino acids. For transpeptidases (see Chapter III), energy released from a cleaved bond is 
harnessed to make the new bond. More commonly, energy is consumed in the form of ATP in order to 
activate the donor or acceptor molecule via amino acyl adenylates or acyl phosphate intermediates.  As 
can be observed in Figure 4.17, in acyl phosphates the substrate is directly phosphorylated and ADP is 
released. In contrast, in acyl adenylates the substrate is directly linked to AMP through a phosphodiester 




Figure 4.17 Activation of substrates as acyl phosphates or acyl adenylates. Activation of L-alanine is 














(lower reaction). In both cases, ATP is consumed. During the generation of acyl phosphate, a phosphate 
residue is directly conjugated to the substrate and ADP is released. In contrast, during acyl adenylate 
generation, the substrate is conjugated to AMP and pyrophosphate (PPi) is released.  In both cases, high 
energy bonds are generated and will provide the energy for subsequent reactions. 
 
Formation of amino acyl adenylates is the more frequent way to activate amino acids and this 
occurs in both ribosomal and non-ribosomal peptide synthesis [56, 57]. In conventional ribosomal protein 
synthesis, tRNA synthetase generate amino acyl adenylates which are rapidly transferred to the 3’OH 
group of the tRNA [58]. Homology searches for proteins with a tRNA synthetase-like activity that could 
be involved in α-L-polyGln biosynthesis, did not yield additional proteins besides tRNA synthetases (not 
shown). Non-ribosomal peptide synthetase was also considered as another alternative for the biosynthesis 
of α-L-polyGln. Mtb only has two non-ribosomal peptide synthetase: the Mbt proteins involved in 
mycobactin synthesis [59] (see Chapter I) and Rv0101. Rv0101 is composed of two adenylation domains 
that have homology to the ones present in Mbt. However, Rv0101 was considered a second tier candidate 
for α-L-polyGln biosynthesis, as M. smeg encodes for a similar protein (Msmeg_4511) despite not 
producing α-L-polyGln. Recently, several lines of evidence have suggested that Rv0101 encodes for a 
non-ribosomal peptide synthetase involved in the biosynthesis of a hereto uncharacterized lipopeptide 
[60, 61]. In regards to acyl phosphates involved in the formation of peptide bonds, the classical example 
is the Mur proteins participating in peptidoglycan biosynthesis [62]. Interestingly, in this case the 
accepting peptidoglycan stem is the activated molecule instead of the incoming amino acid (donor). The 
folC protein (Rv2447c) that catalyzes the biosynthesis of folyl-polyglutamates was the only protein 
identified during bioinformatics analysis searching for Mur-like proteins that could be involved in α-L-
polyGln biosynthesis (not shown). This strong resemblance between the Mur proteins and folC had been 
reported several years ago and a special family of amide ligases was proposed [62]. Interestingly, CapB 




activity of the latter proteins, experimental evidence suggests that during poly-γ-D-Glu biosynthesis, 
CapB activates via an acyl phosphate the elongating polymer as opposed to the incoming D-Glu [30]. 
However, folC is also conserved in many microorganisms [63] and was not considered to participate in α-
L-polyGln biosynthesis.  Altogether, after this extensive but unsuccessful analysis searching for other 
genes involved in Mtb’s α-L-polyGln biosynthesis, it was decided that the rv0574c and rv2394 loci would 
be the initial focus of this study and future work would be dictated by the biochemical and phenotypic 
analysis of the mutant strains. Indeed, the major finding in this study consisting of reduced amount of Glu 
and ammonia in the cell wall of both rv0574c and rv2394 mutants tends to support the hypothesis that 
these loci are involved in α-L-polyGln biosynthesis. Noticeably, both mutants behaved similarly during 
biochemical analysis and animal studies, further substantiating that Rv0574c and Rv2394 could be 
involved in the same pathway despite not being encoded in the same locus.  
Capsular poly-γ-D-Glu is completely essential for B. anthracis virulence [22]. The proteins 
involved in this biosynthetic pathway are encoded in the pX02 plasmid [23, 24], one of the two B. 
anthracis plasmids. The other plasmid, pX01, is also essential for its virulence as it encodes for the potent 
protective toxin [64]. The role of poly-γ-D-Glu in B. anthracis virulence is intimately related to its 
subcellular localization and structure. This product is present in the bacillus capsule which is exposed to 
the immune system.  In contrast to non-encapsulated B. anthracis, the poly-γ-D-Glu capsule inhibits 
phagocytosis [29]. Thus, the bacterium remains extracellular where it can readily multiply. Furthermore, 
as the capsule is composed of D-Glu residues forming γ-linkages [65], host proteases are less able to 
digest this product. In turn, lack of antigen processing and presenting makes poly-γ-D-Glu poorly 
immunogenic [65]. In terms of vaccine development, poor immunogenicity for bacterial surface products 
had been encountered with the polysaccharides present in Neisseria meningitides, Haemophilus influenza 
and Streptococcus pneumonia [66]. In order to circumvent this lack of immunogenicity, successful 
vaccines were engineered by covalently linking the polysaccharides to a carrier protein [66]. Interestingly, 




developed against poly-γ-D-Glu conjugated to a carrier protein was shown to enhance in vitro 
opsonophagocytosis [67]. More importantly, recent in vivo studies using the same vaccine approach 
partially prevented the development of anthrax in guinea pigs [68]. S. epidermidis has also been shown to 
synthesize capsular poly-Glu, but in contrast to B.anthracis, the polymer consists of both D and L amino 
acids [69]. However, S. epidermidis polymer also protects against neutrophil phagocytosis and anti-
microbial peptides. S. epidermidis mainly causes nosocomial infections, specifically those involving 
catheters. Despite successful attachment and biofilm formation ex vivo in catheters, S. epidermidis lacking 
poly-Glu did not thrive in vivo after the contaminated catheter was implanted in an animal [69]. 
Altogether, results with these bacteria have highlighted a role for poly-Glu in predominantly inhibiting 
the innate immune system.  
In contrast to B. anthracis poly-γ-D-Glu, no role in pathogenesis has been attributed to Mtb’s α-
L-polyGln. Mutants for the rv0574c and rv2394 genes putatively involved in α-L-polyGln biosynthesis 
were engineered in order to test in animal models the hypothesis that the polymer’s presence in virulent 
Mycobacterium is associated to pathogenicity. Interestingly, at early time points increased bacterial 
burden was observed in the lungs and spleens of mice infected with these mutant strains. As disease 
progressed, the difference waned and mutant and WT strains behaved similarly in terms of bacterial 
burden. In contrast, histological analysis revealed that lungs from mice infected with mutant strains had a 
tendency to be more compromised and this persisted throughout the acute and chronic stages of infection. 
This could rule out a CFU-dependent effect on pathological severity. Instead, phenotypic differences 
between mutant and WT strains could more likely account for this observation. If Rv0574c and Rv2394 
participate in α-L-polyGln biosynthesis, than the more pronounced effect early after infection with these 
mutants, might suggest that this polymer could also affect the innate immune system as described for B. 
anthracis poly-γ-D-Glu. However, despite its localization in Mtb’s cell wall, α-L-polyGln is not currently 
considered to be surface exposed [70]. If this is true, it probably does not have a direct role during the 




Alternative roles for Mtb’s α-L-polyGln in TB pathogenesis could be sought in poly-Gln 
expanding diseases. This group of diseases is characterized by mutations that increase the numbers of Gln 
repeats normally present in human proteins [71]. Pathogenesis in poly-Gln expanding diseases is 
attributed to a loss of function of the mutated protein and more importantly, to the insolubility and 
aggregating tendency of longer Gln stretches [72], a biophysical effect that could also explain α-L-
polyGln insolubility. A major finding in expanding poly-Gln diseases is proteasome malfunction 
attributed to its inability to degrade the aggregated proteins [73, 74]. A similar situation might occur with 
WT Mtb and its α-L-polyGln could constitute an evasion mechanism against antigen presentation. Loss of 
α-L-polyGln in both mutants could lead to more efficient proteasome-mediated antigen processing and 
presentation. In turn, enhanced inflammation could ensue due to increased Tcell priming and activation. 
Furthermore, diminished NF-κB function has been observed in expanding poly-Gln diseases as a 
consequence of proteasome malfunction [75, 76]. In the absence of α-L-polyGln, enhanced NF-κB-
mediated signaling could increase the inflammatory response against mutant Mtb.  Cell biology studies 
with purified α-L-polyGln could help elucidate a direct role for this polymer. After all, it seems that 
during the course of Mtb infection the immune system encounters this product, as anti-α-L-polyGln 
antibodies were detected in the rabbit model of TB [70].  
Abrogating Mtb α-L-polyGln biosynthesis could have an indirect as opposed to a direct role in 
TB pathogenesis. For instance, cell wall modifications could probably induce a compensatory effect [4]. 
In fact, mutations abrogating the synthesis of diacyl and polyacyltrehalose led to alterations in Mtb’s 
capsule and this affected the bacillus-host cell interaction [77]. Specifically for α-L-polyGln deficient 
mutants rv0574c and rv2394, it seemed that increased concentration of PDIM might be present in the pool 
of extractable cell wall lipids. Thus, in vivo results with α-L-polyGln mutants could instead be attributed 
to the pro-inflammatory effect mediated by PDIM, a major Mtb virulence factor [78, 79]. Compensatory 
effects involving PDIM have also been reported for mutants in SL biosynthesis [80]. In this case, excess 




of methylmalonyl-CoA is shunted into PDIM biosynthesis resulting in SL mutants containing higher 
abundance of longer PDIM molecules [80]. In turn, increased PDIM concentration could explain why no 
in vivo growth defect for SL mutants was observed in the guinea pig model [54]. A similar metabolic 
effect leading to enhanced PDIM biosynthesis could also be envisioned for both α-L-polyGln mutants 
rv0574c and rv2394.  
It is well known that Gln is an excellent anaplerotic molecule that enters the TCA cycle as 
ketoglutarate after consecutively losing its amido and amino group [81]. If the rv0574c and rv2394 
mutants do not incorporate Gln into α-L-polyGln, then excess Gln in the form of ketoglutarate could be 
entering the TCA cycle. In the TCA cycle, excess ketoglutarate would be converted into succinyl-CoA, a 
precursor of methylmalonyl-CoA [80]. Thus, mutations in both SL and α-L-polyGln could have similar 
metabolic consequences consisting of excess methylmalonyl-CoA, which could be shunted into PDIM 
biosynthesis. As a corollary to this hypothesis, PDIM length could also be increased in α-L-polyGln 
mutants. From a metabolic perspective, an additional interesting observation with both mutants was the 
absence of TAGs during apolar lipid analysis. Accumulation of TAGs is considered an important marker 
of dormant Mtb [82, 83]. In fact, rv1330c, the gene encoding the most active triacylglycerol synthase, is 
part of the dormancy regulon [84, 85]. Interestingly, the rv0574c locus described herein to participate in 
α-L-polyGln, is also part of the dormancy regulon [86]. One consideration is that α-L-polyGln is a Gln 
depot system (discussed in Chapter V). Thus, the dormancy regulon could be shifting Mtb into 
“hibernation” mode in which carbon and nitrogen sources are stored as TAG and α-L-polyGln, 
respectively. In contrast, reduced carbon or nitrogen depots seem to be present in the rv0574c and rv2394 
mutants and these strains would be less likely to enter a dormant phase. A constantly higher metabolic 
activity in mutant strains could also lead to the increased inflammation observed in infected mice, as this 
could be associated with enhanced protein secretion known to contain multiple enzymatic activities [87].  
Extrapolating results from animal models to human TB can be challenging taking in 




methodology in animal models. However, results reported herein are especially compelling in the context 
of some recent epidemiological observations done in cattle and humans. A strain of M. bovis was detected 
to have quickly spread in cattle in West Africa [88]. Molecular epidemiology techniques confirmed that 
this strain of M. bovis had a deletion affecting Mb0586c to Mb0590c, equivalent to Mtb’s rv0575c to 
rv0571c. Furthermore, mutations encompassing rv0571c-rv0572c have been identified in human clinical 
isolates [89]. In both studies it was suggested that mutant strains had a selective advantage over WT and 
this advantage had only recently become important as these genes are conserved in most other clinical 
isolates. Even though these studies were exclusively epidemiological and were not accompanied with 
histopathological analysis, results obtained in the murine model with the rv0574c and rv2394 mutant 
could give some insight into the epidemiological findings. As occurred in the murine model, mutations 
did not seem to affect microbial fitness in either humans or cattle.  Selective advantage for the mutants 
could instead be attributed to increased transmission, explaining its fast dissemination in West Africa 
[88]. For both α-L-polyGln deficient mutants, faster replication kinetics was observed in the initial stages 
of infection and this correlated with enhanced inflammation. It is well known that Mtb transmission 
requires substantial inflammation and tissue damage. Thus, one possibility is that these clinical strains are 
being transmitted quicker because of their initial faster growth and lung damage leading to cavitation 
[90]. Development of transmission models could help evaluate this hypothesis.   
If the role of Rv0574c and Rv2394 is to transport α-L-polyGln and crosslink it in or to the cell 
wall respectively, which Mtb gene(s) encode for proteins involved in amino acid activation and 
polymerization? After thoroughly analyzing both loci, the following α-L-polyGln biosynthetic pathway is 
proposed on theoretical grounds but experimental evidence is required (rv2394 locus is discussed in 
Chapter III). The proposed pathway starts with Rv0573c, encoded only 9 bp downstream of the rv0574c 
gene mutated in this study. This genetic proximity is a common finding when consecutive genes are in an 
operon, constitute a transcriptional unit and participate in the same biochemical pathway. However, 




described for Rv1330c [47]. Interestingly, recombinant Rv1330c was indeed shown to have nicotinic 
phosphoribosyl transferase activity but this was not the case for recombinant Rv0573c. Instead, 
Rv0573c’s nicotinic phosphoribosyl transferase activity was inferred from mutagenesis experiments. 
Whereas single mutations of either rv1330c or rv0573c did not affect the nicotinic acid pool, this was 
accomplished by double mutations. However and consistent with the lack of nicotinic phosphoribosyl 
transferase activity in recombinant Rv0573c, it is possible that in the context of an Rv1330c mutation, a 
‘moonlighting’ nicotinic phosphoribosyl transferase could be present in Rv0573c. Hence, a ‘pseudo-
redundancy’ might be concluded. It is clear that Rv1330c’s substrates are phosphoribosyl pyrophosphate 
(PRPP) and nicotinic acid and the enzyme catalyzes a nicotinic phosphoribosyl transferase activity (Fig. 
4.18, left reaction). Recombinant Rv0573c did not utilize nicotinic acid, but taking in consideration its 
high homology to Rv1330c, its respective cognate substrate should be similar to nicotinic acid. Picolinic 
acid (Fig. 4.18 center, top row), is a catabolyte from the tryptophan pathway [91] and is an isomer of 
nicotinic acid only differing in the position of the carboxylate in reference to the pyridine ring. 
Remarkably, picolinic acid’s structure is very similar to pyrroline carboxylic acid (Fig. 4.18, right, top 
row), a cyclized form derived from Glu-γ-semialdehyde [92], an intermediate in Glu, Pro and Ornithine 
metabolism. Taking in consideration the similar structures of these compounds, a possibility is that 
Rv0573c catalyzes a reaction in which PRPP and pyrroline carboxylic acid are linked together by a 
glycosidic bond and form a novel compound, pyrroline carboxylate-D-ribonucleotide (Fig. 4.18, reaction 






Figure 4.18  Rv0573c’s substrate could be pyrroline carboxylic acid which resembles nicotinic and 
picolinic acid. Picolinic acid (top row, center) is an isomer of nicotinic acid (top row, left). The 
carboxylic group is located in the second and third position of the pyridine ring, respectively. Pyrroline 
carboxylic acid only has a five atom ring (top row, right). However, for both pyrroline carboxylic acid 
and picolinic acid, notice the similar position of the carboxylic acid in reference to the nitrogen group. 
Rv1330c’s activity is depicted on the left, resulting in the generation of nicotinate-D-ribonucleotide. 
Rv0573c’s hypothetical activity is depicted on the right. Its activity produces a hypothetical compound: 
pyrroline carboxylate-D-ribonucleotide. PRPP, phosphoribosyl pyrophosphate. PPi, pyrophosphate. 
 
It is possible that this reaction could contribute to the previously reported increased hepatic 




Pyrroline carboxylate-D-ribonucleotide could then be the substrate for Rv0575c. As observed in Figure 
4.4, an oxygenase domain was detected in Rv0575c. Interestingly, Rv0575c’s oxygenase domain is 
homologous to the one present in salicylate monooxygenase.  
As implied by its name, this latter enzyme adds a hydroxyl group to salicylic acid, a carboxylated 
ring-based molecule sharing some features to the pyrroline carboxylate moiety putatively present in 
pyrroline carboxylate D-ribonucleotide. Thus, Rv0575c could introduce one oxygen atom to the ring 
structure present in pyrroline carboxylate D-ribonucleotide (Fig. 4.19). Double bonds would 
spontaneously reaccommodate in this hydroxylated molecule, to form pyroglutamate-D-ribonucleotide. 
Pyroglutamate (pyroGlu) is a cyclized form of Glu/Gln. 
The last steps of this pathway would be catalyzed by Rv0571c, hypothesized to be a bi-functional 
protein with two independent domains (see Fig. 4.5). The C-terminus domain of Rv0571c has homology 
to hydrolases, in particular to dienelactone hydrolases capable of hydrolyzing ring structures [94]. Thus, 
this domain would hydrolyze the pyroGlu ring present in pyroGlu-D-ribonucleotide and convert it to Glu-






Figure 4.19 Role of the genes encoded in the rv0574c locus in a putative biochemical pathway 




pyrroline carboxylate to PRPP in an analogous way as nicotinic phosphoribosyl transferase (Fig. 4.17). 
Rv0575c would then insert an oxygen atom to pyrroline carboxylate-D-ribonucleotide, which becomes 
pyroGlu-D-ribonucleotide after spontaneous reaccommodation of the double bonds. Rv0571c has two 
domains: a hydrolase domain and a phosphoribosyl transferase domain. The hydrolase domain would 
open the pyroGlu ring and generate Glu-D-ribonucleotide. Finally, the phosphoribosyl transferase domain 
would release Glu and catalyze a covalent bond between this Glu residue and the free carboxylate moiety 
from another pyroGlu-D-ribonucleotide. Ribophosphate would be a by-product of this reaction.  
 
Glu-D-ribonucleotide is analogous to an amino acyl-tRNA involved in conventional ribosomal 
protein synthesis [58].  In amino acyl-tRNA, both molecules are linked by an ester bond between the 
amino acid’s α-carboxyl group and the ribose’s 2’ hydroxyl group. Instead, in Glu-D-ribonucleotide the 
linkage would be a glycosidic bond between Glu’s α-amino group and ribose’s anomeric carbon. During 
Rv0571c’s phosphoribosyl transferase activity, the amino terminus of the Glu residue would be released 
from the ribose ring and be covalently linked to the carboxyl group of and incoming pyroGlu D-
ribonucleotide. Similar to transpeptidases which crosslink amino acids by harnessing the energy released 
from a cleaved bond, the energy to join the Glu and pyroGlu D-ribonucleotide could come from the 
cleaved bonds catalyzed by Rv0571c: pyroGlu hydrolysis and/or phosphoribosyl transferase. An iterative 
reaction consisting of crosslinking Glu and pyroGlu-D-ribonucleotide would occur until the growing 
poly-Glu chain has achieved a critical size. 
Multiple unknowns remain in this hypothetical pathway. For instance, identifying a role for 
Rv0572c is hampered by its lack of characterized functional domains. In addition, enzymes and 
subcellular localization of Glu amidation converting poly-Glu to α-L-polyGln is not known. Finally, 
besides postulating that Rv0574c could participate during extracellular transport of α-L-polyGln, the 
mechanism and source of energy is still unknown. The proposed pathway could be evaluated using in 




95]. In the first case, individual proteins from the rv0574c locus would be heterologous expressed in E. 
coli and recombinant proteins would be purified. As described in [47], an initial phosphoribosyl reaction 
would be performed using PRPP and pyrroline carboxylic acid. In this case, pyrroline carboxylic acid 
would be the radiolabeled substrate as it is the precursor for all subsequent steps. In a step by step 
sequence described in Figure 4.19, each product would be subsequently exposed to the respective 
enzyme. Intermediate products could be confirmed using TLC and/or mass spectrometry analysis.  The 
final product should constitute of small oligopeptides of Glu residues in an α-linkage. Alternatively, the 
pathway could be evaluated in M. smeg after introducing a cosmid with the rv0574c locus. As previously 
described in the discussion, several genes in the rv0574c locus are regulated by the dormancy regulon 
[86].  Thus, expression of the genes included in this cosmid would require inducing dormancy in M. 
smeg. Fortunately, it has been described that M. smeg conserves the two-component regulatory system 
that regulates dormancy in the presence of low oxygen concentrations [96]. In this case, after inducing 
dormancy in recombinant M. smeg containing the cosmid, oligopeptides of Glu could be obtained in the 
cytoplasm. Glu oligopeptides could also be recovered in the supernatant instead of the cell wall, as this 
recombinant M. smeg would lack the rv2394 locus that encodes for the GGT that crosslinks the 
oligopeptides (see Chapter III).  
In conclusion, in this Chapter candidate genes for α-L-polyGln biosynthesis were identified and 
mutated in order to obtain preliminary results into a biosynthetic pathway and a putative role in 
pathogenesis.  Biochemical analysis identified reduced amounts of Glu and ammonia in the cell wall of 
rv0574c and rv2394 mutant Mtb strains. As Gln is hydrolyzed into Glu and ammonia, lower amounts of 
these compounds is a good indication that biosynthesis of α-L-polyGln had been affected in the mutant 
strains. Finally, mice infected with Mtb mutants for rv0574c or rv2394 had higher bacterial burden in the 
early stages of disease and this correlated with faster extra-pulmonary dissemination. In these mice, more 
severe lung pathology was present during the earlier stage of disease and persisted throughout the course 




immunomodulatory function. Unfortunately, the initial phenotype consisting of high Glu/DAP ratios for 
the WT strain, was not observed while evaluating complementation. Instead, similar Glu/DAP ratios were 
seen for WT, mutant and complemented strains. Thus, it was not possible to document if 
complementation could restore the normal ratios in the mutant strains. Further experiments are warranted 
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“For we cannot stop where we are, nor at once accept as a solution to all our difficulties the theory 
which has its avowed basis in experiment and not in clinical observation, and which is as yet rather the 
fruit of the laboratory than of the hospital” James E. Pollock, Croonian Lectures, 1883. [1] 
 
Epidemiological studies evaluating skin test positivity have estimated that one third of the 
world’s population is infected with Mtb [2]. Approximately 90% of the infected individuals will never 
develop TB and are therefore considered to have latent TB infection (LTBI) [3]. In contrast, 10% of these 
infected individuals will develop active disease during their life time and maintain the infectious cycle of 
Mtb. Thus, 3% (10% of 30%) of the world’s population will develop TB at some point during their life 
and this staggering number of sick patients has overwhelmed health systems, leading to the current global 
health problem. In developed countries where TB isn’t a significant health problem, guidelines have been 
clearly established to identify and treat individuals with LTBI having underlying risk factors for 
developing active disease [4]. Even though 9 months of prophylactic treatment with INH effectively 
accomplishes this [5], treatment of individuals with LTBI in developing countries is simply not feasible. 
Alternative methods to control developing active disease from LTBI are urgently needed and probably 
will come from better understanding the bacteria’s and immune system’s physiology during this stage. 
Unfortunately, one major drawback is that LTBI is mainly observed in human beings the natural host of 
Mtb and this limits the amount of interventions that can be applied to collect significant information [6].  
Even though several animals are susceptible to Mtb and have been fundamental in understanding many 
aspects of TB, our current animal models don’t recapitulate LTBI. Besides some experimental data 
obtained with non-human primates [7], LTBI is not seen in the more commonly used guinea pig, murine 
and rabbit models. Instead of LTBI and in stark contrast to only 10% of infected humans, a chronic but 
progressive disease is observed in 100% of experimentally infected animals [8]. It should be stated that 
this holds true even when infecting with doses as low as 10 bacilli [9], which mimic the estimated Mtb 




guinea pigs with air obtained from hospital wards housing TB patients [10-12]. By skin testing, it was 
shown the majority of exposed guinea pigs got infected and developed an acquired delayed-type 
hypersensitivity (DTH) to Mtb antigens [12]. Remarkably and in agreement with human infection, only 
12% of infected animals developed active TB. Thus, the remaining infected guinea pigs with a positive 
skin test behaved as humans with LTBI as they didn’t develop active disease [12]. In this final Chapter 
and in the context of Mtb physiology and metabolism, I attempt to give an alternate insight into the role 
that Mtb dormancy could play during transmission from infected to naïve indiviudals. This could have 
implications towards understanding human LTBI and could be applied to develop animal models of LTBI 
for drug and vaccine development. 
LTBI is a clinical term that refers to individuals with a positive skin test to Mtb antigens in the 
absence of clinical symptoms [3, 13]. This DTH is mediated by Tcells and is attributed to a recall 
response to a previous exposure to Mtb. It is well known that false positive results during skin testing can 
be attributed to BCG vaccination [13] and exposure to other non-tuberculosis mycobacteria, but this will 
not be further discussed in this Chapter. As patients with LTBI are asymptomatic, skin testing is currently 
the principal technique to detect them. Ideally, further evaluation of these patients is performed by 
obtaining a chest X-ray [3]. This allows identification of patients with asymptomatic active disease that 
require immediate treatment, as well as leading to antibiotic treatment of exposed high risk individuals 
that might develop active disease in the future [4, 7]. Unfortunately, the majority of the patients with 
LTBI don’t have any radiological evidence of prior infection, instead having inconspicuously normal 
chest X-rays [3]. In these patients, a DTH response is the only evidence that a previous infection 
occurred. In contrast and as reported in the Profit study in England, approximately 10% of patients who 
converted to a positive skin test against Mtb antigens, had X-ray findings compatible with a primary 
infection [14]. These findings principally consist of what has been referred to as the Ghon complex [15] 




(the primary lesion). If the primary lesion heals and calcifies, the Ghon complex is referred to as the 
Renke complex [15] and in the clinical setting, this is associated with good prognosis.  
From a pathogenesis perspective, the Ghon complex is a reflection that Mtb was able to colonize 
and multiply, recruiting host immune cells which ultimately coalesce to form the primary lesion. In fact, it 




 bacilli [3, 16]. The obvious question is 
why the majority of individuals with LTBI fail to develop a primary lesion (as evidenced by a lack of 
radiological findings) but have a DTH response to Mtb antigens?  Besides the aforementioned possibility 
that this DTH response could be due to cross reaction to BCG vaccination or exposure to non-tuberculosis 
mycobacteria, several alternative hypotheses could be envisioned. A simple scenario is that Mtb was 
efficiently eradicated by the host immune system and was not able to multiply. This is consistent with the 
results obtained when guinea pigs were exposed to air from TB hospital wards [12]. Alternatively, the 
amount of bacterial multiplication was not sufficient to recruit enough inflammatory cells. Furthermore, 
the individual’s immune system could be compromised such that it is not able to mount a significant 
inflammatory response. This has been observed in some AIDS patient with normal X-rays despite being 
diagnosed with TB by sputum culture [17]. One last consideration is that Mtb was able to colonize but 
remains in a dormant stage with minimum multiplication (bacterial dormancy will be discussed below). 
Indeed, several studies have confirmed the presence of Mtb in completely normal lung tissues. Several 
decades ago, it was shown that transferring macroscopically normal human lung tissue to guinea pigs 
would result in the animal developing TB [18]. Additionally, conventional acid fast staining and 
molecular techniques such as PCR have identified bacilli and Mtb gDNA respectively, in microscopically 
normal human lung tissue obtained from individuals dying of other cause besides TB [16].  In contrast in 
the guinea pig model, imaging techniques such as magnetic resonance imaging (MRI) have observed 
primary granulomas in equivalent numbers to the desired infection dose [19]. Thus, it seems that in 
contrast to humans, in our animal models every bacillus replicates, induces significant inflammatory cell 




As mentioned, LTBI could be attributed to the presence of Mtb in a dormant state. Dormancy 
refers to a bacterial physiology state consisting of low replication and metabolism. In vitro studies 
characterizing Mtb dormancy were pioneered by Wayne et al [20]. In their studies, the stimulus to induce 
dormancy of Mtb was gradual oxygen depletion [21]. As determined by densitometry measurements and 
methylene blue reduction, Mtb would replicate until microaerophilic conditions occurred. At this point, 
small increases in OD were observed and attributed to an increase in cell size rather than increased 
bacterial numbers. When complete hypoxia occurred, OD of Mtb cultures completely stopped increasing. 
Dormant bacilli could resume growth by simply transferring cultures to normal oxygen conditions. The 
fact that Mtb stopped growing during hypoxia, resumed growth during normoxia, and more importantly to 
separate dormancy (bacterial physiology) from latency (clinical term), led to some investigators coining 
the term “non-replicative persistence” instead [20]. It is widely known that Mtb is an aerophilic 
microorganism and this characteristic is used as a biochemical parameter to identify Mtb in the clinical 
setting [3]. Even though oxygen deprivation still remains as the “gold standard” to induce Mtb dormancy, 
recent studies have shown this also occurs when cultures are subjected to nutrient deprivation [22], high 
nitric oxide [23],  and carbon monoxide concentrations [24], low pH etc. Indeed, it has been suggested 
that all these conditions could coexist in vivo and Mtb dormancy was observed in vitro in a model 
simultaneously replicating all of these [25]. Thus, it seems that bacterial dormancy is a general response 
when unfavorable conditions incompatible with bacterial multiplication are present. From a biochemical 
perspective, Mtb dormancy was associated with increased nitrate reduction as a surrogate terminal 
electron acceptor when oxygen is lacking [26]. Increased isocitrate lyase (icl) activity was also found in 
dormant mycobacteria and suggested to metabolize glyoxylate resulting from Gly deamination [27].  
A major boost in the field of Mtb dormancy occurred with the identification of defined 
biochemical pathways leading to it. Dormancy was shown to be dependent on the activation of a two-
component regulatory system involving the kinases DosS and DosT and the response regulator DosR, 




DosS/DosR and the name dormancy regulon was coined to refer to them [29]. The function of several 
proteins belonging to the dormancy regulon has been characterized and include proteins such as Rv1915 
(icl1, isocitrate lyase) [31] , Rv3130c (tgs1, a triglyceride synthase) [32], Rv3097c (lipY, a lipase) [33], 
Rv2031c (hspx, a small chaperonin) [28] etc. It should be mentioned that more important functions have 
been recently attributed to icl beyond Wayne’s suggestion of its role in Gly metabolism [31]. Mutating 
the icl1 gene abrogated the bacillus ability to survive in in vitro cultures containing lipids as principal 
carbon source. Significantly, mutated bacteria did not thrive during the chronic phase of the murine TB 
model [34]. The icl shunt or bypass pathway is critical in organisms using lipids as only carbon source as 
it allows conservation of carbon units for gluconeogenesis [35]. Thus, it was hypothesized that during the 
chronic phase of infection Mtb switches to using lipids as carbon source. However, it was later shown by 
mutating both icl1 and icl2 genes that Mtb probably uses lipids as carbon source during its entire host life 
cycle [34]. The proposed carbon source switch is probably a reflection of the fact that Mtb is principally 
grown in vitro in media containing glycerol or glucose as major carbon sources (discussed below). 
Paradoxically, it was reported that icl expression predominantly in non-necrotic granulomas where 
hypoxia is not present [36]. Further studies are required to explain why this gene is highly upregulated 
during in vitro oxygen deprivation but not so in vivo in necrotic granulomas where hypoxia and dormancy 
have been well documented. In addition to specific protein upregulation and function, several phenotypic 
characteristics have been determined to be present in dormant Mtb and became important biomarkers for 
this physiological state. For instance, Rv3130c’s triglyceride synthase activity leads to the bacillus 
accumulating intracellular lipid bodies [25, 32, 37], which are readily detected by Nile red staining and 
this staining technique is routinely used in dormancy studies [38].  However, one aspect that has not been 
considered during dormancy is the counterintuitive upregulation of enzymes simultaneous synthesizing 
(Rv3130c) and catabolizing lipids (Rv3097c), possibly ensuing a futile cycle. An additional critical 
phenotypic characteristic is that dormant bacteria are resistant to antibiotics [22, 39]. Antibiotic targets are 




antibiotics against Mtb have only been around for approximately 60-70 years. In contrast, the dormancy 
regulon is conserved in several members of the Mtb complex that underwent different selection pressures 
after diverging thousands of years ago [40]. Even though dormant Mtb is a cause for the protracted 
antibiotic treatment of TB, antibiotics have not been the driving cause for the conservation of the 
dormancy regulon. Instead, the conservation of this regulon in different mycobacterial species is a clear 
testimony that it has a key but still unknown role in pathogenesis.  
Considering the critical role of DosS/DosR in dormancy and the possibility that it could answer 
some questions about TB pathogenesis, it was highly anticipated that mutants in this pathway could be 
enlightening. However, this was not the case and at least in mice it seems this pathway doesn’t have a 
significant role [41]. In other animal models, conflicting results have emerged with DosS/DosR mutants 
[42-44] but it seems like many in the TB field have moved away from it. Instead, focus has been shifted 
to a set of genes known as the enduring hypoxic response (EHR) [41]. This name highlights the fact that 
in contrast to genes in the dormancy regulon, expression of genes in the EHR remains for a prolong 
period of time after Mtb cultures are moved into hypoxic conditions. Unfortunately, so far no in vivo data 
has been reported for mutants in the EHR. It was assumed that Mtb mutants in the dormancy regulon 
would not thrive in the chronic phase of TB. This seems like an erroneous assumption for several reasons. 
In our current animal models, curves enumerating bacterial burden show exponential growth until 
approximately day 30 post-infection. This is followed by a plateau characterized by a constant number of 
bacilli. It had therefore been considered that bacterial multiplication did not occur in the chronic phase of 
TB [45]. However and in contrast to dormant bacteria, recent mechanistic data following the loss of a 
plasmid as a “replicative clock” has contradicted this belief and it seems clear that Mtb replication 
continues during the chronic phase [46]. Furthermore and again in contrast to dormant bacteria, most Mtb 
present in the chronic murine model (>30 days) of TB are susceptible to antibiotics [47, 48]. This is also 
observed in the chronic guinea pig model as bacterial burden rapidly declines when conventional 




surviving or persisting into chronic stages of TB do not display at least two major characteristics present 
in dormant Mtb: lack of replication and phenotypic resistance to antibiotics. Thus bacterial persistence in 
chronic stages of the disease should not be equated to dormant bacteria. As only a small fraction of bacilli 
would be dormant in chronic stages of TB, dormancy mutants wouldn’t significantly impact bacterial 
burden. Lack of distinction between these two situations could have led the field to prematurely move 
away from the dormancy regulon.  
What then is the role of the dormancy regulon in the pathogenesis of TB and LTBI? Two 
independent observations could hold the key to answer these questions. Abundant lipid-loaded Mtb, an 
indicator of dormant bacteria (see above), were recently reported to be present in sputum of TB patients 
[38, 50]. In addition to staining with Nile Red, transcriptional analysis confirmed the expression of 
dormancy genes quite similar to those reported from in vitro dormant cultures [50]. By 
immunohistochemistry techniques, multiple phenotypes of Mtb have been reported in lung lesions [51, 
52] and the presence of bacteria with a dormant phenotype in sputum could simply be a casual finding. 
But what if dormant bacteria are actually important during Mtb transmission, hence their presence in 
sputum? The second observation was reported decades ago and actually represents one of the initial 
suggestions that in vivo Mtb preferentially uses lipids as carbon source [53]. Importantly, Mtb isolated 
from infected lungs could only be stimulated to respire in the presence of infected but not naïve lung 
extracts. In vitro subculturing of Mtb isolated from tissues would abrogate the bacteria’s respiration 
reliance on extracts from infected tissues. This result could be attributed to essential metabolites 
conducive to bacterial respiration and multiplication, being present only in infected but not naïve lungs. 
Metabolic differences between naïve and infected tissue should be expected taking in consideration the 
drastic changes occurring during inflammation. For instance, the enhanced vascular permeability 
occurring during inflammation could increase metabolite tissue concentrations. Furthermore, as 
inflammatory cells become activated, their metabolism is radically changed. Instead of using lipids or 




Warburg effect) [54]. Despite the presence of oxygen, activated cells metabolize glucose into lactate and 
perform increased glutaminolysis in order to provide building blocks for macromolecular biosynthesis. 
Indeed, metabolite differences compatible with the Warburg effect were observed in nuclear magnetic 
resonance (NMR) analysis of whole lungs obtained from naïve vs. Mtb infected animals [55]. Further 
insight into the metabolite composition of Mtb infected lungs was achieved after laser assisted dissection 
of human necrotic granulomas. By thin layer chromatography (TLC) and mass spectrometry analysis, 
abundant triacylglycerols and cholesterylesters were characterized in these lesions and could represent the 
carbon source being accumulated in lipid bodies of extracellular Mtb [56]. In fact, Mtb accumulation of 
lipid bodies could start during its intracellular life cycle inside macrophages.  A pathological observation 
in TB is the presences of ‘foamy’ macrophages harboring intracellular Mtb [57]. ‘Foamy’ macrophages 
also accumulate intracellular lipid bodies giving the cell its ‘foamy’ appearance. It has been reported that 
Mtb can obtain its carbon source from the lipid bodies present inside ‘foamy’ macrophages [58, 59].  
Besides carbon, a source of nitrogen is also required for macromolecular biosynthesis. 
Specifically for Mtb, it has been shown that Gln could be an important nitrogen source. The NMR study 
previously mentioned, also reported that Mtb infected lungs contain an abundant concentration of Glu 
[55], the precursor for Gln synthesis. Mtb genome encodes for four Gln synthatases, with Rv2220 (glnA1) 
being the most physiologically relevant one [60]. In vitro studies have shown that rv2220 mutants failed 
to thrive in macrophages [61]. In addition, pharmacological inhibition of Mtb Gln synthatase was shown 
to reduce in vivo bacterial burden in the guinea pig model [62], and therefore has been considered as an 
alternative antibiotic target. Interestingly and as discussed in Chapter IV, the dormancy regulon includes 
rv0574c-0571c [29], the putative α-L-polyGln biosynthetic machinery. As implied by its name, α-L-
polyGln is a polymer of L-Gln residues [63]. Even though the function of this polymer is currently 
unknown, one possibility is that analogous to the role of glycogen as a glucose storage system, α-L-
polyGln could represent an L-Gln depot. In a concerted action between Rv2220 and the biosynthetic 




lungs and replenish its L-Gln stores for future needs.  Indeed, inhibition of Mtb Gln synthatase with 
antisense nucleotides led to reduced α-L-polyGln [64]. Similar to the role played by B. anthracis CapD in 
regulating polymerization or release of poly-γ-D-Glu [65], Rv2394 (Chapter III) could have a dual role in 
the physiological role played by Mtb α-L-polyGln. While Mtb is storing Gln as α-L-polyGln, Rv2394 
could be crosslinking oligopeptides of α-L-Gln into an insoluble polymer that remains associated with the 
cell wall. In contrast, when Mtb requires Gln, Rv2394 could be releasing Gln oligopeptides that Mtb 
could import and use. The dual function in Rv2394 as a hydrolase and a transpeptidase, empowers the 
enzyme to regulate α-L-polyGln concentration. Indeed, experimental evidence was obtained suggesting 
that in the presence of physiologically relevant acceptors, Rv2394 could mediate a transpeptidase 
reaction. If acceptors were not present, Rv2394 could perform a hydrolase reaction and cleave the donor. 
Finally, in regards to nutrient storage, it was recently reported that inflamed lungs contained high intra 
and extracellular deposits of iron [66], an additional micronutrient required by Mtb. In conclusion, in 
contrast to naïve lungs, inflamed lungs constitute a nutrient-replete environment where Mtb can obtain 
and accumulate carbon and nitrogen sources, as well as iron. These metabolite alterations are not 
circumscribed to the inflamed tissue but are also present systemically. Specifically in chronic 
inflammatory conditions such as TB and cancer, adipose tissue and muscle catabolism resulting in 
cachexia are probably fueling tissular accumulation of metabolites.  
In this order of ideas, I propose that during transmission from a sick to a naïve individual, 
dormant as opposed to actively growing Mtb gives the bacillus the best probability for efficient 
colonization of the new host. This is in contrast to the current dogma that actively growing Mtb is 
responsible for transmission. As Mtb is transmitted from infected to naïve lungs, the bacilli will suddenly 
be confronted with a nutrient-deficient environment. Similar to what occurs during an abrupt oxygen 
withdrawal [21], this sudden loss of nutrients could be catastrophic to actively growing bacilli. This is 
consistent with the abrupt respiration shutdown in an ex vivo model of Mtb transmission [53]. In contrast, 




minimized respiration and can actually survive with significantly reduced intracellular ATP 
concentrations [39]. Furthermore, dormant Mtb would have an abundant supply of its required carbon and 
nitrogen source stored in its lipid bodies and α-L-polyGln, respectively as well as iron stored in 
bacterioferritin. In fact, triacylglycerols present in mycobacterial lipid bodies have been shown to be 
consumed when bacilli are transferred from hypoxic to normoxic conditions [67]. Thus, acquisition of 
nutrient depots in the former host empowers dormant bacilli with the ability to colonize after transmission 
into the new host. These dormant bacilli would slowly adapt and start obtaining host nutrients as its 
depots are limited, but sufficient for the colonization process. In essence, colonizing dormant bacilli could 
silently persist without inducing lung damage and be responsible for LTBI seen in the majority of Mtb 
infected individuals. In contrast, after transmission and in order to acquire nutrients, actively growing Mtb 
might rely on the induction of inflammation of the recently colonized lung. A similar scenario is 
envisioned for Mtb with mutations in genes participating in the dormancy regulon. As these mutants 
would lack a source of endogenous nutrients, inducing inflammation to facilitate nutrient acquisition is a 
priority. Indeed, faster and more significant inflammation was observed for mice infected with Mtb 
mutants lacking the ability to synthesize α-L-polyGln (Chapter IV). A similar phenotype has been 
observed for Mtb mutants lacking either the two-component system regulating the dormancy operon [42] 
and for hspX, which is highly expressed in dormancy [68]. Finally, in the context of inducing 
inflammation to acquire nutrients, an important product that could mediate this event is the extracellular 
Mtb RNA described in Chapter II. The mechanism allowing RNA release is not clear, however, it was 
observed that a progressive increase in its extracellular concentration paralleled bacterial mass 
accumulation and the quantity of secreted proteins.  A possibility is that RNA is simply being released 
during Mtb replication. It has become evident that an innate immune response can be elicited against 
Shigella and Legionella RNA and this has also been correlated to bacterial replication [69, 70]. Thus, 
RNA released during Mtb replication could be an early event modulating the host immune response. It 




feedback loop can be envisioned in which as the bacilli starts to replicate, the released RNA deactivates 
the macrophage, in turn leading to more Mtb replication.  The fact that Mtb RNA also induced host cell 
apoptosis can start the cell death process that eventually leads to necrotic granulomas and further down 
the line, liquefaction and cavitation.  
As a corollary for this discourse and if wanting to mimic the natural history of human TB in 
animals models, the methodology for in vitro culturing infectious stocks of Mtb should be revisited. In 
general, the current protocols involve culturing in media containing glucose or glycerol as opposed to the 
abundant body of literature pointing out to lipids as the primary carbon source. Even though oleic acid or 
polysorbate 80 (Tween-80) is routinely supplemented in media, the concentration of glycerol and/or 
glucose still exceeds that of lipids. As in vitro Mtb has been reported to simultaneously metabolize sugars 
and lipids [21], the inclusion of both carbon sources could have biochemical and physiological 
consequences in a bacterium that apparently only uses lipids when transferred into the host [34, 71]. 
Furthermore, cultures are harvested during logarithmic growth when most bacilli are actively growing. To 
the best of my knowledge, there has only been one attempt to infect animals with dormant bacteria and 
this was accomplished after intranasal inoculation [72]. Unfortunately and in order to follow Wayne’s 
protocol for inducing Mtb dormancy, in vitro culturing was performed in Dubos media which has 
abundant glycerol and glucose concentrations.  In addition, even though it has been noticed that in vitro 
Mtb grows better in a carbon dioxide (CO
2
)-containing environment which resemble in vivo conditions 
[3], inclusion of CO
2
 is seldom, if at all, done when preparing infectious stocks. Finally and to make 
matters worse, infectious stocks are frozen at -80˚C for prolonged periods of time. How this affects the 
bacterial’s physiology is unknown. To better mimic LTBI in animal models and in descending order of 
ideal methods for experimental infections, the following could be considered: a) as performed with guinea 
pigs breathing air from tuberculosis wards, animals could be infected with airborne bacilli being 
expectorated by patients, b) animals could be infected with bacilli obtained from sputum, c) animals could 




most cases. Instead in vitro culturing is required in most circumstances, so a fourth option could be to 
infect animals with bacilli grown inside a CO
2
 incubator in medium composed of extracts from infected 
lungs. 
In conclusion, I propose that transmission of dormant bacteria could be responsible for LTBI. By 
having reduced metabolic requirements and carrying its own source of nutrients in the form of depots, 
dormant as opposed to actively growing Mtb would be better equipped to deal with the colonization 
process of the nutrient-deprived environment encountered in naïve lungs. Actively growing Mtb procures 
its source of nutrients by inducing inflammation but this becomes a two-edged sword as the bacillus could 
be eradicated by the influx of inflammatory cells. In contrast, dormant Mtb could persist for long periods 
of time without inducing tissue damage (latency), until the presence of more favorable conditions 
minimizing the risk of being eradicated. The role of dormancy in the physiology and pathogenesis of Mtb 
should therefore be sought during transmission and not chronicity, the first vs. the last step in Mtb life 
cycle, respectively. In agreement with Pollock’s quoted statement, clinical observation should be the 
driving force to understand TB. In this regard, understanding human LTBI and the role played by 
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